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General Introduction 
In 1983 the isolation of a previously unknown human retrovirus was first associated with 
a newly recognized acquired immune deficiency syndrome (AIDS), characterized by unusual 
opportunistic infections and malignancies (II). Subsequently repeated retrovil1Is isolations from 
individuals with AIDS or from individuals known to be at risk of acquiring this disease were 
reported (53,99,133). These retroviruses were characterized as members ofa separate group of 
primate lentivil1lses, the human immunodeficiency viruses (HIV). They were indeed identified 
as the etiological agents of AIDS (29,143,153). Within this group two major subtypes are 
presently distinguished: HIV-I and HIV-2 (26,27,64). The lentiviruses identified to date which 
may cause AIDS like syndromes in infected animals include simian immunodeficiency virus 
(SIV) and feline immunodeficiency virus (FIV). Both SIV infection of macaques and FIV 
infections of cats are presently used as animal models for HIV infections in humans (97). I-I ere 
a concise overview of the biology of HI V-I is presented, with special attention for the process 
of HIV-I induced membrane fusion which is at the basis of viral entry and syncytium 
formation. 
I. HlV-1 AND IT'S REPLICATION. 
1.1. Virion morphology and structure. Mature HIV-I particles, as typical lentivirus 
structures, arc approximately 110 11m in diameter and consist of a cone-shaped capsid 
surrounded by a lipid envelope membrane (Fig. 1)(55). Electron microscopical studies have 
revealed 72 glycoprotein spikes projecting from the envelope membrane that are 9-10 nm in 
size (Fig. 1)(56,127,165). These glycoprotein spikes are tri- or tetrameric structures which each 
consist of heterodimers of a gpl20 surface glycoprotein, associated with the gp41 
transmembrane protein anchoring the heterodimer into the host cell derived virion membrane 
(38,43,180). In addition to the virus encoded envelope glycoproteins cellular membrane proteins 
arc also present in the virus membrane (8). Biochemical and immunochcmical studies have 
revealed a number of other viral proteins (Fig. 2). The nucleocapsid (core) is composed of the 
Imtior Gag (group specific antigen) protein p24, which contains two positive sense, single-
stranded genomic RNA molecules closely associated with the viral Gag proteins p7 (p9) and 
p6 in addition to the reverse transcriptase. Also the virus encoded integrase enzyme is present 
within the capsid (55,56). The myristylated matrix protein p17, forms an icosahedlycallayel' 
between the core and the virion membrane and is required for incorporation of the envelope 
protein into mature virions (127,165,188). 
1.2. Organization of the genome and encoded proteins. The linear proviral DNA 
integrated in host cell DNA is about 9.8 kb in size and is flanked by long terminal repeats 
(LTR) at each end. The LTR contains signals for integration, transcription initiation and 
regulation, and poly-adenyl at ion of messenger RNA's. Like in other retrovimses the viral 
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genome contains Gag, Pol, and Env genes in the order 5' to 3'. However, in contrast to other 
less complicated retroviruses, the genome of lentiviruses including mv -I contains several 
additional genes that code for regulatory and accessory proteins (Fig. 2) (105). Gag and Gag-
pol precursor polyproteins of HIV-I are translated from full-length viral RNA, whereas the 
other (precursor) proteins are produced from single or multiple spliced smaller messenger 
RNA's (Fig. 3). The Gag-pol precursor protein, that is synthesized through a translational 
frameshift, is cleaved into a RNA and DNA-directed polymerase (reverse transcriptase), the 
integrase involved in viral DNA integration, and the viral protease (105). 
FIG. 1. Electron micrograph of mature HIV-I particles, showing different core orientations. Virus surface 
projections represent the envelope glycoproteins. Photomicrograph cout1esy of Dr. H.R. Gelderblom, Berlin. 
The Gag polyprotein (p55 Gag) is cleaved into the matrix protein p17, the capsid protein 1'24, 
the nucleocapsid protein 1'7, and three smaller proteins 1'6, 1'2 and pi (73,74). The translation, 
processing, and maturation of the envelope glycoproteins are discussed below in section 3.1. 
In addition to the structural genes, the mv -I genome contains at least six additional genes 
coding for the regulatory proteins Tat and Rev (34) and the four accessory proteins: Vif, Vpr, 
Vpu, and Nef (163). The Tat, Rev, and Nef proteins are synthesized from early Rev-
independent (see below) multiply spliced mRNA's, while vif, vpr, and vpu are expressed late 
from Rev-dependent singly spliced mRNA's (163). 
1.3. Replication cycle. The replication cycle of HI V-I infection stmis with the fusion of the 
target cell outer membrane and the viral membrane (108, I 6 I). For HIV -I this membrane fhsion 
is typically initiated by the binding of the envelope glycoproteins to the cellular CD4 receptor 
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FIG. 2. HIV-I genome organizntion and virion stnlcture. The viml genome flanked by both LTR's, and the 
location of the genes is shown at the top. The viral proteins indicated in the virion are: matrix protein (MA), 
capsid protein (CA), nucleocapsid protein (NC), viral protease (PR), reverse transcriptase (RT), integrase (IN), 
surface glycoprotein gpl20 (SU), and transmembrane protein gp41 (TM). Reproduced by kind permission from 
Annu. Rev. Biochem. 1991,60:577-630. 
and results in release of the nucleocapsid into the cytoplasm (36,133). This envelope 
glycoprotein controlled fbsion process is discussed in detail in section 3. Upon enlly in the 
cytoplasm viral replication is initiated with reverse transcription of the viral single stranded 
RNA genome, into double stranded DNA by a process requiring two strand-transfers (124). 
Negative-strand DNA synthesis by the viral reverse transcriptase is primed by cellular tRNA", 
and is associated with RNase H activity of the reverse transcriptase, digesting the viral RNA 
once duplicated into DNA. Subsequent positive strand DNA synthesis by the same polymerase 
is presumably initiated at two sites on the first DNA strand but now primed by viral genome 
RNA sequences. This process of reverse transcription is particularly error prone since no 
proofreading is involved, and thus results in high genetic variation in progeny vims (135,138). 
Template switching during reverse transcription resulting in l'etroviral recombination also 
contributes to the high level of HI V-I genetic variability (135). Linear double-stranded DNA 
with two identical LTR's is subsequently transported into the nucleus and insetted into host cell 
DNA by the viral encoded integrase (13,61). Both steps in viral replication, reverse transcription 
and integration, are only fully completed in dividing host cells (162,189) Once integrated, viral 
DNA (the provirus) represents a transcription unit ready to initiate the production of a next 
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FIG. 3. Syncytia induced in transfected SupTl cells upon expression of an SI virus derived envelope gene 
(env. gene 16.1, chapter 4). 
generation of viruses. This transcription unit is also passed to progeny cells like resident cellular 
genes. HIV gene expression fi'om the 5' LTR is controlled by both cellular and viral factors 
(105,141). The viral Tat protein plays a central role in HIV transcription regulation by binding 
to the Tat-responsive RNA-element (TAR) located at the 5' end of all viral mRNAs. Tat-TAR 
interaction upregulates viral gene expression including Tat gene expression itself, which results 
in a positive feedback loop, responsible for a strong increase of vims expression (33). Such a 
burst of expression may be initiated by a wide variety of external stimuli, including the lectin 
PHA, certain cytokines, phorbol esters, and cellular factors that may also be expressed upon co-
intection with other vimses and thus induce HIV expression (141). The LTR directed 
transcription results in full length RNA molecules of which most are spliced into smaller 
messenger RNA species. The t\lll length RNA transcripts serve either as genomic RNA to be 
encapsidated or as mRNA for the Gag and Gag-pol polyproteins. However, like the single 
spliced mRNA coding tor the envelope glycoproteins, these long RNA molecules are only 
exported to the cytoplasm in the presence of the Rev protein. Rev acts as a post-transcriptional 
trans-activator, regulating the expression of viral structural genes in an indirect fashion (81). 
Newly enveloped viruses are generated through a budding process at the cell surface. This 
process is belicved to stali with the formation of immature cores of Gag and Gag-pol 
polyproteins at the interior surface of the cell plasma membrane (54,56). In the subsequent 
budding process the nucleocapsid Gag domain interacts with the psi packaging sequence on the 
viral genomic RNA (59) and the c)'ioplasmic tail of gp41 of envelope oligomers interacts with 
the myristylated matrix Gag domain (60). During the last stages of the budding process and in 
newly-released virions the Gag and Gag-pol precursors are cleaved in trans by the viral 
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protease. This cleavage process is required for viral infectivity (86) and is held responsible for 
the morphological maturation of virions in which the corc condenses to form the typical 
electron-dense conical structure (56). The envelope glycoproteins expressed at the cell surface 
of infected cells may interact with the CD4 receptor expressed at the surface membrane of 
adjacent cells. Such an interaction may lead to membrane fusion similar to the situation in viral 
entry, and results in the formation of multinucleated cells (syncytia, Fig. 3) (100,10l). CD4-
gpl20 based interactions between neighbouring cells may also be at the basis of direct cell to 
cell spread of the infection (144). 
2. HlV-I INFECTION IN HUMANS. 
2.1. Coul'se of infection. During the early stage of HIV-l infection, about half of the 
individuals develop influenza like disease symptoms (30,170). In this early stage, high virus 
titers in plasma and high numbers of infected peripheral mononuclear blood cells (PBMC) are 
observed. The initial virus load is markedly reduced when the immune response develops 
(25,35). At this stage a transient low CD4:CD8 ratio is observed presumably due to an 
increased number of circulating CD8+ immune effector T-cells together with a reduced number 
of CD4+ cells (93). The immune response however, does not prevent early wide spread 
dissemination of HIV -I. In addition to the cells of the haematopoietic system, the virus may 
be detected in cells of several organs including the skin, the gastrointestinal tract and the brain 
(98). After returning to a near normal level after acute infection, the CD4+ cell numbers 
gradually decline during the subsequent asymptomatic phase of the infection (93). This 
asymptomatic phase may last for more than 10 years, but impaired immune functions are 
observed, as evidenced by hypo-responses to antigenic and mitogenic stimuli (114,156,166). 
Several mechanisms are postulated for the obscrved depletion ofCD4+ cells contributing to the 
eventual immune collapse. These include direct cytopathic effects (100,158), immune mediated 
cyto-lysis (I92), and programmed cell death (apoptosis) (63,1l2). Recently determined viral 
loads in the asymptomatic period are several orders of magnitude higher than previously 
estimated and the frequency of infected lymphocytes in lymphoid tissues proved to be 
significantly higher than in the peripheral circulation (44,129). Other more recent studies with 
experimental drugs that are potent inhibitors of viral replication revealed a highly dynamic 
process of HIV -I replication (77,179). It was shown that rcplication of HIV -I in vivo is 
continuous and highly productive, driving a rapid turnover of CD4+ cells. These data favour 
the view that AIDS is primarily the consequence of a direct virus- and immune-mediated killing 
of infected cells caused by a continuous high level of virus replication. AIDS is ultimately 
marked by the occurrence of nOflnally rare malignancies like Kaposi's sarcoma, opportunistic 
infections, neurologic abnormalities and gastrointestinal disorders (98). 
2.2.IIlIlI1une I'esponse. Both the humoral and the cellular effector arms of the immune 
system are active in response to HIV-l infection. These responses are detectable shortly after 
infection and persist throughout the lifetime of the host. Humoral responses have been detected 
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to both structural and non-struchlfal viral proteins. However, most of the antibodies active in 
functional assays measuring virus neutralization or antibody dependent cellular cytotoxicity 
(ADCC) are directed to the viral envelope glycoproteins (46,102,181). Neutralizing antibodies 
are predominantly directed to the V3 loop and the CD4 binding domain of gpI20 
(82,1l7,I36,I93), but many other regions of gpI20 and also of gp41 may elicit virus 
neutralizing antibodies (17,66,78). The role of the humoral immune response in the 
pathogenesis of HIV-I infection is still controversial. Longitudinal studies have suggested a 
relationship between declining neutralizing antibody titers and disease progression (78,171,173) 
and similar studies using autologous virus - serum pairs demonstrated the rapid emergence of 
viral variants escaping from neutralizing antibody responses (1,177). Whether ADCC is 
clinically relevant in HIV -I infection is not known either, and conflicting data have been 
presented on its correlation with an asymptomatic stage in patients (46, I 02, 103,148). Finally 
the demonstration of enhancing antibodies has complicated the interpretation of experiments 
aiming at the elucidation of the role of antibody responses in the pathogcncsis of HIV-I 
infection (62,140). 
The strong suppression of antigenemia in primary infection, often before the detection of 
neutralizing antibodies, suggests an important role for cell mediated immunity in ElV-I 
infection (6). Indeed, the early appearance of T-helper and cytotoxic T-Iymphocyte (CTL) 
activity was reported to coincide initial control of viraemia in HIV and SIV infections (88, 
personal communication A.M. Geretti). Also the prolonged asymptomatic period in certain 
individuals has been attributed to the presence of strong cellular responses (98). 
2.3. HIV-l genetic and biological variation related to pathogenesis. Comparison of the 
tlrst nucleotide sequences available, revealed the variable nature of HIV -I (65,137,187). Soon 
it was recognized that this diversity is not only reflected in antigenic variability of the virus, 
but also in signitlcant variation of other biological propcrties shared by different HIV-I 
isolates. These variable properties included cell tropism, syncytium inducing capacity, 
cytopathicity, and kinetics ofreplication(lO,45). Correlating these biological characteristics of 
isolates with the stage of disease has been the subject of many studies. It was first recognized 
that vimses isolated from asymptomatic HIV -I infected individuals fi'equently differed in their 
biological properties /i'om vimses isolated from individuals with AIDS (10,22,50,167-169). 
Viruses isolated at a late time point in infection tended to have: an increased capacity to induce 
syncytia, an extended host range (replication in T-cell lines), and a higher replication rate 
relative to viruses isolated early in infection. Based on these biological differences two main 
viral phenotypes have been distinguished; the syncytium inducing (Sl) and the non-syncytium 
inducing (NSI) variants (167). These two categories largely overlap with the so called rapid-
high and slow-low phenotype designation used by others (50). Upon transmission, infection is 
likely to be established by NSI variants (174,186,190,191). The selective outgro,,1h of these 
variants may be based on their tropism for macrophages (113). The emergence of Sl variants 
in the course of infection, as observed for about half of the infected individuals has been shown 
to correlate with an increased decline of CD4 cell numbers and was shown to be predictive for 
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progression to AIDS (87). In the studies presented in this thesis we used SI and NSI variants 
isolated from single individuals as representants of genetically highly homologous viruses 
differing in their capacity to mediate membrane fusion. 
3. HIY-I INDUCED MEMBRANE FUSION IN YIRAL ENTRY AND SYNCYTIUM FORMATION. 
The process of membrane fusion underlying viral entry and syncytium formation in HIV-I 
infection, is initiated by a complex interaction of the viral envelope proteins with the cellular 
CD4 receptor. Here the cellular expression and molecular structure of both membrane proteins 
is described, and related to the mutual interactions of these molecules in membrane fusion with 
a special focus on structure fimction relationship. 
3.1. HIV-l envelope proteins The HIV-I envelope precursor protein is synthesized as an 
88 kD polypeptide on membrane-bound ribosomes from a single spliced messenger RNA 
(3,139). The amino terminal hydrophobic signal sequence directs insertion of the growing 
polypeptide chain into the endoplasmic reticulum (ER). Upon translocation this signal peptide 
is removed by a host encoded endoprotease and the nascent protein is modified by the addition 
of oligosaccharide side chains through N-linked glycosylation of asparagine residues with 
predominantly mannose residues esterified into long chains (39,96). There are 30 to 38 potential 
asparagine-linked glycosylation sites present among different HIV-I strains, most if not all of 
which are utilized for oligosaccharide attachment (96,125). A stop-transfer sequence near the 
carboxy terminus of the precursor protein holds the moleculc anchored in the lipid membrane 
(51,52). Intramolecular disulfide bonds produce a folded monomer, which subsequently forms 
oligomeric complexes (Fig. 4). Both the formation of trimers (56,180) and tetramers 
(43,130,149) have been repmied. Following transport to the Golgi complex, many mallllose 
residues are trimmed from the side chains and othcr carbohydrates are added to yield envelope 
proteins containing complex carbohydrate side chains (58). Recently it has been demonstrated 
that the envelope proteins are also modified by O-linked oligosaccharides (12). The fi.lly 
modified monomeric precursor envelope protein has a molecular mass of 160 kD, implying that 
the added carbohydrates contribute to approximately 45% of the total mass. Proteolytic cleavage 
of the envelope precursor into the surh1ce protein gp 120 and transmembrane protein gp41 in 
the oligomeric structure takes place in the Golgi compaliment by a cell encoded trypsin-like 
protease (176,183). The subunits are not disulfide linked but associated through non-covalent 
interactions (90, 111,176). On gp 120 the most crucial residues for gp41 attachment cluster in 
the C I and C5 regions (see below) respectively close to the amino and carboxy terminus (72). 
The complementary regions on gp41 have not been mapped conclusively, but the disulfide loop 
has been shown to be involved (104,152). Correctly folded and assembled envelope 
glycoproteins are transported out of the Goigi compmiment and inselied into the cellular outer 
membrane. At the cell surfhce the envelope oligomers may be incorporated in the virions during 
the budding process or may mediate cell-cell filSion with CD4 expressing neighbouring cells 
resulting in syncytium formation. A considerable amount of the oligomeric envelope proteins 
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FIG, 4, Disulfide bond and carbohydrate (primary) structure of the HIV-I surface glycoprotein gp120. 
Variable regions (VI-V5), conserved regions (CI-C5), and oligosaccharide structures are indicated. Amino acid 
numbering is based on the HIV -1 llIB sequence, Reproduced by kind permission of Annu. Rev. lmmulloi. 1991, 
9:649-678. 
however dissociates to release the surface protein due to the weak binding of gp 120 to gp41 
(57,150). Different isolates of the virus displayed substantial heterogeneity in their DNA 
sequence, and much of it is clustered within the envelope gene, particularly the coding region 
for the gp 120 glycoprotein (2,184). Genetic analysis of different HIV -I isolates identified five 
distinct hypervariable regions (V I - V5) which are interspersed with more conserved regions 
as indicated in Fig. 4 (116). 
3.2. The CD4 receptor for HIV -1. The CD4 surface glycoprotein is predominantly 
expressed on cells of the T-cell lineage. The CD4 molecule acts in concert with the T-cell 
receptor in binding to class-II MHC molecules loaded with antigen on the surface of antigen-
presenting cells. This binding governs thymic selection, the development of CD4+ T cells (T-
helper cells) and their subsequent antigen dependent activation in the immune response (164). 
The progressive specific depletion of the CD4+ subset of T-cells led to the identification of 
CD4 itself as the major receptor for infection ofT-helper lymphocytes and monocytes by HIV-
I (36,84,85). The CD4 glycoprotein has a molecular mass of 55 kd and is a member of the 
immunoglobulin superfamily which is reflected by its structural organization into four 
ectodomains designated DI to D4 (three of which contain disulfide linked loops) (107). These 
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domains are tandemly arranged and consist of double anti-parallel beta-plated sheets (185). Thc 
first N-terminal domain (D I) is most similar to Ig variable domains, and although less 
strikingly D2 and D3 display sequence similarities with the constant domains ofIg (164). The 
third and the fourth domain each contain aN-linked glycosylation site that when expressed in 
CHO cells are both occupied by carbohydrates (19). The DI domain is involved in both MHC-
II association and gpl20 binding (79). In the Dl domain complementarity determining regions 
(CDR's) are identified, especially CDR2 plays an important role in gpl20 binding (see section 
3.4). The short cytoplasmic domain (only 38 amino acid residues) is separated from the 
ectodomains by a typical transmembrane anchor of hydrophobic amino acids. The positively 
charged cytoplasmic domain interacts with tyrosine kinase p56'" and is thought to be involved 
in signal transduction (172,175). 
3.3. A secondary receptor for HIV-l? Although the CD4 molecule filllctions as the 
receptor for HIV-I, and it is the specificity of this virus-receptor interaction that dictates HIV-l 
tropism for T cells and monocytes/macrophages, CD4 expression alone is not sufficient for 
HIV-I entry. The inability of HIV-I to infect human CD4 exprcssing murine cells, may 
suggests that another molecule or receptor is required for entry (106). Most studies addressing 
this issue favour this option (15,40,67). The cellular restriction to virus entty however, varies 
with the vil1ls-cell combinations tested (23,80). To explain this phenomenon, it has been 
postulated that the factor required may comprisc different molecules or alternatively a single 
molecule belonging to a polymorphic family (157). No secondary receptor for HIV-l has been 
identified unequivocally to datc. The putative secondaty receptor may interact directly with the 
envelope proteins or may interact exclusively with the CD4 receptor, inducing conformational 
changes in this molecule, essential to mediate filS ion (see below). 
3.4. CD4-gp120 binding regions. The observation that antibodies to CD4 could block HIV-
1 induced membrane fusion processes, as demonstrated by inhibition of viral infection and 
syncytium formation, contributed to the identification of CD4 as the major receptor for HIV-I 
(36,85). Subsequently on gpl20 and CD4 regions involved in mutual binding have been 
identified. 
Initial studies demonstrated that the C4 region of the surface glycoprotein gpl20 is involved 
in CD4 binding (31,95). Other studies however showed the implication of additional gpl20 
regions in CD4 binding (32,90,126). It is now apparent that the CD4 binding site on gpl20 
contains multiple regions, including C2, C3, and C4, separated in the primary sequence but 
brought together in the folded molecule (126). This notion is consistent with the observation 
that most of the anti-gpl20 monoclonal antibodies that interfere with CD4 binding, recognize 
conformational epitopes (76,134,154). These mutational studies do not discriminate between 
residues directly involved in CD4 binding or residues that interfere with CD4 binding by 
indirect conformational cffects. Proteolysis protection studies suggested that especially regions 
in the C-terminal half of gpl20 comprising C2 and C4 directly contact CD4 (131). The 
construction of a minimal CD4 binding surfacc glycoprotein in which the 62 N- and 20 C-
terminal residues along with the entire V I, V2, and V3 regions were deleted is in line with 
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these data (132), which demonstrated that these deleted regions are dispensable for CD4 
binding. While glycosylation of the envelope precursor protein is required for proper folding 
and processing, leading to a protein capable of binding CD4, deglycosylation after biosynthesis 
under non-denaturing conditions revealed that glycans only marginally contribute to CD4 
binding (47,48). Similarly, studies in which potential glycosylation sites were removed, or in 
which carbohydrate addition or processing was inhibited, indicated that in general the glycans 
of the HIV-I envelope proteins are dispensable for syncytium formation or viral entry (49). 
The gpl20 binding site on the CD4 molecule was first mapped with monoclonal antibodies 
that cluster with Leu3A and OKT4a (111,145). Extensive mutational analysis further 
characterized the gpl20 high affinity binding site and localized it within in the first N-tenninal 
domain D I. Finally a small region (residues 40-55) within the CDR-2 like sequence of D I lVas 
identified as most critical for gpl20 binding (7,9,14,28,92,115,128,151) but also residues 
outside this region have been identified as potential contact sites (9,16). Interpretation of these 
data is facilitated now that the structure of the D I and D2 regions of CD4 is defined by 
crystallography (142,178). In these analyses the residues involved in the high amniI)' binding 
site form a protruding ridge (the C'-C" ridge). Possibly the gpl20 molecule has a 
complementary groove in the CD4-binding region. Several residues outside the CDR-2 region, 
which also appear to be involved in the interaction with gp 120 were shown to reside on 
adjacent p-strands. Of these residues some have side chains projecting towards the C' -C" ridge, 
suggesting direct interactions. Other residues are located further within the body of the protein 
and may only indirectly affect gpl20 binding (18,142). Finally, it is postulated that binding to 
gpl20 may involve dimerization of the CD4 Illolecule (42,94). 
3.5. Receptor mediated activation of membrane fusion. The process of viral membrane 
fi.Jsion has been studied most thoroughly for intluenza vil11s infection and this is the current 
paradigm for virus mediated fusion mechanisms (160). Upon viral attachment and receptor 
mediated endocytosis influenza virus mediated membrane fusion is triggered by a pH reduction 
within endosomes. This pH shift induces conformational changes in the viral glycoprotein (HA) 
resulting in the exposure of the hydrophobic fusion domain of the transmembrane protein. The 
fi.Jsion domain then perturbs the cellular lipid bilaycr and initiates fhsion with the viral 
membrane. Similarly HIV-l induced membrane lhsion is thought to be invoked by the gp4l 
Nwterminal fusion domain exposed on the envelope glycoprotein l11ultimcre through 
conformational changes (Fig. 5). mV-l induced membrane fusion has been shown to be pH 
independent, and conformational changes are triggered through receptor binding, enabling viral 
entry at the cell surface at neutral pH (108,110,146,147,161). Such a receptor induced fusion 
mechanism was indicated by experiments in which HIV-2 infection ofCD4 negative cells was 
demonstratcd upon soluble CD4 (sCD4) incubation (24). Incubation with (subinhibitory) doses 
of sCD4 also enhances HIV-2 and SIV infection (4,24,155,182) of CD4 positive cells. 
3.6. Receptor induced conformational changes. Indirect evidence for a receptor activated 
fhsion mechanism was provided by several studies demonstrating that (soluble) CD4 binding 
induces conformational changes in the envelope protein complex. Recently, it was shown that 
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sCD4 binding results in increased exposure of gp 120 regions recognized by antibodies 
(146,147), the dissociation ofgpl20 from gp41 (68,83,119,121,122) and the unmasking ofgp41 
epitopes (146,147). The complete array of conformational changes observed favours a model 
in which CD4 binding to gp 120 leads to a fbsogenic dissociation intermediate of the envelope 
protein complex (118). Binding studies revealed that the sCD4-virion binding affinity is 
temperature dependent (119,121). This may imply that initial contact of CD4 induces a 
conformational change in the envelope complex that converts a low affinity binding site for 
CD4 into a high affinity site (119,121). The CDR-2 region on CD4 serves as the initial contact 
site whereas other CD4 regions contribute to the subsequent increase of affinity. Since also CD4 
induced shedding of gp 120 appeared to be temperature dependent, it is likely that the 
conformational change that increases the affinity with CD4 directly destabilizes the gp120-gp41 
interaction (121). This view is supported by the identification of monoclonal antibodies directed 
to CD4 that neutralize HIV -I through inhibition of the high affinity binding of gp 120 and that 
simultaneously reduce CD4 induced gpl20 shedding from virions (123). Also the observation 
that primary isolate virions with reduced affinity for sCD4 have a more stable gp120-gp41 
interaction compared to T cell line adapted HIV -I strains, suggested that these processes are 
intimately linked (120). It remains to be determined whether complete gpl20 dissociation is 
necessary for fusion to take place. The enhancement of infection by HIV-2 and SIV which both 
show reduced gpl20 shedding upon incubation with sCD4 suggests that relatively stable 
dissociation envelope intermediates can cause fusion (5). However, associated gpl20 might 
allow the virus to remain attached to the cell while e.g. gp41 dissociated from gp 120 could 
trigger the actual filsion process. Furthermore other conformational changes, independent of 
gpl20 shedding, have been described to occur after sCD4 binding including increased exposure 
of the VI, V2, and V3 loops on gp120, and two regions on gp41 (70,147). For all these regions 
a role in the fusion process post CD4 binding has been reported. 
Retroviral transmembrane proteins have common structural features, such as two regions 
predicted to form alpha helices, separated by a cysteine loop, of which one displays a leucine 
zipper like motif and the N-terminal fusion domain (37,52) (Fig. 5). Since leucine zipper 
regions are frequently implicated in protein-protein interactions forming coiled-coil structures, 
the leucine zipper was supposed to constitute an oligomerization domain of gp41 (37). 
However, alpha-helix disrupting mutations in the leucine zipper domain inhibit membrane 
filSion but not oligomerization pointing to another fimction for the zipper motif (41). On the 
basis of these data and peptide inhibition experiments Matthews et.al. proposed a model in 
which a sequence of conformational rearrangements leads to a "fusion-attack complex" of gp41 
in which the filsion domain interacts with the target membrane (109). In this fusion model 
leucine zippers on different gp41 molecules self-associate to form coiled-coils in the activated 
fusion-attack complex. FUl1hermore the alpha helical structure adjacent to the transmembrane 
region of gp41 either functions in preventing the formation of the coiled-coil in the native 
envelope complex or promotes coiled-coil formation in the fusion-attack complex (109). A 
recent report showing that amino acid residues in the C-terminal segment of the leucine zipper, 
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Membrane 
Spanning 
"., Domain 
Fig. S. Primary structure of the lllV-l transmembrane protein gp41. Oligosaccharide structures are indicated 
by (\!). The disulfide loop (at the tip), the membrane spanning domain and the fusion peptide (fusion domain) 
are also shown. Amino acid numbering is based on the HIV-I IIIB sequence. Reproduced by kind permission 
of AIDS Res. Human Retrov. 1992,8:165-173. 
that is located close to the cysteine loop, may form a gpl20 contact site (21) suggesls that this 
site transduces the trigger for gp41 conformational changes as started with CD4 binding to 
gp120. Conformational changes in CD4 are probably also essential for the n.sion process (20). 
First, the virus binds to 0 I of CD4, a region at the most distal end of the receptor molecule. 
To present the gp120/gp41 complex into close proximity of the target-cell membrane a 
considerable distance must be bridged. Secondly, it is likely that the conformational changes 
in the envelope protein complex that occur during the strengthening of binding CD4 parallel 
conformational changes in CD4 itself. It is postulated that CD4 bends at a putative hinge region 
between 02 and 03 (91) in the n.sion process. This is supPOlied by the fact that monoclonal 
antibodies directed to 03 close to this region block HIV-I cell n.sion without interfering with 
CD4 binding (69). 
HIV-I infection and syncytium formation generally both rely on the interaction of gpl20 
with CD4 and the subsequent conformational changes in both molecules. Additional information 
is however required to clarify the differences observed between syncytium formation and viral 
entry (71,75,89,159). Similarly, the differences in the membrane fusion processes responsible 
for the entry of different cell types are yet not resolved. Determinants responsible for the 
differences in theses processes are mapped on both the envelope proteins and cellular 
components other than CD4. 
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4. OUTLINE OF THIS THESIS. 
The studies described in this thesis focuses on the role of the HIV -I envelope proteins in 
virus induced membrane fusion processes. First the contribution of envelope glycoprotein 
sequence variation to HIV -I syncytium formation and cell tropism is determined by genetic and 
filllctional analyses of two sets of envelope genes obtained from two different donors (chapter 
2 and 3). Chimeric envelope genes generated from one of these two sets are constructed and 
transiently expressed, in order to identifY envelope regions and the related sequence variation 
in these regions which determine syncytium formation and cell tropism (chapter 4 and 7). 
Subsequently, the impact of naturally occurring sequence variation in one of the envelope 
regions identified on the process of syncytium formation is studied in more detail (chapter 5). 
A large number of envelope gene nucleotide sequences is aligned, in order to allow the detailed 
analysis of variable regions with sequence length variation (chapter 6). Finally, the efficiency 
of HIV-l entty in the presence of specific monoclonal and polyclonal antibodies as well as 
sCD4 is studied (chapter 8). The results of the studies presented in this thesis are discussed and 
summarized in chapter 9. 
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ABSTRACT 
To study HIV-I e"\'elope-mediated syncytium formation we ha\'c amplified, cloned, expressed, and sC(luenced 
individual em'elope genes from a set of eight biological HIV·l clones. These clones were obtained from two 
patients lind display either a syncylium-indudng (51) or nonsyncylium-inrlucing (NSI) phe-ootype. Upon 
expression through recombinant ,-aceinia "irus, indh'iduul envelope gene products display heterogeneous 
syncytium-inducing capacities which rencet the phenotype of the parental biological HJV-l clones in all cases. 
For the eight biological HIV-l clones presented here, \'ariaUon of the em-elope gene alone is sufficient (0 explain 
theobsen'ed \'ariable syncytium·induclng capacity of the respectiw parental \'iruses. In addition we determined 
the complete nucleotide sequence of these em'elope genes. The predicted amino acid sequence revealed a 
considerable amount of \'ariation located mainly in the pre\'iously denominated variable regions. In \'arious 
regions ofem'clope genes obtained from the same patient, phenotype associated amino acid variation was found. 
This phenotype associated amino acid Yariation however, is not conserved between the twosetsofeuvelopegeues 
deriwd from different patients. Four eD\'elopesequences deri\'Cd from clones obtained from one patient showed 
phrnotype·associated amino acid Yal"iation In the fusion domain. Sequencing of 12 additional fusion domains 
re\'ealed that this same \'ariation is found in four additional clones. Howewr, a functional lest prrformed on 
recombinant vaccinia expressing mutant en"elope gcnrsshowrd thaI Ihisobscn'cd fusion domain "ariation does 
not contribute to the \'ariation in syncyliulll·inducing capacity of the em'elope gene product. 
INTRODUCTION 
I SOLATES OF HUMAN 1.\IMUNODEFlCIE.:"CY VIRUS type I (HIV~I) differ in their in vitro biological propertics such as 
replication rale, cytotropism, and syncytium-inducing capac-
ity.I~J Based on these in vitro properties one can distinguish 
syncytium-inducing (SI) isolates which have a high replication 
rate in primary cells and are generally able to grow in continuous 
cell lines on the one hand, and nonsync}1ium-inducing (NSf) 
isolates on the other hand, which have a moderate to low 
replication rate in primary cells and do not grow in continuous 
celllines. J 
In an earlier lon£itudinal study, we demonstrated that detec-
tion of SI variants in asymptomatic individuals is strongly 
lL'>socialed with subsequent rapid decline of CD4 -+ T-cell num-
bers and progression to acquired immunodeficiency syndrome 
(AIDS), whereas from stable asymptomatic individuals only 
slow replicating NSI isolates can be recovered. This suggests 
different roles for SI and NSI variants in in vivo pathogenesis.4 ,5 
It has been demonstrated that syncytium fomlation is mediated 
by the envelope g[ycoproteins of HIV~I although the exact 
mechanism has not been clarified,6.7 Furthermore, several 
studies with pairs of recombinant proviruses have directly 
implicated the envelope gene as containing the primary determi-
ILabomlOTY of Immunobiology, Nationallmtitute of Public Health and En\CironOlcntal Pwtc(lion, P.O. Box I, 3720 BA Bilthoven, The 
Netherlands. 
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nants in controlling biological variation of HIV _I, !\---I(l whereas 
only minimal functional variation has been found so far in thc 
regulatory genes or long lenninal repeat (L TR) of IIIV -I isolates 
with varying biological properties. II-l~ In the present compJr-
ative study we analyze a set of envelope genes to elucidate the 
genetic basis of the observed variation in syncytium-inducing 
capacity. 
The envelope glycoprotein~ are synthesized as a glyco~ylated 
precursor gp160, which undergoes several processing steps 
including oligosaccharide modification and proteolytic cleavage 
into two subunits; gp41 and gp120. 16 The transmembrane 
glycoprotein gp-t I noncovalently ant'hots the external glycopro-
tein gp120. TIle mature glycoprotein complex probably fonm 
telramers or a mixture ofletramers and dimers on the ~urface of 
the virion and infected cells. 17-19 Sevenll detenninants on the 
envelope glycoproteins appear to be involved in the process of 
membrane fusion which is necessary for the infection of target 
cells by HIV-I and for HIV-I-induced syncytium formation. n.2o 
In the first step HIV-J gpl20 binds directly to the CD-i receptor 
molecule on target cells. 21.22 Variation in CD4 binding afiinities 
of the gpl20 molecules of different H1V-1 isolates ~uggcsts 
direct or indirect involvement of the CD-i binding site on gpl20 
in dctcmlining such biological properties of the virus as the 
ability to induce ~yncytia. H.l~ As a result of this binding event 
the hydrophobic amino temlinus of gp-ll is exposed probably 
through a series of conformational changcs. 2_~ r-,·lutational anal-
yscs have shown direct involvement of thi~ region to the eosuing 
membrane fusion and it is therefore denominated the fusion 
llomain.l(>-2\1 Mutations in the fusion domain of simian immu-
nodcfit'ien('y virus (SIV) re,ulted in either rcduction or enhance-
ment of SIV envelope-induced syncytium formation depending 
on the hydrophobicity of the introduced amino acid which 
indicates that natural variation in this region of HIV-I may 
contribute to determining the biological phenotype of the vi-
rm.l(, Other regions of the envelope glycoproteins (e.g., the 
hypervariable V3 region) appear also to be involved in the 
proce,s of membrane fusion following the gp120·CD4 bind-
ing. JO In addition, variation in the V3 region has been shown to 
affect the biological properties of recombinant H1V-1 provirmes 
especially with regard to cell tropism. 31 
Here we describe the amplification, cloning, expression and 
sequencing of eight complete envelope genes derived from two 
sets of biological clones of IlIV-1 with different in vitro 
biological properties. This approach allows us to correlate the 
~yncytium-forming capacities of the individual envelope genes 
to their respective amino acid sequences and 10 the syncytium 
inducing capacity of the parental mv -I clones. 
MATERIALS AND METHODS 
SlIbjects 
Virus was recovered from seropositive individuals visiting the 
outpatient clinic of the Academic Medical Centre, Amsterdam. 
or partieipating in a large cohort s\udy.J2 
Clonal virus isolarion 
To obtain clonal populations of HIV-I directly from patient 
peripheral blood mononuclear cells (MNC). virus isolation was 
38 
perfonned in 96-well microtiter plates as dcscribed previ-
ously . .\.l liriefly, paticnt MNC (10.000/well) were cocultivated 
with 100,000 phytohemaglulinin-stimulatcd MNC fftlm heaUhy 
~cronegative blood donors. Under these conditions productive 
HIV-J infection wii.~ ob~erycd in Ie~s than a third of the wells, 
indicating clonality according to the Pois~on dbtribution. The 
thus obtaincd biological III V -I clones were then charaderized 
a~ syncytium-inducing (SI) or nonsyncylium-inducing (NS!) 
according to previously published criteria. J Following this 
prm:edure, multiple clones were obtained from MNC of 30 
~eftlpmitive individuals. For this study four individuals 
(IIIVach320, HIVams16. HIVam~93, and HIVach373 fUrlhcr 
referred to as, respectively, #320, #16, #93, and #373) were 
selected whose uncloned HIV-I isolates. obtained as described 
prcviously/ had a SI phenotype. By clonal isolation both NSI 
and SI elollCs could be obtained from MNC ofthese individuals. 
FrOfllone individual(#373) in whom overtime a tmn"ition from 
NSI to SI phenotype had been observed,3~ HIV-J clones ob-
tained from two time points (as indicated) were included in this 
study. 
Polymerase chain reactio/j (PCR) amplificatioll of 
clIl'l'lope .l't'qllt'IIC('S. 
High-mokcular wcight lJNA from MNC infected with clonal 
isolates were subjected to 3S cycles of PCR, using a ~et uf 
primers either spanning the complete envelope gene or a 423 bp 
subregion of the envelope gene (pllsition 7092-7514, HIV-
HXB2J5). The 423 bp region encodes the t'arho.".:y tcmlinal part 
of gp120. the envelope eleavage site, ;md the fU';ion peptide 
loeated at the amino temlinal end of gp4l. The primers "HJSI" 
and "FUS2" (5'-GGAAAAGCAATGTATGCCCCrCC-Y and 
5'-CCAGACTGTGAGTIGCAACAGATGC-3', rc~pccti\'dy) 
were used to amplify this 423 bp envelope region. To amplify 
the compkte cnvelope gene the primcrs "SOOO" and "7500" 
(S'-GACGTCCCCGGGCAGAAGACAGTGGCAATGA-
GAG-3'and S'-GCATGCCCCGGGCTITTTGACCACITGC-
CACCC-3') were used. The primer "5000" includes the tlrsl 
sevcn nudeutides of the em'e1upe open reading frimle. fixing 
these nucleotides for alt amplified cnvdope genes. Xmal restric-
tion sites (underlined) were incorporated into the primers "SOOO" 
and "7S00"to facilitate cloning. PCRcondition~ were: 35 cycles 
of I '95¢C, I 'S5cC, and 2.5' 72~C with 0.7 fJ.M primers. 2 mM 
Mg2 t • and 200 fJ.M dNTP for thc complete em'clope gcne and 
35 cycles of I' 9SoC. I' SYC, and 2' nee with S fJ.M primers, 
4 mM MgH and 200 f-lM dNTP when amplifying the 423 bp 
region. 
COlls/rlle/ioll of recombinant vaecillia virlls 
Envelope genes dcrived from biological dones obtained from 
patient #320and #16 weredoned into the Xmal site of plasmid 
veclor pSCI1. Jfi Hela cells infected with vaccinia virus (strain 
WR) were transfeelcd with calcium phosphate-precipitated 
pSCll-t'lIl' constructs ii.~ previously described.J6 Upon 5-bro-
modeoxyuridine (BudR) selection in 143 cells. recomhinant 
virus plaques were visualized by their blue color upon overlay 
with 5-hromo--4--<'hloro-3-indolyl-pD-galaclopyr,moside (XGal) 
due to the coexpression of the lacZ gene derived from the pSC II 
vector. lndepcndent plaques were plaque-purified three times 
and the recombinant vaccinia viruses were grown to large stocks 
in RK13 cells. All recombinant vaccinia viruses were assayed 
for HIV-I envelope expression by radioimmunoprecipitution 
(see below). The recombinant vaccinia virus containing the 
envelope genes from clones 320.2a.7 and 16.2 failed to express 
the expected gpl60/gpl20 products and the~e C/II' genes were 
subsequently reamplified from the same genomic DNA. Recom-
binant vaccinia virus containing the ('/11' genes from this second 
PCR now expressed the expected bands and these were used for 
all further experiments. 
RadioifllfllllllOprecipitation 
For radioimmunoprecipitation (RIPA) BeLa cells were met-
abolically labeled for 8 hOllrs with e5Sjmelhionine and 
e5Sjcysteine (ICN Biomedicals) 12 hours after infection with 
10 plaque-fonning units (PFU) of recombinant vaccinia virus 
per cell. Supernatant was collected and cells were lysed 5 hours 
after reconstitution of the medium with unlabeled methionine 
and cysteine. Subsequent immunoprecipitation was perfomled 
with polyclonal shcep anti-gpl20 senJm (kindly provided to us 
by Dr. M. Page through the MRC AIDS reagent program) as 
previously described.,H The precipitated proteins were analyzed 
by sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SOS-PAGE, 10% aerylamide), according to Laemmli.)8 
CD4 hinding 
Secreted envelope glycoproteins were metabolically labeled 
as described for RIPA. Supernatant was incubated with 150 ng 
soluble CD-I for 3 h at 4cC and subsequently immunoprecipi-
tated with excess monoclonal antibody to CD-I (OKT4, Ortho 
Diagnostic Systems Inc.). The precipitated proteins were ana-
lyzed as described for RIPA. 
S)'llc)'/illfll-jormillg aHa)' 
The I\INC (3 x 105 ) from different donors were infected with 
recombinant vaccinia virus or wild-type vaccinia virus (wt) at a 
mUltiplicity of infection (1-.101) of 30. Infections were allowed to 
proceed for 48 h, at which time Ihe cultures were assayed for 
synC)'tia. Relative sizes and numbers of sync)'tia found per well 
were scored independently on coded samples by two indepen-
dent researchers. 
Seqllence allalysis 
Se{luenCe analysis of eight complete envelope genes was 
performed: four were Se(luenced by the dideoxynuclcotide chain 
termination melhodJ9 using T7 polymerase (Amersham) and 
four others were sequenced on an Applied Biosystems Inc. 
automated DNA sequencer by Ihe Central European Facility for 
HIV genome analysis (Georg-Speyer-Haus, Frankfurt, Ger-
many). The amplified 423 bp fragments were analyzed by direct 
DNA sequencing. For direct sCtluencing the PCR products were 
purified by Centricon 30 (Amicon) filtration, denatured with 
NaOH andelhanol precipitated after primer annealing (FUSI or 
FUS2). The precipitated DNA was then scquenced using a 
motlified T7 polymerase ac;;ording to the protocol provided by 
the manufllcturer (U.S. Biochemical). From each isolate unam-
biguous DNA sequences were obtained, even in the hypervari-
able regions,40 confimling the c10nality of these isolates. The 
sequence data were analyzed using the Lasergene (DNAslar) 
computer programs. All sequence comparisons were perfomled 
with the gap penalty set to zero. 
Sile-direcled IIIlIlagenesis 
Oligonucleotide-directed mutagenesis was performed on two 
envelope genes cloned in the filamentous phage MI3 by the 
method described by Kunkel et al. 41 using supplies from 
Bio-Rad. Oligonucleotides 5'-CATAGCTCCTATCGITC-
CCACTGCTC-3' and 5'CATAGCTCCTATCATTCCCACT-
GCrC-3' were used for mutating the fourth codon of gp41 
coding region of the envelope gene of biological clones # 16.1 
and #16.3 from ATG to ACG and from ACG to ATG, 
respectively. The mutagenesis reaction changed the fourth 
amino acid residue of the fusion domain from methionine (0 
threonine and reverse. The mutant envelope genes were partially 
resequenced for examination of the desired mutation. 
RESULTS 
Conslmclioll oj recoII/bil/alll mccinia l'iruses Ihal 
£'.\press env genes derh'edjrom biological HIV-J 
clolles 
To examine the role and function of the envelope glycopro-
teins in delennining tlie varying syncytium-inducing capacity of 
HIV-I, we constructed a collcction of eight recombinant vac-
cinia viruscs e:-tpre5sing the cnvelope genes of a sci of biological 
HIV-l clones. 1llese biological HIV-I dones were ohtained 
from two patients; selected clones show similar replication mtes 
in MNC (data not shown) but differ in their capacity (0 induce 
syncytia in MNC cultures (Table I). The complete envelope 
genes of these eight dones were amplified by PCR using a sel of 
primers introducing Xmal sites to facilitate cloning of the 
envelope genes downstream the P7.5 promoter of the vaccinia 
expre~sion vector pSC11. 42 
E.tpl'essioll oj HIV-l ellvelope glycoproteills 
Recombinant vaccinia virus-mediated expression of the 
HIV-I cnvelope glycoproteins was demonstmtcd by RIPA. 
HeLa cells infected with recombinant vaccinia virus or wild-
type vaccinia virus, were radiolabc!ed and the proteins were 
analyzed by immunoprecipitation followed by SDS-PAGE and 
autoradiography. Figure I, panel A shows the recombinant 
\'llccinia virus induced expression of gp 160. Onty in the Iysates 
or recombinant vaccinia virus infected cells the precursor glyco-
protein gpl60 wa.~ precipitated by polyclonal sheep ~erum 
directed to the HIV-I envelope protein. Under these labeling 
conditions the cleaved gpl20 wa.~ also demon.~lrated in the 
Iysatcs of most of the infected cell cultures (Fig. I, panel A), and 
could easily be detccted in the supernatants of all the recombi-
nant vaccinia virus infected l'ell cultures (Fig, I, panel B). In 
order to demonstrate the receptor-binding capacity of the ex-
pressed envelope proteins, gpl20 present in ~upcmatant was 
alsocoprecipitated with soluble CD-1 (sCD-I-). Coprecipitation of 
gpl20 by the monoclonal antibody OKT4 (directed to CD-1) 
after incubation with sCD-1, demonstrated that the eight ex-
pressed envelope proteins were all able to bind CD-1 (results not 
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TABLE I. SYNCYTIUM-INDUCING CAI'ACm' 01' RECOMBINANT 
VACCiNIA VIRUS EXPRESSED ENVELOPE GENE PRODUCTS 
IN RELA110N TO TIlE PHENOITPE OF THE PARb"ITAL 
BIOLOGICAL CLONES 
Parenllli biofogictd 
HfV-/ clones 
320,2a.5 
.7 
.3 
.6 
16.1 
.2 
.3 
.4 
SI 
SI 
NSI 
NSI 
SI 
SI 
NSI 
NSI 
SyfICyliul/I-;ndllcillg t'llpacilY" of 
co"espondi/l,~ env genes 
expressed by rW 
+++++d 
+++++ 
+++++ 
+++++ 
+ 
aThe origin of each done (andlor the corresponding re<,ombi-
nant vaccinia virus expressed envelope gene) is indicated as 
#xx.yy.z (or xx.z) where x:o; indicates patient code, yy the 
number of the particular isolate (if applicable), and z represents 
the done number. 
hSyneylium-inducing capacity of the parental biological 
HIV -1 clones is determined in ~'1NC according to TerslIlelte 
et al. 3 
"Syncytium-inducing capacity of the recombinant vaccinia 
virus expressed gene products are detemlined in MNC. 
dSymbols: -, no syncytia; +, <20 small syncytia !Xr well; 
+++++, >200 large syncytia per well. 
shown). This coprecipitation of gpl20 was dependent on addi~ 
tion of ~oluble CO·t, shoWing the specificity of the reaction. 
Biological actil'l't)' of tile expressed eln'e/ope protelllS 
To determine the syncytium-foml ing <' apacit y of the envelope 
proteins, human MNCs were infected with recombinant vac-
cinia virus or wild·type vaccinia virus. Fomlation of syncytia 
was assayed 48 h after infection. Syncytium induction by 
envelope genes expressed in MNCs through recombinant vac-
cinia viruses is shown in Figure 2. Theresults are summarized in 
Table I. The syncytium-fonning capacity of individual HIV-I 
envelope genes expressed by recombinant vaccinia virus corre-
sponds to that of the HIV-I clones from which the envclope 
genes were derived, TIle syn<")'tium-fomling capacity of each 
cnvelope glycoprotein expressed in MNCs obtained from differ-
ent donors yielded no significant differences, 
Em'elope gene sequence analysis 
In order to define the genetic detemlinants of the syncytium-
inducing property of HIV -I, the complete nucleotide sequence 
of the eight expressed envelope genes was determined. Figure 3 
shows the predicted amino acid sequences of the amplified 
envelope genes with their origin (patient and biological done) 
and the in vitro determined phenotype (Sf or NSf). Comparison 
of these sequences rcvealed a substantial amount of amino acid 
variation located mostly in the hypervarlable regions VI through 
V5.40 In these regions mutations as well as sequence length 
variations were observed. The over.111 conservation is 74.8%: 
653 of the 873 predicted amino acid residues of the 
40 
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FIG. I. Expression of HI V -I envelope gene products by HeLa 
cells infe<'ted with recombinant vaccinia virus (or wi vaccinia 
virus). Metabolically labeled proteins from infected celilysates 
(panel A) or from supernatant (culture medium)ofinfecled cells 
(panel B) were immunoprecipitated with sheep polyclonal an-
tiserum to gpl20 and analyzed by SOS-PAGE. Lane I, wt; lane 
2, 320.2a.5; lane 3, 320.2a.7; lane 4, 320,2a.3; lane 5, 
320,2a.6; lane 6, 16.1; lane 7, 16.2; lane 8, 16.3; lane 9, 16.4. 
Sce legend to Table I for description of the cxpre~sed envelope 
genes. Arrows indicate the preCUrsor glycoprotein and Ihe 
surface glycoprotein gpl20 (panel A) or gpl20 shed in the 
medium (panel B), respectively. 
envelope glycoprotein are identical for all eight clones, mean 
amino acid homology is 88.9%. Envelope genes derived from 
biological c1onesobtained from the same patient display a higher 
degree of conservation: 90.2% en 95.0% for patients #320 and 
#16, respectively. Table 2 shows the percen(3ge amino aeid 
homology for all single pairs of envelope ~equences. Envelope 
genes obtained from the same patient and displaying the same 
phenotype upon expression, show the highest degree of se-
<Iuence homology; 95.6-99.0%. 
Fusion domain variation 
We havc demonstrated previously that mutations in the SIV 
envelope fusion domain that affect the hydrophobicity of this 
region influence the syncytium fomling capacity of the SIV 
envelope glycoproteins. 26 The predicted amino acid sequences 
of the four envelope giy<'oproteins obtained from patient # 16 
display a phenotype associated sequence variation at position 
number four of the fusion domain (Fig. 3). The SI envelope 
proteins share a methionine at this position (the fourth N-termi-
nal amino add residue of gp4l, the fusion domain) whereas the 
NSI biological done-derived envelope genes have a threonine at 
the same position. Tocxamine if (his mutation, which affects the 
hydrophobic character of the fusion domain, prevails in more 
HIV-I isolates, we amplified and sequenced specifically an 
envelope gene fragment around the fusion domain of twelve 
additional biological clones. Figure 4 shows the predicted amino 
add sequences with their origin (patient and isolate) and in 
vitro-determined phenotype of the parental biological done (SI 
or NSI). This extended sequence analysis of the fusion domain 
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FIG. 3. Predicted amino acid sequence of eight envelope proteins. Sequences were obtained from PCR-amplified envelope genes 
derived from biologicall-lIV -I clones (codes as indicated in Table I). 11le amino acid Sequence is presented in the I-letter amino acid 
code and alignment was perfonlled using Clustal. In the top line a consensus sequence derived from these clones is gh·en. Identity 
with the consensus Sequence is indicated by (.), (-) indicates the absence of an amino acid residue at the particular position. 11le 
symbol" in the consensus sequence indicates that no consensus amino acid residue could be assigned for that position, Amino acid 
numbers are indicated as well as the signal peptide, the hypervariable regions VI through V5, thegpI20-gp41 cleavage site, and the 
fusion domain. Sequences obtained from NSJ clone derived envelope genes are bold printed. 
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TABLE 2. SIMILARITY MATRIX OF EIGHT PRED!CTED ENVELOPE AMINO ACID SEQUENCES 
320.2aS lOOt>.:: u 
320.2a.7 99.0 100 
320.2a.3 86.1 86,7 100 
320.2a.6 86.1 86.6 96.9 100 
16.1 86.6 87.1 85.1 86,1 100 
16.2 86.2 86.6 85.0 86.2 95.6 100 
16.3 86.1 86.5 84.8 86.3 93.5 94.5 100 
16.4 86.5 86.9 84.6 86.4 93.2 93.9 99.0 100 I 
320. 320. 320. 320. 16.1 16.2 16.3 16.4 
2a.5 2a.7 2a.3 2a.6 
aOrigin of envelope sequences as indicated In Ihe legend of Table I. 
bNumbers represent percenlage amino acid homology between each pair of sequences according to alignment of Figure 3 wilh gap 
penalty set to zero. 
cBold print is the observed amino acid variation occurring between H1V-1 biological done envelope sequences displaying the 
same syncytium-inducing capacity. 
d Shaded area represents observed amino acid variation between amino acid sequences obtained from the same patient. 
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FIG. 4. Predicted amino acid sequences of the fusion domain containing N-tenninal region of the lransmembrane glycoprotein 
gp41 0[20 biological HIV-I dones. In the top line a consensus sequence derived from these 20cJones is given. Codes indicate the 
biological H1V-1 clones "from which the en\'elope sequences are obtained (see legend of Tab!e I). Identity with the consensus 
sequence is indicated by (.), (-) indicates the absence of an amino acid residue at that particular position. The symbol * in the 
consen~us sequence indicates that no consensus amino acid residue could be assigned for that position. 'Ine phenotype of the clones 
is indicated: +:SI and -:NSI. Phenotype associated (SI vs. NSI) amino acid variations are boxed. 
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A rVV # parental fusion domain amino acid sequence syncytium 
phenotype (first 11 residues) inducing 
capacity 
16.1 51 N-Ala-Val-Gly-Met-Ile-Gly-Ala-Met-Phe-Leu-Gly- +++++ 
16.3 N51 N-Ala-Val-Gly-Thr-lie-Gly-Ala-Met-Phe-Leu-Gly-
-
------ -- -------- --------------- -------------------------------------------------------- ------------------
mutant 16.1 "81" N-Ala-Val-Gly-Thr-Ile-Gly-Ala-Met-Phe-Leu-Gly- +++++ 
mutant 16.3 "NSI" N-Ala-Val-Gly-Met-lie-Gly-Ala-Met-Phe-Leu-Gly-
-
c 3 4 
• 
FIG. 5, Panel A: Syncytium-inducing capacity of parental and nlutated envelope gene products. The fir,'.1 elc\'cn amino acid 
residues at the amino tcnninus of gp4! are shown. Codes and symbols as indicated in table I. PI/lid 8: Syncytia induced in MNC 
upon infection with recombinant vaccinia virus expressing an envelope gene with a mutated fusion domain as indkatcd in panel A. 
Panel C: Expression of HlV-1 mutated envelope gene products by HeLa celL~ infected with recombinant vaccinia virus. 
Metabolically labeled proteins from infected celllysates (lanes 1 and 2) or from supernatant (culture medium) of infected cells (lanes 
3 and 4) were immunoprecipitated with sheeppolycional antiserum to gpl20and anal}'7ed by 80S-PAGE. Lane I, mutant 16.1 ; lane 
2, mutanJ 16,3; lane 3, mutant 16.1; lane 4, mutant 16.3. Arrows indicate the precursor glycoprotein and the surface glycoprotein 
gp120, respectively. 
revealed that the in patient #16 observed phenotype associated 
sequence variation also occurred in patient #93 but not in 
patients #320 and #373 (both isolates). 
FWlcfiollai s/Ildy of fhe observed phenotype-associated 
fliSioll domain l'ariation 
To assess the functional contribution of the observed pheno-
type associated fusion domain variation to the phenotype of 
mV-1 isolates, the methionine/threonine mutation was in-
versely introduced in the envelope glycopruteins originally 
derived from biological clones #16.1 and #16.3 as shown in 
Figure 5 panel A. When expressed through recombinant vac-
cinia virus, these mutated em'elope genes did not display an 
altered syncytium-fomling capacity (Fig. 5 panels A and B), 
Figure 5, panel C shows that these mutated envelope glycopro-
teins were expressed properly. A coprecipitation with sCD4 
demon<;trated that these mutated gp 120 molecules were still able 
to bind the CD~ receptor (results not shown). 
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DISCUSSION 
In this study we determined the syncytium-inducing capacity 
and the nucleotide sequence of envelope genes derived from a 
set of phenotypically well-characterized biological HIV-I 
clones obtained from two patients, 
TIle envelope gene product of lab-adapted synC)1ium-inducing 
HIV-I isolates like HlV~llIm ha.~ been ~hown to induce synqlia 
when expressed in heterologous expression systems which demon-
strates that the envelope glycoproteins of HI V-I arc by themselves 
sufficient to induce syncytia, ",.111 is not knO\\TI whether the lack of 
syncytium-inducing capacity of NSI field isolates must be attrib-
uted to functional differences behveen the envelope proteins of SI 
and NSI isolates or whether dejenninanL~ located ouL~ide the 
envelope gene (e.g., regulatory genes, L TR, or otherwise) modu-
late this syncytium-inducing capacity. A limited numberof~tudies 
using recombinant HIV-I pnwiru<;es have implicated the envelope 
gene prodUCL~ a~ the major culprit in dctcmlining biological 
variation of HIV -1, lI-Hl although evidence pointing to other virJ.1 
genes has also been presented. IIA] 
We have expressed the complete envelope genes of eight 
biological clones of HI V-I (4 SI and 4 NSf clones) to determine 
their SI capaeity in activated human MNC. The results show that 
only the envelope gene products obtained from SI clones readily 
induce large syncytia whcn expressed by recombinant vaccinia 
virus whereas those obtained from NSf clones did not, despite 
the fact that they are functionally intact as demonstrated by their 
ability to bind sCD4. Only the NSI clone 16.4-derived gene 
product induced some small syncytia in MNC culture but always 
much less than was observed for the SI clone derived envelope 
genes (Table I). This observation fomlally proves that envelope 
gene variation alone is sufficient to explain variable syncytium 
inducing capacities of HlV-1 isolates. For the eight HN-I clones 
presented here genetic variation outside the enrelope gene need not 
to be invoked to explain the viral phenotypic variation. 
In addition to the phenotype we also detemlined the nucle-
otide sequence and thus the predicted amino acid sequence of the 
eight expressed envelope genes. The predicted protein se-
quences exhibited considerable amino acid variation which is 
mainly located in the previously denominated variable regions. 
Mean amino acid homology is 88.9% (range 84.6-99.0%; Table 
2). Mean amino acid variation of envelope sequences obtained 
from the same individual was less, 90.2% and 95.0% homology 
for patient #320 and # 16, respectively. Envelope glycoprotein 
sequences derived from biological clones obtained from the 
same individual with the same phenotype with regard to syncy-
tium induction, exhibited the least variation (95.6%--99.0% 
homology; Table 2). This is a refle<:tion of the presence of many 
amino acid positions displaying phenotype-associated variation 
between sequences with different phenotypes but obtained from 
the same patient. This phenotype-associated amino acid varia-
tion can be found throughout the whole sequence (e.g., in the V I 
and V2 regions, in the V3 region which plays a role in the fusion 
process and which is the major determinant in HIV-I neutraliza-
tion, in theCD4 binding region, in the fusion domain, and in the 
external region of gp4I). None of these variations appear to be 
conserved between the biological clones from the two patients 
(# 16and #320), at least not with regard to the exact sequences. 
At one position in the V3 region (amino acid 21), however, we 
observe consistent variation concerning charged amino acids, 
This change in particular could have functional consequences 
based on observations by others that charge density of the V3 
region be important for fusion. 44 .45 These and other mutations 
that could induce structural changes in gpl20 or gp41 are of 
particular interest for further studies, since the lack of exact 
sequence conservation could mean that structUTC of individual 
regions of the envelope protein is more important than sequence, 
at least in determining biological properties. Alternatively, it 
might indicate that in different sets of envelope genes different 
deternlinants control biological variation. It is presently unclear 
whether in different viml populations (e.g., obtained from 
different patients) the biological variation of HI V-I is controlled 
by the same determinants. In addition, much of the phenotype-
associated amino acid variation may be the result of the presence 
of different viral populations distinguished by phenotypic prop-
erties other than their syncytium inducing capacity alone (e.g., 
cytotropism), Such shared or linked phenotypic properties will 
complicate the elucidation of the genetic basis of the separate 
phenotypic properties (e.g., the syncytium-inducing capacity in 
the present comparative study). 
The 23 cysteine residues appeared to be highly conserved 
throughout these eight expressed envelope glycoproteins. Only 
the envelope gene obtained from clone 320.2a.5 codes for a 
phenylalanine at position #233 and the envelope gene of clone 
16.4 codes for a tyrosine at position #854. whereas all other 
genes code for a cysteine al these positions (Fig. 3). TI1ecysteine 
at position #854 of gp41, however, is not conserved over other 
known HIV-I envelope sequences, a tyrosine at this position is 
frequently found. 46 In contrast to the cysteine at position #854, 
the cysteine at position #233 appeared to be highly conserved 
among HIV-I sequences. 46 Interestingly the envelope gene 
product of clone 320.2a.5 which does not contain this cysteine 
residue does induce syncytia. Reexamination of this region by 
direct sequencing of a PCR-derived envelope gene fragment 
could not confirm the presence of this phenylalanine in the 
genomic DNA of MNC infected with HIV-I done 320.2a.5 
(data not shown) which implies that it may have arisen during the 
envelope cloning procedUre (e.g" during PCR amplification). 
111is amino acid switch however, does not abolish CD4 binding 
or the syncytium-inducing capacity of the envelope glycopro-
tein, illustrating that the cysteine at position #233 is not crucial 
for these biological properties of the envelope protein. 
Eight out of 20 analyzed envelope genes show amino acid 
variation at two positions in the fusion domain. The variation at 
position #531 affects the hydrophobic character of the fusion 
domain whereas the variation at position #535 does not (Fig. 4). 
Mutational studies with SIV m~C indicated that changing the 
hydrophobicity of the fusion domain could significantly modu-
late the fusogenic potential of the envelope protein. 26 Although 
the sequence analysis of the extended set of envelope genes 
revealed only phenotype-associated amino acid variation in 
some of the envelope genes, we assessed the functional contri-
bution of this variation by inversely introducing the methioninel 
threonine mutation. When expressed by recombinant vaccinia 
virus, these mutated envelope genes do not displ~y an altered 
syncytium-forming capacity, showing that this fusion domain 
variation does not contribute to the variation in the syncytium-
inducing capacities of this subset of studied envelope genes. 
The expression of chimeras of the here studied genetically 
highly related genes, together with site·directed mutagenesis 
studies, should allow the identification of the specific domains 
within the envelope protein that control the variable syncytium-
inducing capacity of HIV-I. 
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The nucleotide sequences of the env genes of eight ph('notypically heterogeneous human Immunodeficiency 
ylnts type 1 (HIV-l) clones recovered from a single Individual "ithln a 3-week period were compared. In 
addition, the accessory gene sequences for four oflhese clones wel'c obtained. VarlaUon among most accessory 
genes ,,,as limited. In contrast, pronounced phenotype-associated sequence varlaUon was obserYed In the eflv 
gene. At least three of these clones most likely resulted from genetic recomblnaUon ennis In Yivo, indicating 
thai tbls phenomenon may account for the emergence of proYinlses "ith nonl phenotypic propeT1les. Wllhln 
the eIIl' genes of the eight clones, four domains could be defined, the sequence of each of which clustered In two 
groups with high Internal homology but 11 to 30% cluster variation. The extensive env gene variallon among 
these eight clones could largely be explained by the unique manner In whlcb the alleles of these four domains 
were combined In each clone. Experiments "ith chimeric proYiruses demonstrated that the HIV-l em' gene 
determined the capacity 10 Induce sync)11a and tropism for T-cell lines. Amino acids preYiously shown to be 
Involnd In gp120-CD4 and gpl20-gp41lnteracllon were completely consen'ed among these eight clones. The 
finding of Identical V3 sequences In clones differing In tropism for primary monocytes and T.cel! lines 
demonstratcd the existence of determinants of tropism outside the el'v V3 region. 
Human immunodeficiency virus type 1 (HIY-l) isolates 
possess distinct biological properties with respect to cytot-
ropism, replication rate, and capacity to induce syncytia (4, 
7, 30, 31). Previously, we have demonstrated that from 
stable asymptomatic individuals, only non-syncytium-induc-
ing (NSI) HIY-l variants which cannot be transmitted to the 
H9 or MT-2 T-cell lines can be recovered. In contrast, the 
detection of syncytium-inducing (SI) T-cell-line-tropic 
HIY-l variants is strongly associated with rapid CD4 T·ceH 
depletion and progression to AIDS (20, 31). 
Recently, several studies have identified mechanisms and 
rcgions of the HIY-l genome which control biological vari-
ation of HIY-1. We and others have shown that differences 
in cytotropism arc determined at an early level of the virus 
replication cycle prior to provirus formation, which suggests 
involvement of the em' gene (3, 13, 27). Studies with 
chimeric proviruses have formally identified the ellv gene as 
the major determinant responsible for differences in biolog-
ical properties such as cellular tropism and cytopathogenic-
By (24, 28). 
We previously described the generation of a panel of 
phenotypically distinct yet genetically highly homologous 
infectious molecular HIY-l clones (13). These molecular 
clones were derived from HIY-l isolates, mostly recovered 
by direct clonal isolation, from a single individual who 
developed AIDS within half a year after seroconversion. TIle 
clones were obtained from patient peripheral blood mono-
• Conesponding author. 
nuclear cells collected at about the time of transition from an 
NSI to an SI HIY-l phenotype. AJi eight clones were able to 
replicate in peripheral blood lymphocytes. The molecular 
and biological HIY-l clones exhibited differences in Sl 
capacity and in tropism for T-cel! lines and monocyte-
derived macrophages (13, 27). To genetically compare phe-
notypically heterogeneous HIY -I variants and to analyze 
regions of the HIY -I em' gene previously identified as 
determinants of biological properties, we analyzed eight 
envelope sequences obtained from four infectious molecular 
HIY-l clones (13) and from four biological HIY-} clones 
through polymerase chain reaction amplification (1). In 
addition, we determined the sequences of the accessory 
genes of the four molecular clones. The biological pheno-
types of the four molecular HIY-l clones and the four 
biological clonal HIY-l variants are shown in Table 1. 
Clones 320.2A 6, 320.2A 3, 320.2A 2.1, 320.2A 1.1, 320.2A 
1.2, 32Q,2A 5, 320.2A 7, and 320.3 1 will be referred to as 
clones 6,3,2.1, 1.1, 1.2, 5, 7, and 1, respectively. 
Although the Sf HIY-l clones differed in their abilities to 
replicate in the H9 and Sup Tl T-ceH lines, all Sf clones 
productively infected the f>,rr-2 T-cel! line, whereas NSf 
HIY-l clones did not infect the MT-2cellline (Table 1). This 
finding is in accordance with the strong correlation between 
the abilities of field isolates to induce syncytia and tropism 
for the MT-2 cell line (20), SI capacity also appeared to be 
required, although not sufficient, for H9tropism (Table 1). In 
contrast, Sup Tl tropism was also observed for NSf clones, 
indicating that entry in Sup Tl cells is at least partially 
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TABLE 1. Diological phenotypes of biological clonal HIV-l variants and molecular mV-l clones derived from a single individual 
Gone no.~ Transmission 10: 
Patient PllMC' PBL MT-2 H9 Sup T1 
sample Si' MDMfor Biological Molecular 
replicaliond Rep1!cation~ SI Replication SI RepUcation $I 
320.2A 6 + NT 
3 NT 
2 1 ++ + 
1 1 + ++ + 
2 (+) ++ + 
5 + ++ + NT + + NT 
7 + ++ + + + + + NT 
320.3 + ++ + ++ + ++ + + 
a PBMc, peripherat blood mononuclear cell. 
b Biological clonal HIV.I isolates were obtained from palielll PBMC sample na.2A, and molocular clonC3 were derived from biological clonal HIV-J isolates, 
except for clone l. 
"PDL, peripheral blood lymphocyte; -, no syncytia observed; (+), reduced SI capacity; +, S1. 
d MDM, monocyte-deriv(d macrophages; -, nol transmissible; +. trans~sible; NT, not tested.· 
e _, nqt tcan.mllsslble; +. delayed growth kinetics; ++, readily transmL~ible; NT, not tested. . 
independent of the mechanisms involved in syncytium for-
mation. Compared with clones 2,1 and 1. clones 5 and 7 
exhibited delayed growth kinetics in the H9 and Sup Tl 
Tcell Jines, In contrast to NSf Sup Tl-tropic clone 2,1, NSI 
clone 6 replicated less efficiently in the Sup 1'1 cell line, 
The alignments of the deduced amino acid sequences of 
the accessory genes are shown in Fig. 1. Except for the vpu 
gene of clone 1, which did not contain a methionine start 
codon, the reading frames of all sequenced genes encoded 
full-length proteins. In contrast to the other thre~ molecular 
clones, which were obtained from biologically clonal in-
fected peripheral blood lymphocyte cultures, clone 1 was 
obtained from infected H9 cells (13), A nonfunctional VPll 
gene is often found in molecular HIV-l clones derived from 
cell lines (23). The maximum amino acid sequence variability 
for the separate HIV·1 genes is shown in Table 2, The vif, 
vpr, and lief genes showed only minor amino acid variation 
(1.0, 1,0, and 1.9%, respectively), confinning the genetic 
relationship of these clones (Table 2 and Fig, lA, B, and F). 
In contrast, the tat, re)', and vpu genes showed a maximum 
amino acid variability of 7.9, 10,2, and 8,6%, respectively 
(Table 2). The amino acid variability in the tat geQe was 
concentrated in the second exon (exon I, 4,2%; exon 2, 
17.2%) of this regulatory gene, which is located within the 
ellv gene, This amino acid variation, however, was not 
phenotype associated, In spite of the prominent amino acid 
variation in the tat and rev genes, the tat and rev proteins 
were completely homologous in regions thought to be critical 
for their functions (Fig, Ie and D) (9, 12, 14, 17,22,26), This 
is compatible with the finding that th~ clones did not exhibit 
significant differences in replication rate in peripheral blood 
lymphocytes (13), Although the sequence variability in the 
vpu gene was completely restricted to NSI clone 2,1, the 
absence of the initiator methionine codon of the VPIl gene in 
Sl clone 1 indicates that the vpu gene is not required for 
syncytium induction or for replication in T-cell lines and 
primary monocytes (Fig, IE and Table 1), 
Alignments of the deduced amino acid sequences of the 
elU' genes are shown in Fig, 2, Given the fact that all clones 
except clone 1 were derivcd from the same time point, the 
level of variation (up to 14.9% (Table 2]) was surprisingly 
high, Closer inspection, however, revealed t~e existen<;e of 
four distinct domains within the ellv gene (teoned A through 
D in Fig, 3), For each separate domain, the sequences of the 
eight clones fell apart into two distinct clusters (intercluster 
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variation, 11 to 30%) with high internal similarities (96 to 
100%), In each of the eight clones, the alleles of these four 
domains were combined in a unique manner, implying that 
exchange of genetic material had occurred, In particular, 
clones 1.1, 1.2, and 2,1 appeared to result from recombina-
tion events between a clone similar to clone 6 or 3 and a 
clone similar to clone 5 or 7 (Fig. 2 and 3), Clone 2,1 
possessed striking sequence similarity to clones 6 and 3 
between amino acids (aa) 81 and 426 (domain A in Fig. 3) and 
to clones 5 a.nd 7 between aa 653 and 705 and aa 852 and 863 
(domains C and D in Fig, 3), Clones 1.1 and 1.2 are highly 
similar to clones 5 and 7 between aa 87 and 426 (domain A in 
Fig, 3), to clones 6 and 3 between aa 599 and 138, and to 
clone 3 between aa 852 and 863 (Fig, 2 and 3), The transitions 
of sequence similarity between the HIV -1 variants were also 
observed at the nucleotide level (data not shown). Previ-
ously, it has been demonstrated that genetic recombination 
evepts between HIV -1 proviruses can occur in vitro (5), 
Since the env genes studied belonged to single-clone HIV-l 
isolates recovered directly from patient peripheral blood 
mononuclear cells under limiting dilution conditions, these 
findings imply that recombination events occur in vivo as a 
mechanism to generate clonal diversity. 
TIle env gene has been identified as the major determinant 
responsible for differences in biological properties (24, 28). 
To investigate whether in this set of molecular HIV-1 clones 
the ellv gene is involved in determining differences in the 
capacity to induce syncytia and cytotropism, chimeric pro-
viruses were constructed. In the chimeric provirus 320.2A 
1.2 ellV 2,1, an NsiI-XhoI fragment of clone 2.1 coding for 
amino acid residues 108 to 813 of the ellv gene and amino 
acid residues Ito 43 of the lief gene was exchanged for the 
corresponding fragment of the Sup Tl-tropic NSf clone 2,1. 
In the chimeric provirus 32Q,2A 1.2 env I, the same fragment 
was replaced by the corresponding fragment of the H9- and 
Sup Tl-tropic SI clone 1. Construction of the chimeric 
proviruses and determination of the biOlogical properties of 
these constructs were performed as described elsewhere (13, 
28), The finding that these two chimeric proviruses, with 
variations only within the env coding sequence, were differ-
ent in their SI capacities and tropisms for the MT-2 and H9 
T-cell lines provided proof that these phenotypic traits arc 
conferred by determinant.s in the env gene (Table 3). 
Comparison of the biological phenotypes of the eight 
clones and their differences in efW gene sequence composi. 
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FIG. 1. Alignment of the predicted amino acid sequences of the ~'if (A), ~'pr (n), tat (C), ,n' (D), ~Pll (E), and nef (F) proteins of the 
molecular HIV-l clones 2.1, 1.1, 1.2, and 1. For the biological clonal HIV-l variants 6, 3, 5, and 7, the amino acid sequences of the second 
exons of the tat (C) and ,e~' (D) genes are shown. Sequence analysis was performed by the dideoxycbain tennination metbod using Sequenase 
(USB). Amino acid alignments were performed by using CLUSTAL (16). The predicted amino add sequences are presented in the one-leiter 
amino acid code. Amino acid numbers are indicated. Dashes indicate amino acid identities, whereas points indicate gaps. Functional regions 
of the tat and rev proteins are indicated. al, cysteine-ricb region and proposed metal-binding region, which may mediate protein· protein 
interaction; bl, possible activation domain; c1, nucleolar localization signal and putative nucleic acid-binding region; aZ, region involved in 
nuclear localization and transactivation; b2• nuclear localization signal possibly involved in binding to the rev responsive element; c2, region 
near amino acid residues 78 and 79 involved in transactivation. 
tion revealed a remarkable association between particular 
phenotypic traits and each of the four domains described 
above. On the basis of their sequences in the gp120 CI-V4 
region (domain A in Fig, 3), the clones clustered into two 
groups, each with >98.5% internal homology, with one 
containing all SI MT-2-tropic clones and the other compris-
ing all NSI non-MT-2-tropic clones. On the other hand, all 
H9-tropic clones clustered in the same group for domains A, 
C, and D, in contrast to all non-H9-tropic clones. In addi-
tion, clone I, replicating '/lost efficiently in H9 celis, had a 
unique sequence betwee!l' 426 and 535 (domain B). The 
Sup TI-Iropic clones 2.1, 5, 7, and 1 clustered in domains C 
and D. Clone 6, which replicated inefficiently in Sup Tl cells, 
clustered only in domain D with clones 2.1, 5, 7, and 1. 
Finally, clones that could not be transmitted to H9 or Sup Tl 
cells (3, 1.1, and 1.2) clustered in domains B, C, and D (100% 
similarity in all three regions), regardless of their abilities to 
induce syncytia or their MT-2 tropisms (Fig. 3). This indi-
cates that the CI-V4 region of the gp120 molecule is respon-
sible for differences in the capacity to induce syncytia and 
tropism for the MT-2 T-cell line, whereas determinants of 
tropism for the H9 and Sup Tl T-cell lines are located 
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FIG. 2. Alignment of the env proteins of molecular and biological clonal mV-l variants 6, 3, 2.1, 1.1, 1.2, 5, 7, and 1. Sequence analysis 
was performed by tile dideoxy chain tennina{ion metllod using Sequenase (USB). AmIno acid alignments were performed by using 
CLUSTAL (16). Final aiJ'gnments were adjusted by the eye. The predicted amino acid sequences are presented in tile one-letter amino add 
code. Amino add numbers are i.ndicated. Dashes indicate amino acid Identities, whereas points indicate gaps. The signal peptide, 
hypervariable regions (V), constant regions (C), and gp120-gp41 proteolytic cleavage site are i.ndicated. 
downstream of aa 426 in the C-temlinal portions of the gp120 
and gp41 molecules. Although there is an association be-
tween particular phenotypic traits and the overall patterns of 
amino acid sequence arrangements in the four domains 
described, it remains possible that single amino acid alter-
ations are responsible for the observed phenotypes. How-
ever, this possibility is heard to reconcile with the observed 
stability of recessive phenotypic traits of these clones in 
vitro. 
Previous studies have identified regions of the gp120 
glycoprotein involved in CD4 binding and a~sociation with 
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the gp41 transmembrane glycoprotein. Amino acid residues 
Thr-272 and Trp-439 in hydrophobic domains of the C2 and 
C4 regions and amino acid residues Asp-381, OIu-383, and 
Asp-469 in hydrophilic domains of the C3 and C4 regions 
appear to be important for CD4 binding (25). Amino acid 
residues Val-38, Tyr-42, Trp-41, lIe-501, and Lys/Ala-5161 
511 located at the amino and carboxyl termini of the gp120 
molecule contribute to the noncovaJent association with the 
gp41 molecule (15, 19). The corresponding residues as well 
as the residues directly adjacent were completely conserved 
among the eight clones, except in clone 1, which possessed 
TABLE 2. Maximum amino acid variability present in accessory 
and em' genes of phenotypically divergent HIV-l variants 
Gene VariabiJity" (%) 
vi!,., .. , .. ,." ..... ,", ....... , .. ,"',., ..... ,', ..... ,', .... ,", ... ,' 1,0 
vpr""" .. , .. " .. ,.................................................. 1.0 
tat ...... , ................... " ..................................... " 7.9 
rev"" ... """ ...... """" ................. "".... 10.2 
~pu ................. , ........ . , .. , ... ""._" .. ,.,., ... "" .. "", .. , 8.6 
env..................................................... ............. 14.9 
ne!...................................................... ............ 1.9 
a Variability was determined for the accessoTY genes of the four molecular 
H1V-l clones and the env genes of the four molecular HIV·l clones and the 
four biological HIV-l clones. 
a Yal instead of an lie at position 507. Moreover, all clones 
exhibited an Arg instead of a Lys at position 516 (Fig, 2), 
The amino terminus of gp41, which resembles the fusion 
peptides of ortlIo- and paramyxoviruses (11), has been 
proposed as a determinant of SI capacity (2, 21). However, 
the sequence identity between NSI clones 6 and 2.1 and SI 
clones 1.1 and 7 excludes the possibility that this region is 
the sole determinant of syncytium formation, 
Recent studies indicate that the Y3 loop not only is 
involved in type-specific neutralization hut also might he a 
determinant of biological properties such as C}10pathic prop-
erties and cellular tropism. Amino acid changes in the tip of 
the Y3 loop affect the capacity to induce syncytia and alter 
cellular tropism (6, to, 29). A high degree of sequence 
variation within the V3 loop was observed between the 
groups of NSI and SI clones, Recently, we have shown that 
SI HIY-l variants contain V3 sequences with significantly 
(Jp120 ENV gp41 
A B C 
IH H 
3202A 6 -'I I 
320.2A 3 L-, 0 
3202A 21 c::::~O 101 
3202A 1 t 
32Q2A12 
3202A 5 
3202A 7 
320.3 
0 
H 
101 
101 
PBI Transmission t0 2 
SI' MT2 H9 SupTt 
H 
H 
1'1 H 
H NT 
H , 
H H H 
FIG. 3. Amino acid sequence similarity in em' gene glycopro-
teins oflhe eight phenotypically heterogeneous HIV-l variants 6, 3, 
2.1, 1.1, 1.2, 5, 7, and 1. Sequence similarities are indicated by 
identical patterns. The minimum sequence similarities in regions 
with identical patterns are 98.5% for domain A (aa 87 to 426), 100% 
for domain B (aa 426 to 535),96% for domain C (aa 653 to 705), and 
100% for domain D (aa 852 to 863). Biological phenotypes of the 
corresponding molecular and biological clonal HIV-l variants are 
indicated, 1_, no syncytia observed; (+), reduced SI capacity; +, 
SI. 2_, not transmissible; +, delayed growth kinetics; ++, readily 
transmissible; NT, not tested. 
TABLE 3, Biological properties of wild-type and 
chimeric mV-l proviruses 
Molecular Transmission tif: 
clone SI in PBLa MT-2 SupTl 
"' 
2.1 + 
1.2 1+1 + 
1 + + + + 
1.2eflv2.1~ + 
1.2 env l~ + + + + 
a PBL, peripheral blood lymphocyte; -, no synC)1i~ observed; (+), reo 
duced SI capacity; +, ST. 
b _, not transmissible; +, transmissible. 
< aa 106 to 873 of the HIV·} em' gene and the liTht 34 aa residues of the 
HIV-I m:fgene were exchanged. 
higher positive charges than those of NSI HIV-1 variants (8). 
In the highly variable Y3 domain, two amino acid residues 
located on either side of the Y3100p are responsible for these 
differences in charge. In NSI HIY-l variants, these two 
residues arc negatively charged or uncharged, whereas in SI 
HlY+l variants, one or both arc positively charged. This 
correlation is also observed in the presently studied NSf and 
SI HIY-I variants (Fig. 2, aa 321 and 335). Experiments with 
chimeric proviruses suggested that the Y3 loop is also a 
determinant for tropism for T-cell lines and primary mono-
cytes (18, 24, 28, 32). However, the SI HIY-1 variants 
analyzed in the present study, which differ from cach other 
in their tropisms for the H9 and Sup T1 T-cell lines and 
primary monocytes, possessed completely identical Y3 re-
gions (Fig. 2). 
Analysis of these eight HIV+1 clones demonstrated exten· 
sive phenotype-associated sequence variation dispersed 
nonrandomly over the ell\' gene. The observed considerable 
genetic distances between clones with different phenotypes 
may explain the stability of viral phenotypes' even after 
prolonged propagation in vitro. Four clones with intermedi-
ate phenotypes most likely were the products of genetic 
recombination events in vivo, indicating that this mecha· 
nism, next to mutations resulting from errors during reverse 
transcription, may account for the emergence of proviruses 
with novel phenotypic properties during the course of the 
HIY-1 infection (31), 
In agreement with previous reports (24, 28), the ell\' gene 
appeared to be the major determinant responsible for differ-
ences in biological properties. The amino acids previously 
shown to be involved in gp120-CD4 binding and gp120-gp41 
association and their directly surrounding residues were 
completely conserved among these eight clones. This argues 
against variation in gp120-CD4 binding affinity or variation in 
gp120 shedding as a cause of differences in the capacity to 
induce syncytia or cytotropism. 
Sequence variation associated with SI capacity and tro-
pism for the MT-2 T-cell line was concentrated in the CI-V4 
region of the gp120 glycoprotein. In contrast, sequence 
variation associated with tropism for the H9 and Sup Tl 
T-cell lines was completely limited to the gp120-V5 region 
and the gp41 glycoprotein. In contrast to observations with 
other HIY-l clones, the Y3 region of the gp120 molecule of 
these clones appeared not to be critical for their tropisms for 
primary monocytes and the H9 and Sup Tl T-cell lines. This 
finding demonstrates the existence of additional determi-
nants for cytotropism next to the Y3 loop, most probably 
located within the gp120-Y5 region and the gp41 molecule, 
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To llIap the regions orlhe external enw-Iop" glycoproleins of human immunodeficiency yirus type 1 (IlIV·I) 
inYoh'ed in the pro(t'ss of memhrane fusion. we determined the S)'llc),UullI.indudng capacity of a panel of 
Iransicllily eXIJressed chimeric envelop!: genes. This panel was genl'rated by exchanging gene fragments 
between four pre\'lously studied conlope genes that cxhibHcd a 111gb degree of sequence homolog)' yel displayed 
marked differences In s;\'JlC}1iulll·inducing capacity nhen expressed by recombinant yaccinia yirus. The resulls 
demonstrate tbat mUlliple regions of the H[V-l enwlope glycoprotelns are In,"olwd in S;\'JlC}1ium formal ion. 
Some fragments, most notably those containing the V2 or V3 region, can transfer S;\'JlC)1ium·inducing capacity 
10 enwlope proteins preyiously 1I0t capable of Inducing syncylla. Moreoy(~r. It Is shonll Ihat sllch regions 
funcllonall;\' interact \lith other em'elope regions, especially one encompassing the V4 and V5 regions ofgp120 
or II region encompassing IJart of gp4l, to exert their function In membrane fusion. 
Human immunodeficiency virus type 1 (HIY-l) enters the 
cell through a multistep process. Binding of the viral external 
glycoprotein gp12U to the cellnlar receptor CD4 ultimately 
results in fusion of the viral envelope and the cellular 
membrane (6, 22). A similar fusion process between HIV-l-
infected cells expressing viral envelope glycoproteins and 
(uninfected) cells expressing CD4 may lead to the formation 
of syncytia (23, 29). 
HIY-l isolates differ in their capacity to induce syncytia in 
vitro_ On the basis of both this capacity and other in vitro 
biological properties, such as replication rate and cytotro-
pism, syncytium-inducing (SI) and non-S! (NSI) HIY-l 
isolates afC distinguished (35)_ T1lese two categories largdy 
overlap with the "rapid-high" and "slow-low" viruses, 
respectively, described hy others (10). The bolation of 
I-IIY-l varionts with an SI phenotype correlotes with the 
subsequent rapid decline of CD4 t cell numbers and progres-
sion to AIDS (4, 21, 36), which suggests thot the emergence 
of viruses with a cytopathic SI phenotype plays a rolc in the 
pathogenesis of AIDS. Dissection of thc process of mem-
hrane fusion that leads to syncytium formation may contrih-
ute to our understanding of its role in HIV-J biology and 
pathogenesis. 
HIY-l envelope glycoprotcins contain :111 of the viral 
information required for syncytium formation (22, 34), and 
several of the detefminants that mediate the underlying 
membrane fusion process have been identified. Genetic 
variation in such determinants could theoreticalty result in 
differences in Sf c:lpacity between different HIV-l envelope 
genes. For efficient hinding to the cellular receptor CD-l, an 
intact CD4-hinding region is needed. Amino acid residues 
involved in CD4 hinding are scattered among at least four 
different regions of gpl2U (26). The potential effects of 
variation in these regions on syncytium formation has not 
yet been studied in detail. Syncytium formation by hoth 
• Corresponding author. 
simian immunodellciency virus and HIY~l envelope genes 
could be experimentally manipulated by introducing muta-
tions in the fusion domain at the amino terminus of the 
transmembrane glycoprotein gp41 (2, 12). Although natural 
sequence variation in the fusion domain of SI and NSI 
isolates was also found, such variation docs not contribute 
significantly to the differences in sync}1ium formation (1). 
Naturally occurring sequence variation in the Y3 loop, 
however, docs seem to be relevant for the differences in the 
capacities of HIV-l isolates to induce syncytia. Site-directed 
mutagenesis experiments have demonstrated a direct role for 
this region in HIY-l-induced membrane fusion (13, 27), and 
genetic exchange experiments between molecular clones of 
HIY-l with different Sf capacities have shown that such 
differences may map to the Y3 region (5, 8). This same 
region also contains determinants that control HIY-l cell 
tropism (20). Taken together, these data suggest a pivotal 
role for the V3 region of HIY-l envelope. 
Neutralizing antibodies directed against both the CD4-
hinding region and the Y3 region have been described 
previously (16, 17, 28, 30, 32, 37). Such antibodies exert their 
function upon binding to their target sites either by inhibition 
of CD-l binding or through interference with an essential step 
in the process that leads from CD4 binding to fusion. 
Neutralizing antihodies that are directed against envelope 
regions for which no function in the membrane fusion 
process is known {e.g., the Y2 region [141 or the central 
region of gp41171l have also been described. These data and 
the results of studies employing site-directed mutagenesis 
(19, 38) suggest that other regions than those described 
ahove may be involved in the membrane fusion process. 
Nevertheless, in studies in which gene fragments are ex-
changed between pairs of molecular clones with different SI 
capacities, the determinants involved arc repeatedly mapped 
to an envelope gene fragment that always includes the Y3 
region that has already been identified (5, 8). In an attempt to 
screen for additional membrane fusion-mediating determi-
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FIG. 1. Positions of the generated gene fragments relative to the 
complete envelope gene (top bar). The hypervariab1c regions Vl to 
V5, fusion domain (FD), cleavage site (arrow), and the restriction 
enzymes u~ed are shown. The gene fragments are named after the 
flanking restriction sites. 
nants, we performed the mapping experiments described in 
this report. 
The starting material for this study consisted of four 
complete HIV-l envc[ope genes described elsewhere (1). 
Since these envelope genes were obtained from one patient 
at a single time point, these genes arc highly related geneti-
cally, yet they displ<lY heterogeneous SI capacities: two 
induce syncytia in peripheral blood mononuclear cells and in 
SUP-Tl celis, whereas the two others do not. We have 
generated 40 chimeric envc[ope genes, mainly between SI 
and NSI envelope genes, and tested these genes in a syncy-
timn-forming assay. Our rcsults demonstrate that multiple 
regions of the HIV-1 envelope glycoproteins control SI 
capacit}'; most notably, those regions that contain the V2 or 
V3 region can transfer SI capacity to envelope proteins 
previously not capable of inducing syncytia. Moreover, (Jur 
data show that the capacity of the V2 and V3 regions 10 
mediate syncytium formation also depends on additional 
envelope regions encompassing the V4 and V5 regions of 
gp120 or a region encompassing part of gp41. 
MATERIALS AND METHODS 
Construction of chimeric t'nwlope gt'nes. Four previously 
characterized HIV-l envelope genes from biological clones 
obtained from patient 16 at a single time point and designated 
16.1 to 16.4 (1) were used to generate a set of chimeric 
envelope genes. These parental genes were originally doned 
in the pSCll vaccinia virus expression vector (3) and in the 
plasmid pOEM7- (Promega). Chimeric envelope genes were 
constructed by exchanging gene fragments generated with 
restriction enzymes (NdeI, Spel, StilI, HilldII, eVIII, and 
Al'lll) with conselVed restriction sites in all four envelope 
genes and the restriction enzymes Xlwl and Xmal, which 
provide convenient sites in the doning vectors, as depicted 
in Fig. L The resulting envelope chimeras are designated 
according to the exch<lnged gene fragment and the two 
parental envelope genes (sec Fig. 3). All chimeric envelope 
genes were tested by restriction mapping using restriction 
sites that were not conserved in the original four envelope 
genes. Occasionally, chimeric envelope genes were partially 
sequenced to verify the doning procedure. 
Cloning of chimeric envelope genes in transient expression 
60 
yector. The chimeric envelope genes were cloned in the 
simian virus 40-based expression plasmid pSRHS (a gener-
ous gift of Eric Hunter, University of Alabama at Birming-
ham, Birmingham (9]). TIle HIV CillO gene sequences were 
cloned by exchanging the original em' gene of HXB2 with 
KplII and Sma! restriction enzymes (Fig. 1). All the ex-
pressed chimeric envelope genes thus contain the signal 
peptide and the first 13 amino acids of the HXB2 envelope 
protein. 
DNA lransfection and syne.ytium formallon assay. All gen-
erated constructs were transfecled in CEMx174 cells (31) by 
electroporation. Five million cells were mixed with 20 tJ.g of 
DNA in 250 tJ.1 of RPM! medium (GIBCO) supplemented 
with 10% fetal calf serum (FCS) in a 4-mm-wide electropo-
ration cuvette (Eurogentec S.A.). After electroporation (200 
V, 960 IlF; Bio-Rad gene pulser), the ceUs were kept on ice 
for 10 min and then transferred to small culture flasks 
containing 10 011 of RPMI medium. Forty-eight hours after 
electroporation, viable cells were isolated on a Ficoll density 
gradient, and 2 x 105 of these cells were cocultured for 16 h 
with an equal amount of SUP-TI cells (33), Syncytia were 
only found after cocultivation. 111e rdative sizes and num-
bers of syncytia found in each culture were scored indepen-
dently by three researchers. The size of syncytia was quan-
tified as follows: small (+), up to live times the size of single 
cells; large (+ + +), giant syncytia estimated to contain over 
100 fused cells (scored as being larger than 250 tJ.m in 
diameter), or intermediate (+ +). For examples of syncytium 
size, see Fig. 2. 
l'II~' exprt'ssion. At the time that the cultures were scored 
for syncytium formation, separately cultured portiuns of the 
Ficoll-purified cells were treated as follows: (i) spotted onto 
microscope slides and fixcd with icc-cold ethanol (70%) for 
immunofluorescence and st{Jfed at -2WC and (ii) lysed with 
1% empigen BB (25) and frozen at -7(PC for enzyme-linked 
immunosorbent assay. Finally, a sample of the culture 
supernatants was frozen and also tested in an ELiSA. 
(I) Immunofluorescenct'. The percentage of envelope pro-
tein-expressing celis was determined by an immunofluores-
cence assay. The fixed cells on microscope slides were 
incubated with patient serum (1:70 dilution) and exposed to 
fluorescein isothincyanate (FITC)-conjugated sheep anti-
human immunoglnbulin 01. The percentages of positive 
cells were scored with a fluorescence microscope. 
(II) gp120 ELISA. To determine the relative amounts of 
envelope protein produced in the different transfected cell 
cultures, a gp120 ELISA that is based on un assay developed 
by Moore et aL (24, 25) was used. Capture antibodies D7324 
(Aalto BioReagents, Dublin, Ireland) were adsorbed on to 
ELISA plates (Costar) by incubation overnight in 40 mM 
NaHCOj , pH 9.6, at 4cC. 07324 is an affinity-purified 
polyclonal sheep antiserum to the conserved carboxy-termi-
nal 15 amino acids of gp120. TIle predicted amino acid 
sequences of the four envelope genes used in this study arc 
completely homologous to this peptide (1). Unbound anti-
bodies were removed by washing each well four times with 
200 tJ.1 of the assay buffer (0.1 M NaC!, 0.1 M Tris, 0.1% 
Tween 20, pH 7.5). All incubations were performed for 1 h at 
37'Cwith assay buffer supplemented with 1% FCS and 0.5% 
normal goat serum and terminated by washing each well four 
times with 200 111 of assay buffer unless stated othenvise. 
The wells were subsequently blocked with assay buffer 
supplemented with serum. Next the wells were incubated 
with lOO-tJ.1 portions of a !)erial dilution of cell lysate or 
culture supernatant for 2 h. Detection of the attached gp120 
was achieved by successive incubation of the wells with the 
FIG. 2. Syncytia induced upon cocultivatinn (If transfectcrl 
CEl\lx174 cells with SUP-Tl cells. (A) No syncytia; intermediate-
size ~yncylia (B); and large ~yncylia (C). 
following: a 1:2,000 dilution of patient serum, a 1:2,000 
dilution of biotinylated goat ilntihuman IgO (Amersham), 
and streptavidin-horseradish peroxidase conjugate (strepl-
ABComplex!HRP [Dako A!S)). Finally, the pliltcs were 
incubated with tetramethylbcnzidine-H20 2• The rcaction 
was stopped by adding 50 fll of 2 M H 2S04 , and the oplical 
density ilt 450 nm was read with a Titertck Multiskiln (Flow 
Laboratories). All gpl20 ELISA values for the different 
constructs were rdatcd to each other and expressed as a 
percentage of the nlaximum value measured. The assay can 
routinely detect 20 pg of recombinant gp120 (Cell tech, 
provided to us through the Medkal Rcsearch Council AIDS 
reagent project). 
(iii) cn .. ELlSA. The CD4 ELISA used was very similar to 
the gp120 ELISA described above. 111e only difference was 
that the envelope proteins arc now captured to the solid 
phase by binding to attached CD4. Recombinant soluble 
CD4 (100 nglwell; American Bio-Technologics; provided 10 
us through the Medical Research Council AIDS reagent 
project) was adsorbed on to ELISA plates (Costar) by 
incubation overnight in phosphate-buffered saline (pH 7.2) at 
4cC, All subsequent incubations were performed as de-
scribed for the gpl20 ELISA, except that the detecting 
patient serum was diluted 1:3,000. 
Nucleotide sequence accessIon numbers. The GenBank ac-
cession numbers for the envelope gene sequences derived 
from biological clones 16.1 to 16,4 arc L08655 to LOS65S, 
respectivcly. 
RESULTS 
Construction of chimeric' cnn:lopc genes. Chimeric enve-
lope genes were constructcd from the four parental envelope 
genes 16.1, 16.2, 16.3, and 16,4 described elsewhere (1). We 
exchanged sL" different fragments between these four paren-
tal envelope genes to gcnerate the 40 chimeric envelope 
genes (Fig. 1 and 3). Thc chimeric envelope genes were 
expressed in CEi\.fx174 cells in transient expression experi-
ments. 
Expression ofgpl20. Expression of the envelope protein in 
the transfeded cells was monitored by ELISA and immuno-
fluorescence. Tn Table 1, the relative amount of gp120 
produced (ccll associated and shed in the culture medium) is 
listed for ellch construct tested. The percentage of HIV-I 
envelope protein-expressing cells in the population of trans-
fected CEMx174 cells varied from 0.6 to 4.6% of the total 
(Table I). 
CO" binding of expressed gp120. By inlmunoprecipitation 
we have previously shown {hilt all four parental envelope 
gene products were able to bind soluble CD..t (1). For the 
present study, we also tested the expressed chimeric enve-
lope proteins for their ability to bind CD4. All chimeric 
envelope proteins produced upon transfection of the gener-
ated constructs were able to bind CD4, as demonstrated by 
the CD4-binding ELISA (results not shown). Tlie exchange 
of envelope gene fragments <lpparently did not interfere with 
the CD..t-binding abilities of these expressed gene products. 
SI capacities of cxpressed en \'elope genes. In a previous 
study (I), we have shown that upon exprcssion in a recom-
biniJnt vaccinia virus, the two parental SI envelope gene 
products 16.1 and 16.2 induce synl-'}'tia in SUP-Tl cells, 
whereas the NSf envelope gene products do not. For the 
expcriments described here, we therefore used SUP-Tl cells 
as CD4-positive fusion partners. Upon transfection of 
CE1\..fx174 cells and subsequent cocultivation with SUP-Tl 
cclls, almost all expressed envclope chimeras gave rise to 
the formation of syncytia. The sizes of the induced syncytia 
differed substantially for the different constructs and were 
highly reproducible. We have defined the SI capacity of the 
chimeric envelope gene products as the maximum size of the 
syncytia they induce in SUP-Tl cells. Within any range of 
the quantitative parameters shown in Table I, small and 
large syncytia were observed. These results indicate that 
syncytium sizc is a qualitative property of the (chimeric) 
envelope and that the syncytium size is not dependent on 
experimental variables that inJIuence the umount of envelope 
proteins produced at least not within the range observed in 
these experiments. 
Figure 3 shows the SI capacities of all generated chimeric 
envelope constructs. Thc data presented are derived from 
single representative cxperiments. Several control experi-
ments were pcrformed, induding multiple testing of thc 
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TABLE 1. QUilntitative expression of gpl20 by ((:himeric) 
envelope genes and sizes of the induced syncytia 
fnl' Syncytium Envelope protein. gp120 
rode~ sizeh cxpre%ing cells ELISA (%r by IFA (~~f 
16,1 +++ 2.6 18 
16.2 +++ 1.9 42 
16.3 3.8 J6 
16.4 2.7 27 
12XS ++ NT 76 
2lXS +++ 1.9 23 
12NC +++ 1.7 17 
21NC +++ 3.4 23 
12HC +++ 4.1 45 
12AX +++ 2.2 23 
21AX +++ 2.8 20 
13XS ++ 3.3 36 
14XS ++ 1.3 27 
13SS ++ NT 52 
14SS ++ 2.0 22 
31SA. +++ 0.6 38 
3lAX +++ 1.0 67 
31HC +++ 4.6 100 
14NC +++ 2.9 2S 
13SA +++ 1.6 77 
USA +++ 2.3 2S 
31XS +++ 1.8 45 
41XS +++ 1.8 19 
13JfC +++ 2.7 28 
14HC +++ 4.2 39 
13AX + 0.9 54 
31NC ++ 3.7 58 
41NC + 3.2 69 
24XS ++ 1.8 29 
23XS + 1.2 44 
42SA ++ 1.5 38 
23HC ++ NT 30 
23NC + 2.6 26 
42NC + 1.9 31 
32NC ++ 3.3 26 
24AX 1.5 29 
42A.,'( +++ 1.8 45 
J2AX +++ 1.2 18 
42HC +++ 1.8 42 
42SSCX +++ 1.5 25 
32HC +++ 3.3 50 
24SA +++ 1.3 34 
23SA +++ 4.6 31 
32XS +++ 1.9 80 
d Chimeric genes were IHilled M) that the n~m~ reflccts con~tnJction of the 
chimeric g~ne. ADCD is a chimeric envelope gene in which gene flagment CD 
from parental <'In' gene A is tran,ferred to gene B. TIle enwlope genes 
obtained from biological clones 16.1 to 16.4 are rderred to a.~ 1104. 
I. SI ~'~pacily of expres~ed cnwlope genes. Symbols: -, no syncytia; +, 
small S)"IlC)1ia; ++, intermediate·size ~yncyt;a; +++, lMge S)7Kytb. 
< Pen::cntage of envelope protein·expressing CE)..h174 .:ell~ as monitored in 
an immunofluorescence a<,s~y (IFA). NT, not tested. 
J Rdath,e amounl of gp120 produce<l by transfc.:te<l CE\h174 c~lls (shed 
ill .:ulture medium and ceU a~sodatcd) expre<,sed as a perc~ntage of the 
ma.ximum observed gpl20 e.xpressioll. 
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same construct and complete reconstruction of some enve-
lope chimeras. In all of these cases, essentially similar 
results were obtained. 
!\fapplng or en,'elope determinants controlling SI capacity. 
Figure 3A first shows the four parental envelope genes with 
the sizes of the induced syncytia in SUP-Tl cells. As in our 
experiments in which these same envelope genes were 
expressed by recombinant vaccinia virus, only SI clone-
derived envelope gene products were capable of inducing 
(large) syncytia (I). The same panel also lists seven chimeric 
envelope constructs in which gene fragments between the 
two SI clone-derived envelope genes (16.1 and 16.2) have 
been exchanged. With the exception of construct 12XS that 
induces intermediate·size syncytia, all constructs consisting 
of solely SI clone-derived envelope gene sequences were 
able to induce large syncytia. 
For further analysis, we divided our constructs in two 
subsets that each had sequences of one of the parental SI 
envelope genes as a common denominator. Figure 3B and C 
summarize the data for the subsets based on the SI genes 
16.1 and 16.2, respectively, which were expected to yield 
infonnation on regions that positively influence syncytium 
formation. Interestingly, dissimilar results were obtained for 
both subsets. 
Analysis of the constructs based on 16.1 sequences re-
vealed two small distinct regions containing determinants 
that are important in syncytium formation. These regions are 
the SS fragment located in the amino-terminal pari of gp120 
(Fig. 3B, top) and the central HC fragment (Fig. 3B, center). 
Both small fragments transfer considerable SI capacity from 
the 16.1 Sf envelope to both NSf envelope backgrounds. The 
16.1 HC fragment alone transforms the NSI envelopes into 
full SI envelopes upon expression. TIle 16.1 SS fragment (or 
the larger XS fragment of 16.1) by itself transfers only the 
capacity to form medium·size syncytia but in the presence of 
other 16.1-derived fragments can transfer full SI capacity 
(Fig. 3B, lOp). 
Chimeric envelopes based on 16.2 sequences show also 
that the same two distinct envelope regions ure important in 
syncytium formation. However, like the SS region of 16.1, 
now both regions transfer full SI capacity only in the 
presence of additional SI·derived sequences in the same 
chimeric envelope construct (Fig, 3C). 
DISCUSSION 
We are studying the process of syncytium formation as a 
model system to unravel the underlying mechanism of HIV-
I-induced membrane fusion. In the present study, we have 
mapped the regions of the HIV-l envelope proteins which 
determine the SI capacity. 
It has been demonstrated that syncytium formation is 
mediated by the envelope giycoproteins of HIV-I, although 
the exact mechanism has not been clarified (22, 34). In a 
previous study (1), we provided evidence that differences in 
the SI capacities of field isolates arc dependent on differ-
ences in the envelope gene itself. To avoid possible interfer· 
ence of long terminal repeat or regulatory gene functions 
with envelope·induced syncytium formation, we have cho-
sen to analyze chimeric envelope genes that arc transiently 
expressed oul of the context of the viral genome. The highly 
homologous HIV-l envelope genes that were obtained from 
a single donor at the same lime point and that were previ· 
ously analyzed genetically and functionally served as the 
basis for the experiments described here. 
Since transient expression experiments lack internal con-
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troIs for protein expression and function, we first studied the 
levels of envelope protein production and the CD4·binding 
capacity. For each lransfcetion, experimental variables, 
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amount of gp120 produced, the number of syncytia, and the 
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FIG. 3. Syncytium size induced by (chimeric) envelope gene 
prodUcts. (A) The syncytium sizes of Ihe expressed parental enve-
lope genes (16.110 16.4) which were used to generate the chimeric 
envelope genes and chimeric envelope gene products based on 
solely 51 clone·derived sequences (16.1 and 16.2). (B and C) 
Syncytium sizes of chimeric envelope genes based on envelope gene 
SI 16.1 (D) or 51 16.2 (C). At the top of each panel, the complete 
envelope gene is represented by a bar and the restriction enzymes 
used to e.,.change gene fragments are indicated. Abbreviations: FD, 
fusion domain; X (left end), XI/OI; N, Ndelj Sp, Spel; 51, Stili; H, 
Hil/dU; C, Cnll; A, AI'rTf; X (right cnd), Xmalj sync., syncytium, 
Symbols: +, small syncytia; + t, intennediate·silc synC)1iaj +++, 
giant syncytiaj -, no syncytia (for more details, sec Materials and 
Methods). 
CD4-binding capacity of the expressed recombinant protein, 
were monitored, Within any range of the quantitative param~ 
eters, small and large sYOl.:ytia were observed, which ex-
cluded the possibility that envelope protein expression was a 
limiting factor in our experiments. This notion was sup-
ported by the observation that none of the quantitative 
parameters correlated with the readouts of the experiments; 
the size of the induced syncytia appears to be a genetic trait 
of each individual construct. Finally, ull expressed (chimer-
ic) envelope proteins were able to bind CD4. 
In our approach, we have transferred fragments of SI 
envelope genes to NSl envelope genes seurching for regions 
that positively ini1uence the SI capucity. All uf these con-
structs therefore contain genetic informution from buth SI 
and NSf envelope genes. We fuund no evidence for NSf 
clone-derived envelope regions that negatively influence the 
sr capacity, but we were able to identify regions from Sl 
genes that transfer SI capacity to NSf backgrounds. The 
mapping experiments show that multiple determinants lo-
cated on several envelope gene fragments contribute to 
syncytium formation. In our opinion, the effects described 
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FIG. 4. Predicted amino acid sequences of the hypervariable region V2 together with the predicted secondary structures and charge 
differences. Amino acids identical to those of the consensus sC'quence (.) and deletions (-) are indicated. The predicted secondary structures 
of the SI and NSi gene products are al~o given, at the top and onttom of the ligure. The corresponding amino add is predicted to be in the 
following configurations; helical (H), extended stretch {El, turn (T) and coil (C). The underlined regions are predicted to have significantly 
different secondary structures for the SI and NST clone-derived V2 amino add sequences. The charges are given in boldface type. 
here are the results of multiple functional interactions be-
tween different regions of the envelope glycoproteins, we 
distinguish 51 regions (SIRs), regions which arc by them-
selves capable of transferring considerable 51 capacity, and 
enhancing regions that enhance the 51 capacity of SIRs but 
by themselves are not or hardly cupable to induce syncytia. 
Bolh the SS and HC gene fragments of the 16.1 and 16.2 SI 
envelopes can independently transfer considerable SI capac-
ity to an NSI envelope which identities these regions as 
SIRs. The 16,1 HC fragment alone is sufllcient to transfer full 
SI capacity. This SIR apparently functions independently of 
the background sequence into which it is cloned. For the 
other identified SIRs (the 16,2 HC fragment and the S5 
fragment of 16.1 and 16.2) function is context dependent: 
their SI capacity can be increased by the simultaneous 
transfer of an enhancing region, An alternative explanation 
for the described enhancements uf syncytium formation by 
enhancing regions could be a purdy additive effect, since the 
enhancing regions by themselves can also transfer some SI 
capacity to NSI gene products, However, such additive 
effects are not seen when two SIRs, e.g., the V2 and V3 
regions of 16.2, arc combined in one construct in the absence 
of an enhancing region (construct 23NC [Fig. 3CJ). It is 
therefore more likely that the effects obselVcd upon transfer 
of enhancing regions from SI genes to NSI genes result from 
the "activation" of cryptic SIRs present in the NSI back-
ground through the functional interactions postulated here. 
The SIR-containing HC fragment codes for 107 amino 
acids and encompasses the hypelVariable region V3, which 
suggests that the V3 loop region is a major determinant for 
syncytium formation for the envelope genes studied here, 
The SI clonc-derived VJ loops (16,1 and 16.2) share a 
positively charged amino acid (arginine) at position 25 of the 
V3 loop, whereas the NSf done-derived V3 loops (16,3 and 
16.4) both have a negatively charged glutamic acid at this 
position, This same phenotype·correlated amino acid varia-
lion has also been found in a large set of V3 loop sequences 
(11). The four parental genes, however, also showed consid-
erable amino acid variation just C terminal of the V3 loop 
itself. This region, which is present in the small HC frag-
ment, also contains phenotype-associated amino acid varia-
tions, e,g., the SI genes have a positively charged residue 
(lysine) at position 351, where the NSl genes have a nega-
tively charged glutamic acid residue (1). Additional experi-
ments to demonstrate exactly which residues on the HC 
fragment are respon~'ible for thc obselVed tr,lIlsfer of SI 
capacity are needed. 
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Interestingly, the extremely small SI gene-derived SS 
fragment alone is also capable of transferring SI capacity to 
an NSf gene product. This SS fragment, coding for only 71 
amino acids, encompasses part of the variable region VI and 
the complete variahle region V2, The VI region is identical 
for all four parental envelope proteins, and all amino acid 
variation of the SS fragment is confined to the V2 region. 
Constructs 24XS, 42HC, 32HC, and 42SSCX, all based on 
16.2S1 envelope sequences, demonstr;Jte that the V2 region 
is also an important determinant in syncytium formation for 
the 16.2 envelope. Examination of the amino acid variation 
of the V2 region revealed that the SI done-derived V2 
sequences differ from the NSI done-derived sequences in 
charge and predicted secondary structure. The variable 
amino acids of the SI V2 sequences are often positively 
charged residues, whereas the NSf V2 sequences mostly 
carry polar hut uncharged residues at these positions which 
results in a higher net positive charge for this region in SI 
genes (Fig. 4). Computer analysis (Garnier-Robson analysis 
[15]) shows that the variation of residues Rand 17 greatly 
affects the predicted secondary structure of the V2 loop, In 
contrast to the NSI done-derived V2 region, the SI done-
derived sequence of the N-terminal part of the V2 region is 
very likely to form a stable a-helix (Fig. 4), The importance 
of these V2100p features in syncytium formation is currently 
being tested in site-directed mutagenesis studies. A previous 
report describing the mapping of a virus-neutralizing anti-
body to the V2 region also suggested a role for the V2 region 
ill the infection process (14). Our data !>upport this notion 
and point to a direct role fOf the V2 region in I-lIV-l 
gp120-gp41-mediated membrane fusion. 
Our data suggest that the V2 and V3 regions are mutually 
independent in controlling syncytium formation: when de-
rived from 16,1, both regions transfer considerable Sf capac-
ity, with that of the V2 region further enhanced by an 
enhancing region. Similarly, the same two regions derived 
from 16.2 transfer full SI capacity when the proper enhanc-
ing region, which is the same for both, is present. l1lUs, the 
V2 and V3 regions are the primary SIRs that functionally 
interact with the enhancing regions identified here. Syncy-
tium formation can apparently be achieved through at least 
two different determinants on gp120, ami in the SI envelope 
genes studied here, both arc functional. For the V3 region, 
basie residues at positions 11 or 28 are linked to the SI 
phenotype, and all SI isolates so far appear to have this 
configuration (11). However, it is not known whether the SI 
phenotype of these isolates is mediated solely through the 
TABLE 2. SIRs " ... ith the corresponding enhancing regions 
S)'lKytium siu PlOtdn or flagment cJusing SIR induced by 
SIR e~hanced sm funcli0n 
16.1 
V2 ++ 16.1 gp-ll (AX fragment) 
V3 +++ ? 
16.2 
V2 ++1+ 16.2 CA fragment 
V3 ++1+ 16.2 ('A frJgmcnt 
V3 region or whether the V2 region also plays a role. It 
would be of interest to determine whether a consensus SI 
configuration for V2 can he found in order to answer these 
questions. 
For the context-dependent SIRs identified in this study, 
additional sequences are required for transfer of maximal SI 
capacity. The transfer of SI capacity by the 16.2 V3 region is 
enhanced by simultaneous exchange of at least the eml-
AvrIl envelope region at the carboxy terminus of gp120 
(constructs 24SA and 23SA [Fig. 3CJ). Tu increase transfer 
of SI capacity by the V2 region of the same (10.2) SI 
envelope, this CI'IlI-Avdl region hi apparently necessary 
(constructs 42HC, 42SSCX, and 32HC). This fragment con-
tains the V4-C4-V5 regions on gp120 and part of gp41. 
Interestingly, evidence for physical interaction hetween the 
C4 region and the V3 loop has heen described by others (39) 
and may well explain the obsen'ed functional interaction 
helween the V3 as an SIR and this enhancing region. 
Transfer of SI capacity by the 16.1 V2 region is enhanced 
by the AX region of the same SI gene (construct 31SA). TIlis 
same AX region from 16.1, but not 16.2, could also transfer 
some SI capacity to NSI envelope 16.3, probably through 
activation of a cryptic context-dependent SIR on 16,3. For 
an overview of the functional interactions between SIRs ami 
enhancing regions, see Table 2. 
Identifkation of any region as an SIR or an enhancing 
region heavily depends on the sequences of all other regions 
involved. Prohahly even the context-independent SIR (V3 
region 16.1) functionally interacts with the enhancing regions 
identified here, but the exact sequence of the enhancing 
region is less restricted than for the other SIRs. Cryptic SIRs 
on NSI envelope genes (for instance, 10.3) can be activatcd 
by acquisition of an enhancing region with the proper 
sequence, e.g., through recombination. We have previously 
demonstrated that recombination docs occur in vivo in an 
infected individual (18). This result means that regions 
involved in syncytium formation do not necessarily have to 
coevolve in the same virus to generate an SI variant. Even 
recombination between two NSf envelope genes, one con-
taining a cryptic SIR and the other containing an enhancing 
region could therefore lead to an Sl virus. We are currently 
testing this hypothesis. Such mechanisms greatly enhance 
the dynamics of the evolution of HIV-l. 
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Several studies have demonstrated a fUllctional role for the VI ~ V2 I"egion of 
the HIV-l cnvelope surface glycoprotein gp120 in Illclllbl'anc fusion processes 
underlying viral entry and syncytium induction. In a study with chimeric 
primary envelope genes, we have demonstrated previously that the exchange of 
V2 regions was sufficient to transfcr syncytium inducing capacity to a 0011-
syncytium inducing envelope protein. The exchanged V2 regions, comprising a 
number of variable I1lllino acids, conferred changes to both the predicted 
secondary structure and to the net positive charge of the V2 loops. In a 
syncytium forming assay based on tmnsient envelope protein expression in CD4 
positive SupTl cells, we have extended this observation by lllutating the val'iable 
positions of the V2 region to determine the relative contribution of individual 
amino acids to syncytium formation. It is shown that simultaneous mutation of 
multiple amino acids is needed to interfere with the V2 rcgion determined 
syncytium inducing phenotype. Single amino acid changes cither influencing 
charge or predicted secondary structure of the V2 loop proved to be insufficient 
to abolish V2 region controlled syncytium formation. This robust V2 
organization may allow the virus to accumulate Illutations, while ntaining it's 
biological phenotype. 
Human immunodeficiency vims type I (HIV -I) induced syncytium formation and viral entry 
are the resuit of membrane fusion processes that are both initiated by the binding of the viral 
surface glycoprotein gpl20 to the CD4 receptor molecule expressed on target cells (5,22,23,27). 
This receptor binding induces conformational changes resulting in the increased exposure of 
regions of gp120, dissociation of gpl20 from the transmembrane glycoprotein gp41, and 
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unmasking of gp41 epitopes (16,25,26,28,29). Both cellular and viral determinants involved in 
these events, thus involved in viral entry and syncytium formation have been identified. The 
principal viral determinants involved in these processes are located on the envelope 
glycoproteins (22,32) and their further identification will contribute to the understanding of the 
HIV-I induced membrane fusion processes. 
In addition to studies with mutant - mostly T cell line adapted - vimses, also studies with 
chimeric viruses have helped to identifY determinants that control the biological properties of 
HIV -I. Studies with chimeric viruses have shown that the V3 region of gp 120 is a major 
determinant for cell tropism and syncytium induction (18,31). Similarly, it has been 
demonstrated that the variable envelope regions V I and V2 are also involved in these processes 
(2,4,10,15,19,35). In a study with chimeric envelope genes generated from a small set of 
genetically highly related envelope genes, obtained from a single patient at a single time point 
we recently identified a region on the transmembrane protein gp41 determining syncytium 
formation and tropism (Andeweg el al. unpublished results). 
The V2 region together with the VI region of the surface glycoprotein gpl20 form a double 
loop stmcture through disulfide bonds at a common basis (21). In multimeric envelope proteins 
expressed at the surface of infected cells the V2 loop exposure is increased as a result of sCD4 
binding (26,29), and mutation of conserved amino acid residues of the V2 region was shown 
to interfere with the capacity to induce syncytia while sCD4 binding capacity was retained (33). 
These data collectively suggested a role for the V2 loop in a post-receptor binding event in 
membrane fusion. A fimctional role for the V2 region in membrane filsion was also suggested 
by the detection of neutralizing antibodies directed to the V2 region (6,11,13,17,24). The 
screening of a large set of V2 regions from viruses with different syncytium inducing capacities 
suggested a correlation between V2 region length and syncytium forming capacity (15). In a 
similar study we demonstrated that the increased length of the V2 region is also associated with 
the insertion of N-linked glycosylation sites through AAT triplet reiteration, suggesting a 
mechanism by which epitopes on the V2 loop are masked from immune surveillance (3). 
We have demonstrated that the variation in the V2 region alone is sufficient to considerably 
change the syncytium inducing capacity of transiently expressed chimeric envelope proteins (2). 
The exchanged V2 region harbouring a number of variable amino acids conferred changcs to 
both the predicted secondary stmcture and to the net positive charge of the V2 loops (2). In the 
present study we have extended these observations by mutating the variable positions of thc V2 
region to determine the relative contribution of individual amino acids to syncytium formation. 
MATERIAL AND METHODS 
Construction of mutant chimeric envelope genes. Previously we genetically and pheno-
typically characterized a set of envelope genes frmH biological HIV -I clones obtained from a 
single donor at a single time point that were designated 16.1 to 16.4 (1). For the present study 
we have introduced a series of synthetic V2 regions into the 16.3 NSI envelope gene. The V2 
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A 
B 
V2 region 
primer pair 1 
5' primer: 
Spe I 
5'-CTAATACCACTAGTAGTAATACCAATAGTAGTAGTTGGGGAATGATGGAGAAAGGAGAAA 
TAAAAAACTGCTCTTTCAATATCACCACAG-3' 
3' primer: 
Asp I H R 
5'-CTATTGGGACTACGTCAAGTTTATAAAAAAGTGCATGTTCTCTCCGCACCTTATCTCTTA 
A 
TGGCTGTGGTGATATTGAAAGAGC-3' 
primer pair 2 
5' primer: 
Asp IDS KIF 
5'-TAAACTTGACGTAGTCCCAATAGATAATGATAGTAAAAATATTACCAGCTTTAGGTTGAT 
H 
ACATTGTAACACCTCAGTCATTACACAGGCC-3' 
3' primer: 
Bfr I 
5'-GTTACACTTAAGAATCGCAAAACCAGCCGGGGCACAATAGTGTATGGGAATTGGCTCAAA 
GGATATCTTTGGACAGGCCTGTGTAATGACTGAGGTGTTAC-3' 
FIG.!. III panel A the cloning strategy of synthetic 16.1 based V2 regions into the NSI 16.3 envelope gene is 
illustrated. T7 DNA polymerase (SequcIl8se, USB) extended products of two mutually priming long 
oligonucleotide pairs were ligated at a designed central Asp I site and subsequently insel1ed into the NSf 16.3 
envelope gene using the V2 region flanking restriction sites Spe I and Bfr I (the latter generated by site directed 
mutagenesis) as indicated. In panel B the primer sequences used to constmct the synthetic wi 16.1 V2 region 
are given, Indicated are: the incorporated restriction sites (double underlined), the complementary regions for 
mutually priming (single underlined), and the triplets that were individually or simultaneouslY changed (bold 
printed) to produce the set of different V2 regions as shown in figure 2, For each marked wI 16.1 triplet the 
encoded amino acid is indicated in the 1 ~Ietter amino acid code. 
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regions were produced by cloning T7 DNA polymerase (Sequenase, USB) extended products 
of two mutually priming long oligonucleotide pairs as depicted in figure I panel A. The primers 
used to construct the wild type 16.1 V2 region are shown in figure 1 panel B. Mutant V2 
regions were produced by using similar primers containing the desired sequence changes and/or 
by site directed mutagenesis of yet constructed (mutant) V2 regions according to the method 
described by Deng and Nickoloff (7). The generated synthetic V2 regions were cloned into the 
16.3 NSI envelope gene using the unique Spe I restriction site (already present at a position 
corresponding to amino acid residue #144) (I). and a Bfi' I site created by site directed 
mutagenesis (located at a position corresponding to amino acid residue #242). The introduction 
of this Bfr I restriction and of the designed Asp I restriction site inside the V2 region did not 
change the predicted parental amino acid sequences. This cloning strategy resulted in chimeric 
envelope genes identical to the parental 16.3 NSI gene but coding for different V2 amino acid 
sequences as shown in figure 2. The entire cloned region of all generated chimeric-mutant 
envelope genes was sequenced to verifY correct assembling. 
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FIG. 2. Predicted amino acid sequences of the two parental V2 regions (16. I SI and 16.3 NSI) aligned with 
the generated single and mUltiple V2 region mutants. The amino acid sequences are presented in the 1 letter 
amino acid corle. Identity with the 16.1 sequence is indicated by (.), (-) represents a deletion, Charged residues 
in the SI 16.1 sequence are indicated at the top (+ or -), the net positive charge of all 
listed V2 regions is indicated at the right. The last collum lists whether an a-helical 
stmcture is predicted (+) or not (-). 
Transient envelope gene expression. All generated chimeric envelope genes were cloned 
in the simian virus 40 based expression vector pSRHS as previously described (2,8). 
Subsequently these constructs were transfected into Sup-Tl cells by electroporation. Five 
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million cells were mixed with 20 Ilg DNA in 250 III RPMI (Gibco) supplemented with 10% 
foetal calf serum (FCS) in a 4 mm electroporation cuvette (Eurogentec S.A.) and after 
electroporation (Biorad genepulser, 200 volts, 960 flF) the cells were transferred to culture 
flasks with RPMI medium. One day post transfection, viable cells were isolated on a Ficoll 
density gradient and cultured for an additional four days. At day three post transfection the 
relative expression of envelope protein was determined in both supernatant and cell lysates in 
an ELISA as previously described (2). The catching antibody D7324 (Aalto BioReagents, 
Dublin, Ireland) used in this ELISA is directed to the conserved carboxy-terminal 15 amino 
acids of gp 120, implicating that both gp 120 and gp 160 will contribute to the signals obtained. 
Finally envelope protein processing - and expression kinetics was examined by 
radioimmunoprecipitation assay (RIPA) and by testing multiple cell lysate and supernatant 
samples over time in ELISA. For RIPA: COS-7 cells transfected with the envelope constructs 
were metabolically labelled 48 hours after electroporation for 30 minutes with a mixture of 
["S] methionine and e'S] cysteine (Amersham). Cells were lysed and supernatants were 
collected at 16 and 40 hours after labelling. Inul1unoprecipitation, using 2 fIg of a pool of three 
different monoclonal antibodies; gpl3 (30), 391/95-D (14) and Kl4 (34), was performed as 
previously described (1). 
Syncytium forming assay. Previously we defined the syncytium inducing capacity of 
(chimeric) envelope genes as the size of the syncytia induced in SupT! cells since syncytium 
size and not the number of syncytia emerged in our experiments as a qualitative property of the 
expressed genes (2). Therefor each day the transfected cell cultures were examined for the 
presence of syncytia and relative sizes of the observed syncytia were quantified as small: up 
to five times the size of single cells to large: giant syncytia estimated to contain over 100 fused 
cells (scored as being larger than 250 flm in diameter) and intermediate sizes. To this end the 
cultures were examined at the respective time points, independently by three different 
coworkers. Each envelope gene constl1lct was tested for expression and syncytium inducing 
capacity at least three times in independent assays. 
RESULTS 
Construction of mutant chimeric envelope genes. Sixteen chimeric envelope genes were 
constl1lcted on the basis of the 16.3 NSI envelope gene in which a series of synthetic V2 
regions were inserted. The set of inse11ed V2 regions represents the wild type V2 sequence of 
the 16.1 SI envelope gene and mutants thereof which were mutated toward the 16.3 NSI 
sequence at single and multiple positions (Fig. 2). The transient expression of these chimeric 
mutant envelope genes allowed us to study the contribution of the observed variable amino 
acids in the V2 region to the membrane f\Jsion process underlying syncytium formation. 
Transient envelope gene expression. Expression of the chimeric envelope genes in the 
transfected cells was monitored by ELISA. In table 1, the relative amounts of gpl20/gpl60 
present at day three after transfection are listed, both for cell associated and shed glycoproteins 
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TABLE I. Relative envelope gene expression in the syncytium forming assay,a 
env code cell lysate supernatant ratiob 
wt 16.1 48 37 68 
V2 chimeras: 
16.1 97 78 71 
AV 52 30 52 
R- 69 40 51 
HY 80 64 69 
HR 55 33 53 
DN 80 55 60 
SN 85 48 49 
KT 66 49 65 
J- 60 34 51 
FY 80 43 47 
HN 100 86 75 
mtl 93 75 71 
mt2 80 37 41 
lll.t3 88 100 100 
mt4 79 65 72 
\\1 16.3 74 35 41 
Values given are relative OD450 levels obtained by ELISA in a single representative 
experiment. The level of envelope gene expression for each construct in cell lysate or 
supernatant was expressed relative to the construct for which the highest expression level was 
observed (HN and mt3 for respectively env expression in cell lysate and supernatant). 
b Ratio between the amount of gpl20 present in the culture medium and the amount of 
envelope proteins detennined in cell lysate, expressed relative to the highest ratio as observed 
for construct mt3. 
as ShOMl for a single representative experiment. The ratio between the amount of gp 120 present 
in the culture medium and the amount of envelope proteins determined in cell lysate for each 
construct is also presented. The relative amounts of envelope proteins present in cell lysate and 
supernatant varied two to three fold. On average 35 percent of the envelope proteins present 
at day three was present in the culture medium (data not shown). The observed ratio varied two 
fold when comparing all expressed chimeric genes Crable I). SupTI cells transfected in 
parallel by electroporation with a ll-galactosidase encoding control plasmid (Phannacia) 
demonstrated that under the conditions described 3 to 5 percent of the cells are successfully 
transfected (data not shown). Since we observed a considerable delay in syncytium formation 
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day 1 day 2 day 3 day 4 day 5 
wt -'-='----_ 
wt~~~ ______ ~ ______ ~ ____ ~~ ____ ~ ____ _ 
FIG. 3. Kinetics of syncytium size induced by envelope gene products. The size of the syncytia was quantified 
by classifying the observed syncytia in five arbitrarily chosen categories. The smallest syncytia were about five 
times the size of single cells and indicated by n single square. The largest syncytia were estimated to contain 
over 100 fhsed cells and exceeding 250 ~un in diameter are indicated by a bar affive squares, intennediate size 
syncytia are indicated by bars with a number of squares corresponding to their relative sizes. \Vt 16.1 and wt 
16.3 represents the unmodified 16.1 SI and the unmodified 16.3 NSI envelope gene COl1stmcts. All other codes 
refer to the (mutated) V2 sequences of Fig, 2 expressed in the 16.3 NSf background. The data presented are 
derived from single representative experiments. 
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for some of the constmcts, envelope processing kinetics were determined by RlPA using cos-7 
cells. In this assay we used adherent COS-7 cells since these cells are efficiently electroporated 
(up to 25% of the cells become transfected, data not shown). As demonstrated in figure 4, 
gpl60 expression, cleavage and gpl20 shedding into the supernatant occurred within 16 hours 
for all envelope constructs analyzed. 
A 
B 
'-:>1 ~<o:: 
I I I 
'-:>1 ~ <0:: 
I I I 
>-o::z 
::r::::r::c 
I I I 
gp160 
gp120 
<ilIIII gp120 
FIG. 4. Expression of envelope gene products by cos-7 cells transfected with the chimeric 
envelope gene constructs as demonstrated by RlPA (all V2 sequences indicated were expressed 
in the 16.3 NSI background). Pulse labelled proteins from transfected celllysates (panel A) or 
from culture medium (panel B) lVere immunoprecipitated 16 hours after transfection with a 
mixture of monoclonal antibodies and analyzed by SDS-PAGE. Arrows indicate the precursor 
glycoprotein gpl60 and the surface glycoprotein gp120. 
Syncytium fOl'ming assay. Expression of the chimeric NSI envelope gene 16.3 with a V2 
region sequence derived from the 16.1 SI gene resulted in syncytium formation in Sup-T I cells 
as shown in figure 3, which confirmed data from previous studies (2). Monitoring the 
transfected cell cultures for 5 days revealed that all other chimeric constmcts induced syncytia 
upon expression but significant differences in kinetics and size were observed (Fig. 3). Relative 
to the complete unmodified 16.1 SI envelope the chimeric envelope construct" 16.1 " containing 
the 16.1 SI derived V2 region in an NSI envelope background displayed delayed syncytium 
formation. Further delay in syncytium induction for some of the chimeric V2 envelope 
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constmcts was observed upon the introduction of one or more mutations in this region. The 
most prominent delay was observed with mutant #2 and mutant #4. In contrast to the other 
chimeric envelope proteins, both induced only small syncytia and this after prolonged times in 
culture (Fig. 3). The mutations introduced influenced either the overall net charge of the V2 
region, the predicted secondary structure, or both. These changes are indicated in figure 2. 
Garnier-Robson analysis (12) predicted the formation of an alpha-helix for the SI 16.1 V2 
region, which was not the case for the NSI 16.3 V2 region or for mutants A V, HY, HR, or 
mutant # l. These mutants did not display a significantly altered syncytium forming capacity 
compared to the wild type" 16.1" construct. Likewise, mutants R-, HY, ON, KT, HN, mtl, and 
mt3, which differ in net positive charge from the 16.1 V2 region, did not significantly reduce 
the size of the induced syncytia. Combination of multiple mutations which introduced 
differences in charge and two mutations which abolished the predicted secondary stmcture 
(mutant #4) however almost completely abolished syncytium formation. Mutant #2 contains the 
histidine to arginine change, that was also found in mutant HR. The introduced arginine is 
different from all other changes discussed in this paper in that an arginine was never found in 
this position in all the HIV-l envelope genes sequenced to date, all the other changes were 
based on their Hnatural ll occurrence in 16.3. The HR mutant was constl1lcted since it affects 
only the predicted helix whereas the natural HY variation at this position also affects the net 
charge of the V2 region. As shown in figure 3 the histidine to arginine change at this position 
was not tolerated in combination with the alanine to valine mutation also present in mutant A V. 
The combination of these two mutations in mutant #2 abrogated syncytium formation. 
DISCUSSION 
In the present paper we have shown by mutational analysis based on the natural sequence 
diversity in the V2 region of the HIV-l envelope glycoproteins obtained from one individual 
at a single time point that simultaneOl's mutation of multiple amino acids is needed to interfere 
with V2 region determined syncytium induction. 
Monitoring transfected cell cultures for 5 days revealed that all chimeric envelopes 
constructed in these experiments induced syncytia upon expression, but that also significant 
differences in kinetics and size were observed (Fig. 3). The envelope expression as 
demonstrated by ELISA three days post transfection revealed no major differences in the levels 
of envelope expression in cell lysates and supernatants. Furthermore the ELISA data 
demonstrated that expression of the chimeric envelope genes resulted in the shedding of similar 
amounts of gp 120 in culture supernatant for all the envelope constructs. These envelope protein 
expression levels were similar to levels routinely detected in experiments in which we showed 
that the envelope protein expression was not a limiting factor in syncytium formation. The 
expression levels corresponded to levels at least eight times those sufficient for immediate 
massive syncytium formation (data not shown). Finally all envelope expressing constructs were 
assayed independently for their syncytium inducing capacity at least three different times. 
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Essentially identical results were obtained for each of the constmcts tested. These data showed 
that limited or variable envelope protein expression did not introduce a bias in the observed 
syncytium inducing capacity of the envelope genes tested. 
Relative to the complete unmodified 16.1 SI envelope the chimeric envelope constmct "16.1" 
containing the SI derived V2 region in an NSI envelope background, displayed delayed 
syncytium formation, indicating that the kinetics of syncytium formation is at least in pm1 
determined by regions outside the V2 domain. Further delay in syncytium induction of most 
of the chimeric V2 envelope constructs was observed upon the introduction of one or more 
mutations in this region. The most prominent delay was observed with mutant #2 and mutant 
#4 which, in contrast to the other chimeric envelope proteins, induced small syncytia after 
prolonged periods of time in culture (Fig. 3). To examine a possible correlation between the 
delay in envelope function (syncytium induction) on the one hand and envelope protein 
processing and expression kinetics on the other hand we performed a 
radioimmunoprecipitation assay (RIP A) and tested multiple cell lysate and supernatant samples 
over time in ELISA. The results presented in figure 4 demonstrate that gpl60 expression, 
cleavage and gp 120 shedding into the supernatant occurred within 16 hours for all envelope 
constmcts analyzed including mutant #2 and mutant #4. Moreover celllysates and supernatant 
from cultures transfected with mutant #2 or mutant #4, taken 24 hours after electroporation, 
already showed similar levels of envelope expression as obtained with the other constructs when 
tested in ELISA (data not shown). These results indicate that the delayed appearance of syncytia 
as seen for mutants #2 and #4 is not due to reduced processing - or expression kinetics of these 
envelope proteins. Therefor we conclude that the phenotypic differences obselved are the direct 
consequence ofthe amino acid sequences of the envelope glycoproteins expressed. The efficient 
processing, transport, cleavage and shedding of gp 120 for all the different constmcts suggested 
that the phenotypic differences observed were due to differences in envelope proteins that are 
present at the cell surface and differ qualitatively in the ability to mediate the membrane i\!sion 
process. Our data indicate that the naturally occurring sequence variation in the V2 region does 
not significantly influence the precursor processing and subunit association of the envelope 
proteins. This in contrast to mutations of conselved amino acids in this region of the T cell line 
adapted HXBc2 envelope glycoprotein as demonstrated by Sullivan et.al. (33). 
Garnier-Robson computer analysis suggested that the V2 variation at residues 8 and 17 
greatly affects the predicted secondary structure of the V2 loop (2). The N-terminal part of the 
SI derived V2 region is very likely to form a stable a-helix which is not predicted for the NSI 
V2 region. In addition, the amino acid variation observed results in a more positively charged 
V2 region for the SI envelope gene than for the NSI gene (2). 
We have shown here that the envelope function in syncytium induction is not lost when variable 
residues affecting only the predicted a-helix or the charge of the V2 region are changed. Only 
multiple simultaneously introduced mutations interfered with the SI phenotype demonstrating 
that the SI configuration is a solid propel1y of the V2 region. Mutants R-, HY, DN, KT, HN, 
mtl, and m13, which differ in net positive charge from the 16.1 V2 region, do not display a 
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significantly decreased capacity to induce syncytia. This observation demonstrates that the 
observed differences in syncytium inducing capacity of primary envelope proteins determined 
by the V2 region, is not controlled by charged amino acid residues. These results may indicate 
a fundamentally different role for the V2 region in syncytium formation as compared to that 
of the previously defined role of the V3 region in this process, since the presence of positively 
charged residues in this V3 region strongly correlates with the syncytium inducing phenotype 
(9). Several studies indicated physical or functional interactions of the V2 region with other 
envelope regions like C4 (2,10,26). Interestingly, in the presently expressed chimeric envelope 
proteins, syncytium formation is not affected by numerous changes in the V2 region. Since we 
have shown that the 16.1 V2 region supports syncytium formation in different NSI backgrounds 
(2), functional interactions with other envelope regions in the here described chimeric envelopes 
are not seriously disturbed or lost. This is probably due to the high degree of sequence 
homology in the parental envelope genes used in this study (I). Apparently, the robust V2 
organisation allows the vims to accumulate mutations as a means of escape from immune 
selection pressure (20,36), without necessarily having direct consequences for the biological 
properties. This flexibility would be additional to that achieved by anchoring impOliant 
biological properties in different regions of the envelope glycoproteins, like the association of 
determinants for syncytium formation and cell tropism with multiple variable regions of gpl20 
(VI, V2 and V3) and gp41 either independently or in concert. This complex but flexible 
organization may largely hamper attempts to interfere with the biology of HIV -I through 
immunological or other intervention strategies. 
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Variable regions \Iith ~{'qUl'nc(' length mrialioll in the human immunodeficiency ylrus type 1 enwlope 
l'xhibil an unu~ual pattern of codon usage 'lith AAT, ACT, and AGT together composing >70% of all codons 
used. We postulate thai this distribution is caused by insertiun of AAT triplets followed by point Illutatiolls and 
selectiun, Accumulation of lin.' encoded amlnu acids (usparaglne, serine, and threonine) leads to the creation 
uf new N·linked glycos)'lation sites, nhit'h helps the ,irus to escape frolll the immune pre~sure exerted by 
Yirus·neutrali~ing antibodies. 
The ~urface glycoprotein gpl20 of the human immunodefi-
dency virus type I (HIV-I) contains a numher of regio!l~ with 
a relatively high degree of amino udd .\cquence variation, 
designated variable rt.'gions 1 through 5 (VI to V5 [II J). 
Recently, evidence has heen presented that, like variation in, 
e.g., the V3 region, variation in the VI and V2 rt.'gion~ 
contrihutt.'s to the determination of \'iral tropism und cyto-
paUlk: potential (2, 3, 8,17,19), indicating that the~e reginns 
arc prohably involved ill the prtKe~~ of envelope-mediated 
membrane fusion rt.'~ulting in viru~ enlry or in syncytium 
formation. Sequence varilltion in the\e regiom can then be 
reHeeled in the."e prot'c~\e~, resulting in variations in cdl 
tropbm and (:ytopathkity as described above. Virus-nt.'utraliz-
ing antihOllics to the V2 region that probably diredly interfere 
with virus t.'ntry have aL~o heen descrihed prt.'vinusly (7, lila, 
14), and sequence variation could enable the virus tn t.'~cape 
from such antibodies. The audition of tarb()hydrate~ I.:an alter 
the recognition of envelope gi)'t'opflltcins hy the immune 
system (I, fi). Here we dc~crihe a prnces~ of sequence length 
variation in the HIV-\ envelope gene that results in the 
selective insertion of new N-linked glycosylation ~itt.'s in the 
variahle rq;ions of the envelope glycoprotdns as a !I1t.'t.'hanbm 
to t.'St'apc immune pre~sure exerted by neutralizing antih()dk~. 
The alignments of the variable-kngth st.'quenc{'s found in VI 
and V2 are shown in Fig. l. We have used the HIV-l envelope 
~equence alignment presented hy M)'t.'rs et a!. (12) as a starting 
point and readjusted the alignment hy eye. The numbers at the 
top indicate the codons incorporated in the regions of variable 
sequence length, The underlined blocks of three codons indi-
cate encodt.'d potential N-Hnked glycosylation sites (see be-
low). We have noticed an apparent skewed usage of codons in 
these regions. A relatively high Humber of codons hegin with A 
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and end with T, with an especially high frequcnt)' of AAT 
codons. 
To confirm this ooservation, we have counted the fretluen-
cies of the four nudcotides adcnmine (A), c}1idine (C), 
guanosine (0), and thymidine (T), at thc Ilrs(, second, and 
third po~itions of each codon in the variable-length sequences 
of the VI nnu V2 rt.'gion~. We find sharp deviations from the 
distributions as fOllnd in the whole of gpl20 (we have ust.'d the 
HXD2H grl20 sequence for comparison), :..Io,t notahly, we 
lind that approximatt.'iy S4% of the mdons in fhese regions 
start with A « I % start with C); only I to 4~f, of codons have 
a Tat pmition 2 (compared with 2flr;}, in gp120); and fl7 to 7fi% 
of codon.<. end with T, with ~harp decreased frequencies of A 
and 0 at position 3. We have whscquent1y analyzed the 
frequency distrihutions of all four nuckotides at each codon 
position in the whole cnvelope gene alignment by a ~liding 
window method (see legt.'nd 10 Fig. 2 for details). The results 
ohlaint.'d for A at position I (AI), T at position 2 (T2), and T 
at position 3 (TJ) arc plotted in Fig. 2 for a window size of 20 
codolls shifted by 1 codon, as arc the number of sequenct.'s 
counted in each window to map the rt.'gions with ~etluence 
length variation (bottom panel). It can be seen that sharp 
increases in frequencies or AI und '1'3 with t'oncomilant 
decreases in T2 occur in the VI and V2 regions and also in two 
other regions that di~play a high degree of sequence length 
variation, the V4 and V5 regions. No other regions of the 
em'clope gene dbplay similar concomitant nucleotide fre-
quency distributions. TIle Al and T3 peaks are not as pro-
nounced for V5 because of the relatively small size of the 
r~gion of variable sequence length in V5 relative to the window 
sIze. 
We postulate here that the ~kewed distribution of nucleoti-
des at the first, second, and third positions of the codons that 
make up the regions of variable sequence lenglh is the result of 
the insertion of AAT triplets at these sites followed by point 
mutations and selection for sequences that provide a selective 
advantage to the virus by the insertion of N-linkcd glycosyla-
tion sites, resulting in escape from the immune systcm, as well 
as selection against disadvantageous (in this case, hydropho-
bic) sequences. The implications of this mechanism will be 
discussed helow. 
The use of a severely limited set of nudeotides at position I 
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BIVHII G--TrGAGG •••••• M1 ACT ACT MT Ace MT ••• • •• --1 ""I J.cr GCT MT ••• --C PAT NiT M1 U;C ••• • • • GAC-(:4MCA 
H1VllXB2R G--rtGAAG........................ --1 (!AT ACT MT ;..CC ••• --T IlGT AGI J.GC ••• Gf"_"HG.V,TGAfA 
BlVUl G--i1= ., •••• Ml GCi ACT M.T Ace ••• • •• -~T ""Y U;Y MT N;C ••• --T U;1 ).,Gy u;c ••• G<7...oA-UTGATO 
Bl\'NLl3 G--rTGAJ.:I. ... --1 GIIY ACY MI ACC ... --1 U;1 ).,GT U;C ... GGG,w.v,rGATA 
Ul\'I-!,A G--HGAAG ••• • •• --I GAT Acr MT ACC ••• --I ).,Gr ).,GY MC ••• G;o,wAATGJiTA 
HIVOJII A---6TA...... --1 MY J.CT }g:; ACC ... --I WT AG1 GAr ... TGG OAC J;GG AGGGAAC-GAOM 
1I1VNY500 G--TTOACG... --1 GCT "CT TAT Gce ... --t GOT U;I WT .......... .. 
lIlVNlll G--itOA'?:; ... --1 OTT ACT Mi IITC ... --T MT }.GT JJ;1 ... .. .G.~GGGA ... 
lIlVJfL A--TTGAAG ••• • •• --, an J.CT AAi AiC ••• --I Mi JJ;T ••• •• ,. fGC-GGMAG 
1I1VSHlIBI A--fGGMG JJ;1 !Xi --T NiT }XC U;, MT },CC -~T "GT }:;1 ... ... • ........ HG 
InVDJI G--CTGAAO ... ... ... ... ... ... • --1 &:1 J.Ci Mi ACC MT T(;O }.CO AiG '" .. • ACAC.(]MJAA 
HIVSfl62 A--HGAAG................................. • --T Gcr ACT ........ - T N:<:; ANJ WT JJ;; Mi ... ...TGGAAAO.~G 
HI\Vfl G--GH, •••••••• ~).,GT JJ;T U;1 HO 1m , •.•.• --1 Gcr l,cr •• --i ;..<:<:; ACII U;1 JJ;i AGT '" .•• IGGG.U,KO 
Hlvsnl O--TAFrTG GGG ... • --I Gcr J.er. Mi ,,~C ... --(: MT JJ;r AGi ... '" •• • ••••••• • c-.c-GMMCG 
lIlVCDCI G--TTGAAr I.e! Mi --T f,cr J.CT ••• --T ACT ACT G.'IA CTA rCA lirA AfA GTA GrrrGGOMCM 
HIVSf2 O--HGGC.(] ••• ••• --a GCT An MT ACC ••• --1 U;i WT MT •.• •.• . •• iC<7MLl,G.'IA 
HIVSF2Bll G--rTGCGG... ... ... --G Gn J..CA J..C'~ ...... --r lIGT }.AT AAT ... rC-GMAGAA 
H1V,!k'l O--TATA.H ... ... --, ac<:; "CT ... --c }.Gi AG! •• • .. r=~J 
IIIVP-f G----GCTMC ITG ••• .,. --i C%;i ACi ••••••••• --1 Grc ACT J..GT!Wi AGC • C{;!;'_'GA!.CAATG 
1I1\""~{J2 G--MG...... --(: ;..rr J.CT GilT iOO Jo,J.3 --1 ACA 1-.CII "TA ••• 
HIVTaI12 A--TTGJ.';G ••• ••• , --T GilT "n. . ..... -,,-,-,-,,--
H1VGlN A--rrGGTG ••• ••• --1 GCT ''0 TAT ~T ••• --T Wi WiT •••••.••• '" ••• .,.rGOJAA'-"o; 
1I1VJ..~H9 G--AAHW ... ... ... --T ""I J..Ci MT HG GGQ --1 MT ACT GAT... .. ........ .. 
HIv;..nl G--OArTW 1WG ... ... ... .. .......... --I GAT ... ..... ........................... ." rGGOHCAG 
111\'.'11 G----GCCTCG J.GG ••• M1 GH ACT }.N1 u;a Mi GAi ACT 1. ..... 1 OM --i OCT AC"I GAi .Vii Mi --1 0:;.--...0 lo.CT GCT lo.CT U;, GC"'3 M1, ••• AiLV,C!"AIG 
HI\'\-!.UCDN G--GCaCT AiT N1J\ M'f !XC IICT llii N1J\ ~ MT IICC --i Acr ACT ......... --T J.CT k:;1 U;1 1= •• • ......... .. GCGG.HG1"G 
HIVHII20a G--IKCACT lo.rr N1A '" ••• ACT Mi Aec --i J.<;1 A<;1 Mi ACT ••• --1 N:.i N:;C ••••••••• '" •••••••• • C-GCGHGIG 
HIVR·JS A--rC-GA.~G ... ... ... .• --i OJ.T }.n GAY ACT ... --1 N:<:; An MT ).,G1 AG1 U;, ........ • GC.<JG!IAA'IA 
HH'\',li G--TGTGTA ACT T(;}' '" ••• --. TGt; AC"I MT iTG J.GG --T Gn ACC MT A~C MA Nil NiT J.GC •• A--J[C~';AAAIA 
<XNSWSUS 
IllVJ~CSf 
1I1VJRFL 
HIVf,1.A1 
HlvnVIl 
lIlVJRl 
1I1VSC 
IIIVilALI 
H1ViU2 
IIIIMI 
1I1V,lXll2R 
"au 
HIVNUl 
lI!\l1fJ. 
1I1Vo..'-Il 
HII,-l-fI5CG 
1I!\?,llI\ 
1I1VJfL 
HIVSIMJaI 
HIVDll 
H1YSfl62 
Hlwn 
H1VSf31 
Hl\'CDC1 
HIYSf2 
HIVSf2Bn 
HIVHII.'I 
Hl\'RF 
Hl\"~~\J2 
H1Vlain 
1I1YGUlI 
HIYAan 
H1V1IC?1 
1I1V_'I1 
Hl\l!.\l<:G!/ 
HIVl-'.'-2C8 
Hl\fll.JS 
HI\·~l1 
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cCAHAgH 7a"l n7 ,n in 117 711 ,n in 117 117 7H 11, "111 H? 7f? olIt act age 711 "111 n1 an r~rAHfTq 
C--AT~GAr II .... T A.>JJ '" ••• ••• ••• • A-i M1 ~.(<: . • •• }.'}, -A -GG -A 
C--AT-OH M1 ... '" ... ... ... ... ••• ... ... ... ... ... . A-1 M1 A(': ... AGt; -A -c.o--G 
C--AT-OAT }.AT ... '" ... ... ... ... ••• ... ... ... •• A-T MT A~t; ... J;Gt; -A -TA--G 
C--AT-GAT )AT GAt MA ACT: ••• ••• ••• ... ... ••• •• ••• • A-, ACT ... • •• 1-&\ -A -C-G··O 
C--AT-A.H ••• • •• }.AI I..GT ACC »:; Gill' MT ATA Mo.A MT GAT ••• 1.-, NiT ACC ••• }J]A -A ·OA--A 
C--AT-OAT ••• ---- • J.-T AOO A'$C ••• -A -GG--G 
C--AT-GAr ••• A-i Mi 18T A. ... r MT NJA -A -OO-·G 
C--AT-G.\T ••• A-T GCT }JjC •• _A_-GG_-G 
r--AT-QlT ••• .,. A-i GAT J8T •••••• A~C J.GC -A--GG~-O 
C--AT---<iAr ... ... ;"-T GAr ACT ...... ACC U;C -A--CO--G 
C--AT-OAT ••• • •• ~ alii 1I~1 ••• .• ACC WC -A--CG--G 
C--AT-GAT ••• ••• .,. 11-1' N::C J.GC ••• -A--GG--G 
(--AT---<iAT ... ... ;..-, /eCC IICC ... -A-·GO--G 
C--AT---.GAT}.).!j GCT •• 1.-, ACII J8T •• _A_-CA_--6 
C--AT-G.\!}.).!j (!Ai A-I ACII1= ... -A--CA-·O 
C--AT-GAT}.AI GAT.... ;"-Y Acr }fjt; ... -A .. OO--G 
C--AT---.G.\T MY GII1 '" ••• "-T J.ell Nit; ••• -A--CA---6 
C--AT·GAG ""1 Glli '" J.-i J.Ci }::,<:; •• ' -A--CA--G 
C--AT-GA1' MT GAC '" 11-, Acr 1= ,.. -A -GO-·G 
(--AT-GAT Ml GAi ',. A-Y Ar:A AX.. -A··M--G 
C--AT---.G.H}.).!j M1 ... a Y ACT M...... -T·-GO·-A 
C--AT-GAT Glo.l GAT '" ••• MT Acr ••• ;.. Y Ace }.X •• -A··C."3--0 
C--AT-G.U GA, M1 »_ ...... MT;"cr A<:C ••• ••• ••• • •• ;"-C 1-.AC A~'; • .,. MA -A-·GO--G 
C--Af-GAT ••• ••• • •• Mi GCT Nif IlCi ACT J.CC • • •• ?:::..C rAi ~.(C ••• •• }J-.C -A--GG--G 
C--AT-GAT ...... • •• }.AT GCl }[ji 110 ACT N:C • • •• J.-C TAr A(C •• ". }N:: -A- c,,:;--o 
C--Af-G.H MT ... • .. Mr AN} ACT Nil MT J.OO Glli •• h-. "CT A(C ... • .. }.r;t; -A- TG--O 
C--Af-GAG AAG GGY ••• MT lin NiC (0}J.[j ••• Mi Mi ACT 1,9; •• , A·i }_~, f,cr 1= TilT 001 MC -A -CA -0 
C--Af-AA.!,l 00, GA, ••• Mi •• , II-(;':;T 18i • J-,GA -A -G.~ -0 
C--Af-AAT MT Gll.i ••• J.-i I,CT Afjr'; -A -G<J··O 
C--AI---<iAT, A---G ACA AGr'; • -A--CA--G 
C--AT-OAT ••• ••• • •• MT IlGT ACT N:;'; }oAT • II-i TAT ;..cr ••• Wt; -A -C":; -0 
C--AC-GAT GAT Gll.T .................. • A-, A~C J.X -A -AG--A 
C---6T-GAT Ml un; MT ••• Me Mi ICH MT ••• ••• '" •.• /,-T Mt A"i -A·-7A--G 
C--AT-GaT ••••• , ••• M! G.>..i ft::;i IICT Nn MT MT }.~T AC"i lET Mi 1.-1 TilT An • ~.GI -A--(lG -G 
C--AT-GaT •••••• '" ••• MT Glli }:;, ACT m, A. ... r MT ftAT ACT NiT Mi 1.-, TAT Acr • mi -A--GG-O 
C_-Ar---<iAT MT G.U ". ... ... ... ••• ... ... ••• • A-T ACA }.GC ••• -A-·CG--G 
C-·AT-GAT ...... '" ... Mi GAT }.},), G.~T ... ... ... , A-T A~i /-.G<:; -A--GG -0 
FIG. !. Scquence a!ignmenh uf variahle·length sequences in VI (A) Llnu VI (O). Sequencc\ anu alignment wae adnp1cu from the work (If 
Myn~ et aL (12) and adju'ted hy hand. Numhers in the lop row indic.lte codon'> of th~ v<Jriable·kngth ~etlue\Ke region. Scquences outsidc of the 
variable-length scqucn!.'e' db!.'U~~ed her.; ,IT<;' in ita1ic~. Da~hes indic.lte nucleotide., identical to the !."m,emus sequence (top row), and unl~ inuicCl\e 
ueletioll, relative 10 Ihe comellSUS scqu('nce. Uppcr!.'a,e ktter~ in the enn_cnw., ~equencc indicate ha,c~ l·on.,erHd throughout all aligned 
~cqucnce,; l(l\\"cn:a~e ktter . ., indicate h;N~" found in al least .'iO~(, (hut le,~ thim 101I~"(,) of the aligned scquen!.'c~ in ref.:rc!1!.'c 12. Block\ of Ihr<'<' 
((alons enending a potential N-linked glycosylation ~ite (aspilrClgine-X-sctindthrconine) an: underlined. 
(as, in thi" case, mostly A) is reflected in the encoded amino 
acid sequence. The preferential u~c of codons ~tartillg with an 
A (>80% in the VI anti V2 variable-length sequences) re~ults 
in predominant insertion of holeucinc, methionine, aspara-
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gine, serine, threonine, Iysinl" and arginine. TIle virtual ah-
sence of Ts at r()~ition 2 results in the exdu~ion of i~()1cucille 
(lIe) amI methionine (Met), the only two hydrophobic amino 
acids whme codon starb with an A. Apparently, the insertion 
V1 V2 V4 V5 
VV'noovv 
FIG. 2. Frequency Ul\tribu\ion'> of AI (top panel), T2 (sccond 
p;mel from top), and '1'3 (third pllnel from hlp) in the HIV-I cnvelope 
gene, 11~ well a~ the relative number of ~equenee~ counted in each 
\\imlow (hottom panel). Valleys in the bottom p,mel plot indicate 
region\ of \';triable sequC!KC length. Frequencie~ of each nucleotide at 
eacb po,ition were counted in a window of 20 codon." ~hifted by I 
codun, with the aligned scqu~nces tilken fn1m reference J2. Only AI, 
T2, ilnd T.~ ,He ~h(lwn. Variable region<, VI, V2, V4, llnd V5 arc 
indicllted (e,\c<opt V3). The 95~f. c,mfidence inlen'ill uppa and lower 
limib,cllkul<J.tcd ,i> me,ln :!: L96x standilrd l.kvia\ion following ,quare 
root trarL~ftJmlalil!n of Ihe dilla (0 achievc normality, <J.re a~ fl!lIO\~~: 
AI, 0.71 and 0.15; n. H.5(, ilnd (I.Ui'!; and '1'3, 0,(>3 and 0.05, no,pe~', 
(ively. The Al and T3 pe<J.h in VI, V2. and V.J exceed Ihe~e limib, as 
do the T2 valle)s in VI, V2, V4, ilnd V5. A numbcr of Al pCilks are 
found bC'iidcs the VI, V2, V4, and V5 region'. The Jack ofCOllcomit:lllt 
T2 villley" and 1'3 peaks indicate, that thc\c havc been gener,ltcd 
Ihrough mechanisms differcnt fn)m the one Po.,tu!;l\ed in thi~ p;tper. A 
1'2 peak i\ found at po~iti()n~ ({)rre~poflLling 10 wind,)\\', 754 to 769 
(armw). All codon> \Iith a T at posilion 2 code for hydmphonic ;imino 
acids, and this pC<J.k c(lrre'pond~ 10 the location of Ihe hydrophobic 
memhrane anchor ~~quence, in gp-tL nolh the Lllignments and the 
wlllpuler pr,lgr<Jm u~t'd 10 t'd!culilte thi~ plot arc available f({lm Iht' 
authors UPOIl rcqut'~t. 
of hydrophobic amino add<; in this region of env is disadvan-
tageous to the virus. The strong bias towards T, a remnant of 
the pmtulated originally inserted AAT, and to a le\~er extent 
toward~ C a<; a result of mutation and sc1el.'lion, at position J 
now ~eleclively inserts threonine, a~paragine, and serine at 
these positions. Both threonine and .\crine codons can be 
generated from the AAT and AAC asparagine codons through 
one mutation. Four of the ~ix codons Ihat l'an potentially code 
for serine start with a T rather Ihan with an A, namely, T-e-x. 
TIlesI' codons arc not u\ed in the insertion sequences de-
scribed here, although they normally compose approxinHltcJy 
60%-. of all serine codons in mammalian genes (18) and arc 
used throughout the Env open reading frame (not shown). 
Random insertions and mutations followed hy selection would 
have resulted in a predominant usc ofT-C-x codons for serine. 
The exclusive use of AGT and AGe codons to code for serine 
is therefore a strong point in favor of the postulated mecha-
nism. We have counted the frequency of asparagine, threonine, 
and serine in VI and V2 and compared them with those in the 
gpl20 amino add ~equence of HIVIIX1l2H' In the VI and V2 
variable-length sequences, the combinatinn of Asn, Thr, und 
Ser makes up 75';}, of all amino acid~, compured with only 22';,{, 
of all uminu acids in gp120. 
Insertion of AAT triplels followed by mutation and sekction 
results in Ihe insertion of predominantly a.'.paragine (N), 
threonine (T), and serine (S) as descrined above. Random 
combination of the.'.e three amino acid~ will result in the 
frequent occurrence of N-x-T and N-x-S sequence blocks, 
where "x" .~tands for any amino acid. Both N-x-T and N-x-S arc 
potential N-linked glycosylation sites, and indeed the variable-
length sequences arc characterized hy the occurrence of mul-
tiple potential glyco.<.ylation sites. Approximately 55% of all 
amino acids in Ihe variable-length sequences arc actually 
involved in the formation of N-linked glyco'>ylation ~ites (Fig. 
I), demonstrating the efficiency of the postulated mechanism 
for the generation of such sites. If glycosylation of these 
regions confers .~elective advantage to the virus, then it might 
be expected that virus genotypes that contain such a novel 
glycosylation site would persist and uppear in future vims 
generations. Examples of such glycosylation sites that have 
become stahle features of the HIV-l genome can be found in 
hoth the VI and V2 variable-length sequences (VI codons 13 
to 15and 11)1021 and V2codons l6to I8[Fig_l])andthe V4 
and V5 regions (not shown), TIle occurrence ohequences with 
variable length 5' and 3' of these conserved sites indicates that 
the mechanism of AAT triplet insertion is ongoing; we pOSItI-
late that the accumulation of more glycosylation sites provides 
further selective advantages to the virus through beller mask-
ing of Ihe epitopes in this region from the immune system. We 
predict, therefore, that the number of glycosylution sitcs in 
these regions of the Env glycoproteins of vimses isolated from 
infected indj\'idual~ is directly related to the immune pressure 
exerted on these regions, which may vary from person to 
person, out in all probability will increase over time, especially 
during the asymplomatic period of infection. Olhers have 
shown a statistically signilkant sequcnce length increase and 
addition of a novel N-Jinked glycO.<.ylation site at the V2 
insertion sequence that rorrelates with increased viral viru-
lence (8). l\'lore virulent virus variants generally arise over time 
in infected individuals and, a~ discussed above, so will the 
length of the insertion ~equences because of selective advan-
tages of the vint~es that have acquired more glycosylation sites. 
The nb.<'ervcd correlation between viral virulence and sequence 
length variation in V2, therefore, probably reflects the paral-
Ictism in lime of these two processes. Accumulation of se-
quences rich in potential glycosylation sitcs (both N-Jinked and 
O'linked) has been reported for the VI regions of simian 
immullodeliciency virus (SIV,'\,INE) isolates obtained from 
monkeys that progre,sed toward<; AIDS (13). 11lis region in 
SIV ~hows evidence of ACA Iriplet reHeration (based on Ihe 
SIVcnv ulignment in the work of Myers et a!. (I2] and Oil the 
work of Overbaugh and Rudellsey [13], not shown), which 
results in the accumulation of threonine residues, thereby 
creating potential targets for O-linked glycosylation (13), It 
appears that the highly related lentiviruses SlY and I-IIV have 
adopted very similar but not identical strategies (AAT yen,us 
ACA reHeration) to achieve the same goal: glycosylalion of 
sites on the envelope glycoproteins that are important for the 
virus life cycle, thereny shielding these sites from recognition 
byantihodies, 
The sequences inlhe VI and V2 region playa direct role in 
virus entry, as discussed above, No such functional properties 
have been described for either the V4 or the V5 region, and yet 
it appears from our analysis that they may oe ~ubject to the 
same selective pressures as VI and V2. 11le high degree of 
variation in these regions hampers functional studies, e.g., 
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because of the dit1kulties of raising cross-reactive untibodies.1t 
is conceivable that functional roles for V4 and V5 will be 
described in the future. Alternatively, glycosylation at V4 and 
V5 could help mask other functional regions that are brought 
into the proximity of V4 und/or V5 in the folded molecular 
complex. 
The mechanism by which the dcscribed triplet reiterations 
arise is unclear. Recently, a number of human genetic discases 
characterized by trinucleotide repeats have been described 
(reviewed in reference 15), and strand slippage during DNA 
replication (5) has been proposed as a mechanism that could 
introduce such repeats (16). Tandemly repeated sequences are 
also observed in human hypervariable minisalellite sequences 
(10), and an alternative mechanism involving double-stranded 
breaks and gap repair has been proposed (9), Although it is 
tempting to speclliate Ihal the viral reverse transcriptase is 
primarily responsible for the observed phenomenon, in vitro 
studies of the HIV-I reverse Iranscriptase have not revealed 
direct evidence for triplet insertion, although strand slippage 
during replication of DNA or RNA is observed (4). The 
examples quoted above are compatible with the idea that 
cellular polymerases may be involved. 
We are greatly indebted to Kees Siebelink (or helpful suggcstion\ 
and critical reading of the manuscript and to Albert Ostcrhau~ for 
continued support. 
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Human immuIlodeficiency virus typc 1 entry and virus induced syncytium 
formation arc both membrane fusion processes that are initiated by the binding 
of the vimi envelope glycoproteins to the CD4 receptor. To identify critical 
regions of the envelope glycoprotcins that arc involved in these complex 
processes, we have generated chimeric genes from genetically highly homologous 
envelope genes obtained from a single donor, which display differences in 
syncytium inducing capacity. Through transient expression in SupT1 cells we 
identified a region of the transmembrane glycoprotein gp41 involved in 
syncytium formation. Similarly \'t'e have previously identified the V2 and V3 
regions of the surface glycoprotein gp120 as natural determinants of syncytium 
formation. In an envelope complementation assay the contribution of this 
region, and also of the V2 and V3 regions, to viral entry of different cells was 
determined. Exchange of only the gp4! region, and not the V2 01' the V3 region, 
transferred the capacity of entry into SupT! cells to an envelope protein 
previously not able to mediate infection of SupT! cells, Likc,,,ise infectibility of 
MT2 cells could be trallsfe.Ted through exchange of only the V3 region. These 
results demonstrate that different regions of the envelope protein may play 
distinct roles illmembralle fusion processes underlying syncytium formation and 
viral entry. Furthermore these results show that different envelope regions 
independently control viral entry of different cell types. They also indicate that 
functional interactions of different "iral determinants with cellula I' determinants 
can result in unique combinations leading to the entry of specific target cells. 
Human immunodeficiency virus type I (HJV-I) enters the cell via direct membrane tbsion 
at the cell surface (39,55), The tbsion process is initiated by the binding of the viral surface 
glycoprotein gp 120 to the cellular CD4 molecule, This receptor binding induces conformational 
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changes that result in an increased exposure of regions of gp120, dissociation of gpl20 from 
the transmembrane glycoprotein gp41, and unmasking of gp41 epitopes (28,41,42,47,48). A 
basically similar membrane fbsion process of infected cells, expressing envelope glycoproteins 
at the cell surface, with adjacent CD4-positive cells may result in the formation of 
multinucleated syncytia (37,38,53). Cellular factors other than CD4 are also involved in viral 
entry and syncytium formation (5,8,14,19,21,27). 
HIV-I variants differ in their capacity to enter different cell types (15,22,26,46). Both 
macrophage tropic and T cell tropic HIV -I variants have been described and such variants may 
play different roles in the pathogenesis of HIV-I infection (13,56). A select group of HIV-I 
isolates has the ability to replicate to high titers in immortalized human T-cell lines. This has 
allowed the study of characteristics of HIV-I that could be relevant for in vivo pathogenesis 
like e.g. viral entry and sensitivity to vints neutralizing antibodies. However, T-cell tropic 
viruses represent only a small subset ofHIV-1 variants present in vivo, with properties that may 
be absent from most viruses isolated directly fi'om HIV -I infected individuals. 
Numerous studies have linked HIV-I cell tropism to cytopathicity. T-cell tropic vimses 
appeal' to induce syncytia in vitro whereas this is not reported for macrophage tropic viruses 
(49). In particular these syncytium inducing (SI) vimses are able to replicate in T-cell lines like 
e.g. MT2, which allows the rapid detection of such variants in clinical specimens (35). 
Nevertheless insufficient data are available to positively state that cell tropism and syncytium 
formation are genetically linked features of HIV -I, especially in situations that closely mimic 
in vivo circumstances. Molecular clones of HIV -1 reveal a less than complete correlation 
between T-cell line tropism and syncytium formation. Non syncytium inducing (NSI) HIV-I 
clones that replicate in T-cell lines like SupT!, as well as SI clones that replicate in 
macrophages have been described (16,26). A recent study reveals the widespread tissue 
distribution of l-IIV -I variants in vivo with a genetic signature of macrophage tropic variants 
(see below) but with evidence of syncytium formation, again pointing to potential discrepancies 
between cytopathicity and cell tropism (18). 
Genetic mapping of determinants involved in either cell tropism or syncytium formation has 
identified several regions of the envelope gene products of HIV -I involved in these processes. 
Initial evidence pointed to the hypervariable V3 region as the m'\ior determinant in both tropism 
and syncytium formation (32,52) with a more positively charged V3 region associated both with 
T-cell tropism and enhanced syncytium formation (57). Based on these data T-cell tropic and 
macrophage tropic signatures were assigned to the V3 regions of HIV-I isolatcs (23). More 
recently also genetic variation in other envelope regions like the V I and V2 regions has bcen 
implicated in determining either cell tropism or cytopathic potential of HI V-I (4,7,24,25,34,57). 
Mutational analysis demonstrated that no simple distinction can be made between SI and NSI 
variants of HIV-I on the basis of differences in the V2 region (2), although sequence length 
variation in this region has been linked statistically to cytopathic potential (25). The lack of 
such length variation between V2 regions with widely differing influences on envelope 
mediated syncytium formation however, indicates that the observed correlation is not absolute. 
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Next to the influence of genetic variation of individual regions of the envelope gene products 
on cell tropism and syncytium formation the overall conformation of the envelope protein 
complex is also of prime imp0l1ance since evidence of specific interactions between different 
envelope regions for syncytium formation has been presented recently (24). Identification of 
all of the viral determinants involved in determining cell tropism and cytopathicity will 
eventually lead to the understanding of these complex processes. 
Since HIV-I viral enhy and syncytium formation depend on both the amino acid sequence 
and the conformational stmcture of the envelope glycoproteins, we used naturally occurring 
sequence variation to probe envelope glycoprotein function in these processes. We have relied 
on gain-of- function experiments where syncytium forming capacity was transferred from a 
syncytium inducing envelope gene into a genetically highly homologous but non syncytium 
forming envelope background. This approach minimizes the risk of corrupting the protein 
stmcture, although such undesired consequences camlOt formally be ruled out. In this way we 
have previously demonstrated the involvement of both the V2 and V3 regions in syncytium 
formation (4). However in our previous experiments not all transfer of syncytium forming 
capacity could be explained by variation in V2 and / or V3, since in some experiments 
especially the carboxy-terminal half of the envelope gene products, including gp41 sequences, 
appeared to be involved. In this paper we demonstrate that genetic variation in a discrete region 
of gp41 directly influences syncytium forming capacity of the envelope genes involved, 
independent of V2 and V3. Furthermore we demonstrate that, like the V3 region, this region 
is also involved in determining cell tropism. 
MATEIUAL AND METHODS 
Construction of chimeric envelope genes. Previously a set of chimeric HIV -I envelope 
genes was generated starting from four phenotypically well characterized envelope genes with 
known nucleotide sequence (3). These parental envelope genes were derived from biologically 
cloned viruses obtained from a single individual (#16) at a single time point and were 
designated 16.1 to 16.4 (3). For the present study chimeric envelope genes were constructed by 
exchanging gene fragments between envelope gene 16.2 and 16.3. We selected this envelope 
gene pair since it represents the pair with highest amino acid sequence homology (94.5%) yet 
displaying different syncytium inducing capacity when expressed (3). The gene fragments were 
obtained by digestion with restriction enzymes (Spe I, Stu I, evn I, EcoN I, Avr II, Bgi II and 
Pst I) with conserved restriction sites in these envelope genes and with restriction enzymes (Xho 
I and Xma I) cutting the cloning vector pGEM7- (promega). Occasionally envelope gene 
fragments were subcloned in puc 18 to enable the exchange of gene fragments generated by 
enzymes that are cutting at multiple sites in the envelope gene. The resulting envelope chimeras 
were named according to the exchanged gene fi'agment(s) and the two involved parental 
envelope genes (see Fig. I and 3). All chimeric envelope genes were tested by restriction 
mapping lIsing restriction sites that were non-conserved in the parental envelope genes or by 
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pm1ial sequencing to verilY the cloning procedure. The similarly produced chimeric envelope 
genes 13SS, 23SS, 13HC, and 23HC were previously described (2,4). 
Transient env expression and syncytium formation assay. All generated chimeric 
envelope genes were cloned in the simian vims 40 based expression plasmid pSRHS as 
previously described (4,20). Subsequently the constructs were transfected into Sup-Tl cells by 
electroporation. Five million cells were mixed with 20 ~lg DNA in 2S0 ~ll RPMI (Gibco) 
supplemented with 10% foetal calf serum (FCS) in a 4 mm electroporation cuvette (Eurogentec 
S.A.) and after electroporation (BiOl'ad genepulser, 200 volts, 960 ~IF) the cells were transferred 
to culture flasks with RPMI medium. One day post transfection, viable cells were isolated on 
a Ficoll density gradient and cultmed for an additional three days during which the transfected 
cell cultmes were examined for the presence of syncytia. Relative sizes of the syncytia found 
at day three in each culture was quantified as: small (+): up to five times the size of single 
cells, large (+++): giant syncytia estimated to contain over 100 filsed cells (scored as being 
larger than 2S0 Ilm in diameter) or intermediate (++). At day three post transfection the relative 
expression of envelope proteins was determined in both supernatant and cell Iysates in an 
ELISA as previously described (4). Each construct was tested at least three times in independent 
assays. 
Envelope complementation assay. The envelope complementation assay was performed 
basically as described by Helseth et.al. (29). COS cells Were cotransfected with IS-20 Ilg of the 
pHXB6envCA T plasmid and the same amount of a pSRHS constmct coding for one of 
the (chimeric) envelope genes. Electroporation of COS cells was performed as 
described in the previous section but pulsed at 240 volts. The next day culture 
medium was replaced and the adhercnt viable cells were cultmed for three days. 
Subsequently cell-free supernatants with complemented virions were collected 
by centrifhgation, aliquoted and frozen at _I3SeC. Prior to infection the amount of 
p24 antigen, as determined with the VS Elisa kit from Organon Teknika, lVas standardized and 
the level of envelope protein expression was checked in an Elisa as previously described (4). 
Infection of two million cells (SupTl, MT2 or H9) or five million human peripheral blood 
mononuclear cells (PBMC) lVas performed overnight in I millilitre RPMI (Gibco) 
complemented with 10 % foetal calf senun. The next day fresh medium was added and cells 
lVere cultured for an additional two days. Finally the target cells were washed in PBS, pelleted, 
lysed, and assayed for chloramphenicol acyltransferase (CAT) activity using a phase-extraction 
procedure as described elsewhere (SI). 
RESULTS 
Gp41 determinant ill envelope mediated syncytium formation. Chimeric envelope genes 
were constructed from two genetically highly homologous parcntal envelope genes 16.2 and 
16.3 described elsewhere (3). The transfer ofa series of small 16.2 SI gene derived fragments 
to the 16.3 NSI background envelope gene resulted in a set of 13 new chimeric envelope genes. 
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18.2 W///U'H//H~///m'l//M +++ 
16.3 I::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::j 
23CX I::::::::::::::::::::::::::::::::::::::::::::::::::W~H ~ ++ 
23CA I::::;:::::::::::::::::;:::::::::;:;:;:::;:;:;:;::::W//~A;:::::::;:;:::::::;:::;:::;:;:;:;:::1 
23EX I::::::;:;:;:::::;:::::::;:;:;:::::::::;:::;:;:::;:;:;:::;:::::::;:~~A ++ 
23CEAX 1::;:;:::;:::;:;:::;:;:;:;:::::::;:;:;:::::;:;:;::::0V4'!::;:::::::;:;:::W//~M ++ 
23CE 1;:::::;:::;:::::;:::;:::;:;:::::;:::::::::;:::;:::WMl::::;:;:::::::;:::;:::::;:;:;:;:::::::::::::::::::::::1 
23EA I::;:;:::::::;:::::::::;:::::::::;:;:::::;:;:;:::::::::::::;::::::~A::::::::;:;:::::::;:;:;:::;:;:;:;:;:I 
23AX I;:;:;:;:;:;:;:;:::::::;:;:;:::::::::::::::::::::::::::::::::::::::::::::::::::::::;~~ ++ 
23AP I:::::::::::::;::::;::::;::::;:;:;:;:;:::::::;:;:::::::::;:;:;:;:;:;:;:::::;:;:;::::~M::::::::I ++ 
23BX I;:;:;:;:::::::::;:::::::::::::::::::::::::::::::::::::;;:::::::::::;::::::::::::::;:;:;:;:::;:;:W.hWM 
23ABf'X I::::;:::::;:;:;:::::::;:;:::::::::::::;:;:;:;:::::::::::::::::;::::::::::::;:::::::10@::::::::::::;:;@ ++ 
23AB I::::::::::;:::;:::::;:;:;:;:::::::::::::::;:;:::;:;:;:::::::::::::::::;:;::::::::::WA:::::::::::::;:;::::::::1 ++ 
23BP I:::::::::::::;::::::::::::::;:;:;:;:;:::::::;:;:::::;:;:;:::::::;:;:;:::;:::;:;:::::::;:::::::::W&::::::;:I 
23f'X I:;::;:;;;;;;;:;:;:;:;:;:;:::::::;:;:;:;:;:;:;:;:::::::;:;:;:;:;:;:;:;:::::;:;:;:::::::;:::;:::::;:;:;:;:;:;:;;;@ 
FIG, I. Syncytium size induced by (chimeric) envelope gene products. The syncytium sizes of the expressed 
parental envelope genes (16.2 SI and 16.3 NSI) together with the chimeric envelope genes generated are shown. 
At the top the complete envelope gene is represented by a bar and the restriction enzymes used to generate the 
chimeras are indicated, Abbreviations: V, variable region; FD, fusion domain; Xh, Xho I; Sp, Spe I; St, Stu I; 
C, eVil I; E, Eco NI; A, Avr II; B, Ogl II; P, Pst I; Xm, Xma I. Symbols: arrow, cleavage site; +, small 
syncytia; ++, intermediate size syncytia; +++, large syncytia; -, no syncytia (for more details, see material and 
methods section). 
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Mainly 16.2 SI sequences derived from the 3' half of the envelope gene coding for the 
transmembrane protein were transferred as shown in Fig 1. This set of chimeric envelope genes 
was transiently expressed in SupTl cells to determine the contribution of the transferred SI 
envelope regions to syncytium formation. The expression of envelope protein in the individual 
cell cultures was determincd in both supernatants and cell lysates using an ELISA. Relative 
envelope protein expression for all constl1lcts was at the level routinely detected lor all our 
pSRHS envelope gene constructs expressed in SupTl or CEMxl74 cells. These levcls of 
envelope production corresponded to levels at least eight times those already sufficient for the 
immediate induction of large size syncytia (4) (results not shown). 
Fig. 1 shows the syncytium inducing capacity of the parental envelope genes together with 
the novel constructed set of chimeric envelope genes upon transfection in SupTl cells. As 
previously shown the 16.2 derived envelope induced very large syncytia, in contrast to the 16.3 
envelope, despite their high degree of amino acid homOlogy (3,4). The syncytium inducing 
capacity of chimeric envelope 23CX supports our previous observation that also the carboxy 
terminal part of the encoded envelope protein contributes to the overall syncytium inducing 
capacity of SI envelopes (4). Subsequent repeated transler of progressively smaller regions of 
the 16.2 SI gene to the 16.3 NSI background demonstrated that the transfer of syncytium 
inducing capacity could be achieved by the exchange of only the small fragment generated by 
the Avr II-Bgi II restriction enzyme digestion (Fig. I). All other separately transferred gene 
fragments in this region failed to contribute to syncytium formation, also when transterred 
simultaneously with the AB region. 
Fig. 2 shows the amino acid sequence and location of the AB jj'agment on the 
transmembrane protein gp41 for all four envelope genes originally obtained from patient # 16. 
As few as seven of the only 52 amino acid residues that differ between the two parental 
envelope protein scquences 16.2 and 16.3 are situated in the AB region. With the exception of 
the lysine to threonine change at position 682 all variable residues were tightly clustered around 
position 645. Most of the observed amino acid variation is non-conservative and n'cquently 
involves charged residues. The variation of charged residues in this region however did not 
result in a significant altered overall net (negative) charge when the amino acid sequence o[the 
SI and NSI envelope proteins of patient #16 are compared (Fig. 2). 
Contribution of discrete envelope regions to cell tropism. Exchange experiments in which 
discrete gene fragments were transferred between four envelope genes obtained from patient 
#16 revealed that at least three regions are functionally involved in membrane fusion. In 
addition to the presently identified determinant located on the AB gene fragment, also natural 
sequence variation present in the V2 and the V3 region was previollsly demonstrated to transfer 
syncytium inducing capacity to the 16.3 NSI envelope (4). In order to evaluate the contribution 
of these same three regions to determining cell tropism, the complementation assay described 
by Helseth et.al. was adopted (29). Cotransfection of cells with the generated (chimeric) 
envelope constmcts together with the IllB molecular clone in which the original envelope gene 
was replaced by the CAT reporter gene resulted in virions that may introduce CAT activity in 
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FIG. 2. Location and predicted amino acid sequences of the gp41 AB region of the four envelope genes 
obtained from patient 16. Amino acids identical to those of the consensus sequence are indicated by (.), the 
amino acid positions given correspond to the complete envelope protein amino acid sequence as previously 
published (3). Abbreviations: Y, variable region; FD, fusion domain; TM, transmembrane region. Symbols: 
*. potential glycosylation site; A. amino acid variation between envelope genes 16.2 and 16.3, 
target cells when the envelope protein used for complementation supports entry of these cells. 
Depending on the envelope gene - target cell combination, up to 100 fold increase in CAT 
activity was observed as compared to a control infection in which the plasmid controlling 
envelope expression was omitted or when a potent neutralizing monoclonal antibody directed 
to the envelope protein was present during infection (data not shown). These control 
experiments demonstrated that a true envelope mediated phenomenon was assayed. Each 
complemented virus stock was fiu1hermore monitored for p24 and envelope protein contents. 
The relative amounts of p24 and envelope proteins produced after cotransfection was similar 
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to the amoullts of these proteins expressed upon transfection of a single complete molecular 
clone. The relative quantity of envelope proteins present in the vims stocks after p24 
standardization varied up to threefold. No correlation between capacity to infect and relative 
envelope protein expression was observed (not shown). Finally, repeated functional testing of 
the (chimeric) envelope genes in the envelope complementation assay gave similar results for 
every single construct. 
Fig. 3 shows the results of infection experiments using the foll!' original parental genes and 
a selected set of chimeric genes as envelope protein donors and SupTl, PBMC, MT2, and H9 
gpl20 
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13SE iii;;;;;;;;;;;;;;;;; ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;1 
23SE i;;;;;;;;;;;;;;;;;;;m;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;1 
13HC I;;;;;;;;::::::::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::! 
23HC 1:::::::::::::::::::::::::::::::::::10'101::::::::::::::::::::::::::::;:;:;:::::::::::::::::::::;:::;:;:::::;::! 
23AB I::::::::::::::::':::::::::::::::::::::::::::::::::::::::::::::::::::'::::::::::::::17/4::::::::::::::::::::::::! 
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FIG. 3. Summary of parental and chimeric envelope genes products (see legend of figure I) together with 
their syncytium inducing capacity in SupTI cells and capacity to be involved in viral entry as shown in the 
envelope complementation assay. Syncytium inducing capacity of the 13SS, 23SS, 13HC and 23HC chimeric 
envelope genes have been determined previously (2,4). Arbitrary estimates of syncytium formation: +, small 
syncytia; ++, intermediate size syncytia; +++, large syncytia; -, no syncytia (for details, see material and methods 
section). Arbitrary estimates of CAT activities obtained in the envelope complementation assay are expressed 
relative to the CAT activity induced by virus complemented with the 16.2 envelope glycoprotcins: -, background 
or low CAT activities less than 5 percent; +, 10 to 20 percent CAT activity; ++, 21-35 percent CAT activity; 
+++, more than 70 percent CAT activity. 
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as target cells. We chose SupTl cells since these cells were used in our syncytium forming 
assays, MT2 cells since these are used by others to discriminate between SI and NSI isolates 
of HI V-I (35), H9 as a generic T cell line and PBMC's as primary cells since our envelope 
gcnes are derived from vinlses that have not been adapted to replicate in T-cell lines. None of 
the complemented virus stocks was able to significantly infcct H9 cells and only very low CAT 
activities (less than three times background activity) were found. Both the SI envelope genes 
16.1 and 16.2 however mediated infection of the two othcr target T-cell lines tested (SupTl and 
MT2) which is compatible with the notion that syncytium inducing HIV-I isolates can 
productively infect continuous T cell lines. In all cases the 16.2 SI envelopc gene resulted in 
the highest CAT activities induced in the target cells (58000-69000 cpm). Thc CAT activities 
obtained in the envelope complementation assay for all envelope genes arc expressed relative 
to the CAT activity induced by virus complemented with this 16.2 envelope gene. The NSI 16.4 
cnvelope gene products also conferred tropism for SupTi and PBMC (respectively 25 and 33 
percent), but not for MT2 cells. No CAT activity over background was detected in any of the 
target cells tested when the 16.3 NSI envelope gene was used in the complementation assay. 
The chimeric envelope genes tested next all contained one SI envelope gene fragment in the 
16.3 NSI background. The SS fragment contained the V2 region, the HC fragment contained 
thc V3 rcgion and the AB fragment contained the AvrII-BglII fragment of the gp41 coding 
region of the envelope gene identified as described above (Fig. I and 2). No significant 
increases of CAT activity were found for the 13SS and 23SS constl1lcts in any of the cells 
tested (up to 3 percent). Using the HC ti'agment, either from 16.1 or 16.2 SI envelope, 
signiticant increase in CAT activity was detected in MT2 cells (respectively 21 and 10 pcrcent). 
Thc gp41 AB fragment ti'om 16.2 in the 16.3 background conferred tropism for SupTI cclls 
and PBMC (respectively 24 and 14 percent). 
DISCUSSION 
Functional analysis of chimeric HIV -I envelope genes constl1lcted ti'om genetically highly 
homologous envelope genes demonstrated that a region of the transmembrane glycoprotein of 
HIV-l is involved in syncytium induction and viral tropism. 
Exchange of gene fragments between phenotypically well characterized envelope genes 
obtained at a single time point from a single donor has enabled us previously to identify the 
variable regions V2 and V3 as natural determinants in syncytium formation (4). Here we have 
shown that also the small "AB region" of gp41 controls syncytium induction (Fig. I). Thus the 
differences in syncytium inducing capacity of the simultaneously obtained parental vimses is 
apparently based on amino acid variation situated in at least three envelope regions located in 
either the transmembrane - or the surface glycoprotein. 
The envelope complementation assay as described by Helseth et.al. (29) was used to tcst 
selected chimeric recombinant envelope proteins for their ability to support membrane fhsion 
in envelope protein mediated entry of different target cells. The parental and the chimeric 
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envelope proteins displayed different capacities to mediate infection (Fig. 3). Both parental SI 
envelopes mediated entry in PBMC, SupTl, and MT2 cells in contrast to the 16.3 NSI 
envelope. The complementation experiments with the 16.3 based chimeric envelope genes 
demonstrated that the gp41 AB region determined tropism for PBMC and SupTl whereas the 
V3 region from either 16.1 or 16.2 SI origin provided tropism to MT2 cells. This observation 
is in line with the use of MT2 cells as an indicator cell-line for convenient discrimination of 
SI versus NSI virus variants and this MT2 tropism appears to be determined by the V3 region 
at the level of viral entry. These results indicate that both membrane fusion processes are 
governed by overlapping envelope determinants. However, interesting differences were 
observed. First, the SI derived V2 and V3 regions which transfer syncytium inducing capacity 
to the 16.3 NSI envelope in SupTl cells did not transfer the capacity to mediate entry into these 
cells. Furthermore, different envelope regions appeared to control the process of entry into 
different cells. 
The 16.3 NSI envelope differs in only II amino acid positions throughout the 
transmembrane - and the surface glycoprotein, from the 16.4 NSI sequence (3). As lor 16.4 no 
syncytia were detected in SupTl cells upon expression of the 16.3 envelope gene (4). However 
the 16.3 complemented virus dilTers from 16.4 in its inability to infect SupTl cells and PBMC. 
All the four parental envelope genes were obtained by PCR from vimses biologically cloned 
on peripheral blood mononuclear cells. Neve11heless the 16.3 gene products did not support 
infection of PBMC. Since chimeric envelope proteins containing the V2 region, the V3 region 
or the gp41 AB fragment of SI origin in the 16.3 background, were all capablc of inducing 
syncytia, and two of these chimeric envelopes mediated viral entry, it is unlikely that the 16.3 
envelope proteins were not functional. The inability of the parental 16.3 envelope gene products 
to support replication in PBMC may indicate that the gene products used in the 
complementation assay must interact with another HIV-I gene product encoded by the HXB2 
background and that this interaction is not operational in the case of 16.3. In this view it should 
be postulated that the gp41 AB fragment contains a determinant for this interaction which is 
essential for replication in PBMC and SupTl but not for replication in MT2. Alternatively, the 
inability of the 16.3 envelope proteins to support replication in PBMC, may be due to the fact 
that the 16.3 envelope gene may have been amplified from virus replicating in macrophages, 
present during the biological cloning procedure but absent in the complementation assay since 
CAT activity was only determined in the non adherent cell fraction. We have attempted to 
address this question by using monocyte derived macrophages as target cells in the 
complementation assay. No CAT activities over background were found in these cells for any 
of the four parental envelope genes tested (results not shown). However, it remains to be 
determined whether the envelope complementation assay is sufficiently sensitive to detect low 
level entry or replication in these target cells. 
Since the chimeric envelope proteins tested in the envelope complementation assay were only 
selected on the basis of their actual capacity to induce syncytia in SupTl cells, we can not 
exclude that also other envelope regions, in addition to the AB region of SI envelope origin, 
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may transfer capacity to entcr SupTl cells. However even within the limited set of chimeric 
envelope proteins tested, amino acid variation in different envelope regions was shown to 
contribute to a different extent to membrane fllsion processes involved in syncytium formation 
or viral entry. The observation that amino acid variation in three different envelope regions 
contributes to syncytium formation in SupTl cells whereas only viral entry in supTl cells is 
transferred by the AB region, suggests that membrane nlsion involved in viral entry is more 
restricted, or that the threshold of syncytium formation is lower. This may be due to nlllctional 
differences of envelope proteins on the virion or on the cell surface. Alternatively, it may be 
based on differences in additional membrane interactions like e.g. those exerted by ICAM and 
LFA-I, since it has been reported that these proteins may be involved in syncytium formation 
although not in the process of viral entry (10,30,45). The observation ofa less restricted nlsion 
process in syncytium formation that is controlled by amino acid variation in several regions of 
the envelope proteins is in line with the results of several other studies in which syncytium 
formation usually proved to be inhibited more easily than viral entry (11,29,36,54). As a 
consequence of the observed extension of the cellular host range of vimses isolated from the 
same individual over time, which may be based on amino acid variation in different envelope 
regions for ditTerent cell types (like e.g. V3 for MT2 and AB region for SupTl), the extension 
of the range of permissive cells is likely to coincide with the increased capacity of these vimses 
to induce syncytia. In this view the syncytium inducing phenotype of HIV-l is property 
emerging as a direct consequence of the extended range of permissive cells. Different envelope 
regions which may independently be involved in viral entry, may all individually contribute to 
syncytium formation. 
A nlllctional role for the AB region in the membrane nlSion underlying viral entry is 
supported by rep0l1s of neutralizing antibodies directed to this region (9,31,43). In this light it 
is interesting to note that the observed cluster of variable residues in the AB region is 
surrounded by four of the five potential glycosylation sites in gp41 (3) (Fig. 2) of which three 
are highly conserved in H1V-1 (17,44). Such an addition of carbohydrates may offer the virus 
the opportunity to escape [rom neutralizing antibody since addition of glycans may alter 
recognition by the antibody (1,6). Studies with T cell line adapted vims strains also support a 
role for the gp41 AB region in membrane nlSion. Several mutations of conserved amino acids 
around position 675 were shown to result in increased syncytium forming capacities (12), and 
recentiy two studies reported an inhibitory effect of synthetic peptides, derived Ii'om sequences 
overlapping the here identified AB region, on syncytium formation (58) and virus replication 
(33). It has been postulated that this region, predicted to form an alpha-helix, is involved in the 
conformational rearrangements which lead to a "fusion-attack complex" of gp41 in which the 
nlSion domain tinally interacts with the target membrane (40). Since the AB region links the 
gp41 cysteine loop, that may form pat1 of the gpl20 interaction site (50), with this alpha-helix, 
it may be speculated that the AB region plays a role in transducing the trigger for gp41 
conformational changes as initiated with CD4 binding to gp120. Natmal sequence variation in 
the AB region may thus modulate the capacity of the envelope complex to mediate membrane 
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fusion. 
In conclusion, the present studies demonstrated that natural sequence variation in multiple 
HIV-I envelope regions, on both envelope proteins gp41 and gp120, control syncytium 
formation. These regions however seem to play distinct roles in the membrane fusion process 
underlying viral entry. While different envelope regions independently control viral entry of 
different cells, fhnctional interactions of different viral determinants with (multiple) cellular 
determinants apparently result in unique combinations leading to entry into specific target cells. 
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Schulten ivl, Andeweg AC, Bosch ivlL. Osterhaus ADME. Enhancement of Infectivity of a Non-
Synctium-Inducing HIV-\ by SCD4 and by Human Antibodies that Neutralize Syncytium-Inducing 
HIV-1. Scand J ImmunoI1995;41:1S-22 
Enhancement of virus infectivity after sCD4 treatment has been documented for SIVagtn and HIV -2. It 
has been suggested that a similar phenomenon may playa role in HIV-\ infection. In the present study 
we have analysed biological activities of virus neutralizing polyclonal and monoclonal human antibodies 
and of sCD4, towards HIV -I chimeras with envelope proteins deri\'ed from one donor, which display 
difTerent biological phenotypes. The antibodies, which recognize the V3 and/or the CD4 binding 
domains of the glycoproteins of these viruses and also sCD4 showed different levels of virus neutralizing 
activity toward the syncytium inducing HIV-I strains. In contrast, they all dramatically enhanced the 
inlectivity of an HIV-I chimera with an envelope glycoprotein displaying the non-syncytium-inducing 
phenotype. Given the relatively conserved nature of non-syncytium-inducing HIV-l surface glycopro-
teins eady after infection, these data sugge~t a major role for antibody mediated enhancement of virus 
infectivity in the early pathogenesis of HIV -I infection. 
Prole,I'sol' Dr A. D. ,\1. E. OS/('rllal/s, Ems/1//IS Ullil'ersit)' Rotterdam, II/still/Ie of Virology, Dr 
Moie1l'alerpiein 50, P.O. 80x 1738, 3000 DR Rotterdam, The Nether/ul/ds 
INTRODUCTION 
The identification and chanlctcrization of"irlls neutntiization 
inducing (VNI) antigenic sites on the glycoproteins of HIV-I 
have been the focus of many studies (for review see [I]). For 
practical reasons, HIV-I strains and primary HIV-l isolates 
which elficiently replicate in T cells have predominantly been 
used to study virus neutralization [II. In this context it is 
important to note that macrophage-tropic non·syncytium-
inducing (NSI) variants with low emdcncy of replication in T 
cells predominate in the asymptomatic stage and T cell line-
tropic syncytium inducing (SI) variants arc almost exclusively 
found in late stages of the infection [2, 3J. The macrophage-
tropic NSI strains have been shown to e.xhibit a relatively 
high level of conservation in their VNI V3100p [4J. It has bccn 
suggestt'd Ihat escape from virus neutralizing (VN) antibodies 
is based on the relatively high mutation rale generully 
tCurr<IH addr~jj: BPRC. lango: Kki\\~g 151. 2~.'!S GJ Rij,\\ijk. Th~ 
NethalJuJ5 
tCurr~nl ;ldo.lr~:;s: Region.11 Prinult' Re,~.lr~h Cenla. 1--121 HC.lllh 
Sckn,~.\ C<.'nler SJ-50. Uni~~r;;il)' of W.l,hington. Seatlk WA o,\.~lo,\S. USA, 
observed in the virus envelope glycoprotein. Given the fact 
that also the CD4 binding domain (bd) is relatively conserved. 
another mechanism or escape from VN antibodies may be 
postulated for the relative success of NSI/macrophage-
tropic viruses to persist in the host. To study the basis of this 
apparent paradox, we have used an el/)' complementation 
assay in which the biological activities could be compared of 
human HIV-l-spedfk monoclonal and polyc1onal antibody 
preparations towards identical HlV-1 strains only differing 
in their glycoproleins which displayed an SI or an NSI 
phenotype. 
MATERIALS AND METHODS 
IIl1l11al1 WI/ihodh''i. sCD.J ami HIV-I 1'/II'dOpt' glyf(!profdll~. Th<.' 
human monoclon<ll [lnlibodies (UuMoAbs) used are directed ,lgainst 
(he CD4 binding domain (GP13 and GP68 15]), a highly conserved 
conformational epitope on gp41 (Kt4 (6j) and the HIV-I gpl20 V3 
loop {257-D PD. FUrtherl11Me sCD.t (kindly provided by Dr I. Jont's 
through (he MRC AIDS directed programme) and HIV1G [8]J 
(kindly provided by Dr H. Schuitemaker) were used as VN agents. 
Tht' ('/II' genes used 116.1 (SIl. 16.1 (SIl. 16.4 (NSI). MN and IIIB] for 
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the production of envelope glycoproteins in the capture antibody 
ELISA and for the production of chimeric viruses have pre~'iously 
been characterized and described [9, 10 .... 12J. 
Cap/llrt' IIIlIihody ELISA for me/HI/rt'lIIelll of relalil'e affillity. The 
relative affinity of the HuMoAbs used in the present study was 
detemlined in a previously described ELISA. In short, ELISA plates 
(Costar, Cambridge, MA 02140, USA, cat. no. 3590), coated with 
amnity purified sheep immunoglobulins directed against the carboxy 
terminus of gpl20 (Aalto BioReagents, Dublin, Ireland, cat. no. 
D7324), were incubated for 2 h with cdl lysate of recombinant 
vaccinia virus (rVY) infected HELA [13) cells (16 (NSf) and 16 
(SI)) or HlV-J infected SupTi [14J cells (MN [IlJ and 1I1B [12J). 
Plates were subsequently washed and incubated with serial dilutions 
of previously described HuMoAbs (OPI), OP68 [5) and 257-0 [7J). 
The ELISA was completed and read as previously described [IOJ. 
The relative amount of antigen bound to the ELISA plates was 
calibrated by using the same ELISA protocol with serial dilutions of 
the antigen and a standard excess concentration of polyc\onal serum 
from seropositive individuals. The data presented are the mean 
values of duplicates in one assay which was performed at least 
t\\ice with similar remits. 
Em'dope tralls-complementatioll assay. This asSay was based on a 
previously described /rall~-complementation assay in which an 1'111'-
defective HIV-I provirus, encoding the bacterial CAT reporter gene 
[15J, was complemented for a single round of replication by a set of 
re.::ently described HIV-I envelope glycoproteins [9J. The elll" genes 
encoding these glycoprotcins were derived from biologically cloned 
SI or NSI viruses, isolated from one single donor (number 16) at a 
single point in time in natural target cells (peripheral blood mono-
nuclear cells {PBMCj). In the complementation assay the genes 
encoding these envelope glycoproteins were co-transfected into a 
C04- cellline (COS (16)) together with the ellf-defective molecular 
clone of the HIV·I HID sirnin. This resulted in the production of 
virions carrying heterologous envelope glycoproteins which could 
infect CD4' cells, like the SupTi cells or PHA stimulated PBMC 
used in this study. After) days cell free supernatants were collected 
Table I. Relative affinities of HuMoAbs for different HIV-I 
envelope glycoproteins 
HIV-I strain (phenotype) 
16.1 16.2 16.4 MN 
HuMoAb Specificit>' (SI) (SI) (NSI) (SI) 
K!4 gp41 83' 67 67 33 
OPI3 C04 bd 83 83 33 250 
OP68 CD4 bd 67 67 67 125 
257-0 V3 domain 125 125 125 125 
nm 
(SI) 
67 
250 
250 
• Reciprocal ofdilutionsofMoAbs, starting at 1 pg!ml, still giving 
50% of maximal binding with the respective envelope glycoproteins 
in a capture antibody ELISA as a measure of relative affinity. The 
data presented are the mean values of duplicates in one assay which 
was performed at least twice with similar results. 
t No binding: 00450nm values remained at background le~'e!s at 
the concentrations tested. 
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by centrifugation and frozen at - 135°C. For infcdion the aJnount 
of p24 antigen, as determined with a p24 ELISA kit (V5, Organon 
Teknika, Doxte!, The Netherlands) was calibrated and the level of 
em'dope expression WilS checked with the capture antibody ELISA 
(sec above). infe(:tion was performed overnight at 37'C in I ml 
medium. After 24 h the cells \H're wilshed and cultured for 72 h. 
CAT activity in these ccUs was measured in a previously tbcribed 
CAT assay using a two-phase extmction system (17). CAT activities 
expr<!ssed in the cdls were considered a direct measure of virus 
infectivity in these a~says. 
RESULTS 
Refa/ire o/filli/y (!f HuMoAbsfor HIV-J {'lire/ope 
gl.l'copro/dlls 
The HuMoAbs used in these experiments were selected on 
basis of their epitope specificities and relative affinities in the 
CaplllTe antibody ELISA for different HIV-I em'clope glyco-
proteins (Table I). The same recombinant envelope glyco-
proteins were used in the CII\' complementation assay (Table 
2). Both CD4 bd specific HuMoAbs GPi3 and GP68 showed 
an overall higher relative amnily for the glycoproleins of the 
T cell line adapted HIV-I strains IIIB and ~'IN than for the 
glycoproteins derived from the donor number 16 HIV-l 
strains. The V) loop specific HuMoAb 257-0 showed a 
high relative affinity for the glycoprotcins of the /I.·IN-like 
HIV-l strains and no binding was observed in this ELISA 
with the glycoproteins of HIV -I IIIB (Table I). 
Virus I/eutralization alld ellllflll("('II1(,II/ (!f riml il!fl..'clhity hy 
sCD4 al/d h/ll1lol1 mlfihotiies 
The VN activities of human antibodies and sC04 toward T 
cell line adapted strains HIV-I MN and HIV-I mE (Table 2) 
have been documented previously (lO-i3}. The CD4 bd 
specific HuMoAbs GP13 and GP68 as well as HIVIG and 
sC04, inhibited infectivity of HIV-I 16.2 (SI) only to a 
limited extent « 50%) when tested al u concentration 
(l5J1g/ml) that significantly inhibited infectivity of HIV-I 
IIIB in the e!lV complementation assay (reduction 10 15%. 
12%, 9% and 8% respectively) (Table 2). The V3 domain 
specific HuMoAb tested at the same concentmtion, neutral-
ized HIV-I 16.2 (SI), as was shown by a reduction of CAT 
activities to 0.7% (Table 2). No major biological activity of 
any of the antibodies tested or sCD4, was observed against 
HIV-I 16.1 (SI) as was shown by a reduction of CAT activity 
with 2-9Ojo only, using 1511g/ml antibody (Table 2). 
In contrast to the VN activities observed with the SI 
viruses, the same concentration of all these VN antibodies 
and sCD4 caused a dW.malic enhancement of infectivity of 
HIV-I 16.4 which has a NSI envelope (> six-fold increase in 
CAT activity) (Table 2). In order to demonstrate the dose 
dependency of these phenomena, dose response curves were 
made with the V3 domain specific Hu:l\·loAb 257-0, which 
exhibited the highest allinity for all the envelop proteins 
Table 2. Virus neutralizing and enhancement adi\'ities of human antibody prep(l.r(l.tion'i and ~CD..j 
Viru~ strain (biologi(al phenotype) 
MN" IIiB IIIB 16.1 16,2 ]0.4 
Antibody preparation Epitope (SI) (SI) (SI) (SI) (SI) (NSI) 
none lor/i 100 100 100 
72.401 * 55.065 54.42R [.;,239 
KI4 gp-ll 10J OS 106 
" GPIJ CD4 bd IS 97 05 732
UP@ CD4 bl! + + 12 9J 65 741 
sCD-l CD-l bd + 9 92 S4 620 
257-D V3 97 91 0.7 655 
HIVIG poly + + S 95 95 744 
VN a~~ ... y ell I' complementation a"ay 
t DUl' tn dilfcn::m:cs in the VN a~"i"'}'s u,ed, hiologi(\\1 activities are indicatcd:.ls high (+) or undetectable (-). 
II Pcn.:ent:.lgc of CAT a~ti\'ity rdatiw to the CAT at·tivity ob,cncd in the ah,ence ofantibouy, Thc nlCitll value 
\\ithin one e.\periment obtained \\ith SupTl telh h given. The antibody prepanltions were tested:it least twit,;-
\\ith thL' ,aml' chimeric viru'i yi,;-lding ~imilar re.;uit,. 
"CAT activity in ("!lunt, p¢T minute (("pm). h ... d:ground \' ... [u~s range from 30n to XOOtpm, 
tested (Table I). Clear dose related VN and enhanc('m('nt 
activities were found with this antibody in the 1.'11\' romp!e-
mentation assay with HIV-I 16,2 (SI) and HlV-1 16.4 (NSI) 
fespedivcly (Fig, I). When the,;e experiments were repeated 
in PHA stimulated I'BivlC essentially the ~ame phenomena 
were ohservcd. The overall differences wefe however k,~ 
pronolillced in this system (uvemge enhancement about 
50%) prohably due to a limited cellular host range of this 
virus (A, C. Andeweg '" a/, unpublished observations). 
DISCUSSION 
Using an assay that is highly sensitive for measuring viral 
entry we have shown in the present study that both sCD4 and 
human antibodies which neutralize SI HIV-I strains Illay 
enhance infectivity ofNSI HIV-I strains. 
HIVIG, sCD4 and the CD4 bd specific HuMoAbs GPI3 
and GP68 readily neutralized the HIV-l mB strain whereas 
limited or no VN activity was observed against the primary 
HIV-I strains from donor number 16. This supports previous 
ohservations that sCD4, CD4 bd specific Hul' ... loAhs and 
HIVIG have little or no neutralizing activity against primary 
virus strains (~'1. Schutten, personal observation and [IRJ). It 
has hecn shown by several groups that VN capacity of V3 
loop specific MoAbs toward T cell line adapted HIV-I strains 
is dependent on the affinity of the antibody for the V.1loop of 
the HIV-I strain used [7, 19]. However, in the present 
study we showed that VN activity of V3 loop specilic 
HurvloAb 257-D toward the SI HIV-I strains from donor 
number 16 is not directly related to its relative affinity for the 
glycoproteins involved: identical relative amnitie~ for the 16.1 
(SI) and 16.2 (SI) envelope glycoproteins were observed, but 
reductions in the ('m' complementation a~~ay proved to be 9 
and 99 . .'% respectively. This was unexpected since both 
envelopes exhibit SI capacity and a 95% overall predicted 
amino add sequence homology exists between these envel-
opes fIJI. Since we have previously shown that other domains 
than the V3 domain arc involved in membrane fusion (WI, it 
may be speculated that HIV-I 16.1 is less dependent on the 
V.' domain to establish membrane fusion and infection, 
The efficiency of entry into T celllilles of the NSI HIV-I 
strain 16.4 was significantly lower than that of the SI HIV-I 
strains 16.1 and 16.2 as shown by a > six-fold lower CAT 
activity. The infectivity of the NSI HIV-l strain was however 
enhanced to levels comparable to those of the SI HIV-I 
strains by the administration of sCD4 or antibodies that 
neutralized these SI HIV-I strains, Different mechanisms 
for HIV-I specific antibody mediated enhancement have 
been described, including Fc receptor- and complement-
mediated enhancement [20, 21]. Two observations argue 
against the same mechanism in our experiments. Firstly, 
SupTI cells do not express Fc rcceptors [14) and complement 
was not present in the assays. Secondly, enhancement of HI V-
1 16.4 (NSI) was also observed with sCD4 (Table 2). An 
explanation for the observed enhancement can be found in a 
mechanism previously described for the enhancement of non-
cytopathic SIV agm infeelivity and induction of HlV-2 
mediated cell fusion ofCD4- cells, by sCD4. In these systems 
sCD4 docs not induce dissociation of surface glycoprotein 
(SU) from infected cells [22, 23]. In contrast, sCD4 does 
III 
500 
400 
E fr 300-
'5 
~ [ 
~ 
e 200 
1i 
o 0.01 0.1 10 
concentration 257-D in (P9/ml) 
--B-16.1 * 16.2 -A 16.4 
fig, I. Virus neutralizing and infectivity enhancing activities of 
serial dilutions of HuMoAb 257·D using SupT! ceUs in the ('III' 
complementation assay \\llh HIV-! 16.1 (SI), HIV-J 16.2 (SI) and 
HIV-] 16.4 (NSI) chimeric viruses. Counts per min (epm) obtained 
in the aS5ays with lIlltibndies, arc expressed as percI!nt3gcs of cpm 
obtained in the :lSSay carried nut in thc absence of antibodies. 
Dotted line represents 50% inhibition of virus infeclivity. 
induce dissociation of SU from cells infected with T cell line 
adapted HIV-J strains which are readily neutralized by sCD4 
[24}. We hypolhc~izc that both sCD4 and the antibodies we 
studied, cause conformational changes in the viral envelope 
complex of certain NSI/macrophage-lropic HIV-I strains 
exposing cryptic fusion sites as was also shown in the 
SIVagm and HIV-2 systems {22, 23]. These changes would 
allow a marc emdent virus-cell fusion that is less dependent 
on the presence of CD4 on the t<Hget cell membrane. 
Taken together our data suggest that naturally occurring 
antibodies to the so-called HIV-I VNI antigenic sites, may 
cau~e either neutralization or enhancement dependent on the 
biological phenotype of the virus recognized. If indeed our 
findings arc a reflection of a more general phenomenon of 
enhancement also found in infections with other lentiviruses 
like HIV-2 (23] and SIV<lgm [22], they may explain why early 
after HIV-l infection predominantly viruses with an NSI/ 
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macrophage-tropic phenotype are found and why these 
viruses arc able to persist in the infected host despite the 
conserved nature of their 'VNI' antigenic sites. The observed 
enhancement would actually favour replication of viruses 
displaying the NSI/macrophage-tropic phenotype, whereas 
viruses displaying the SIJT cell line-tropic phenotype arc 
neutralized. 
These observations may not only have implications for our 
understanding of the pathogenesis of HIV-l infection but 
also for the development of immunization strategies. If this 
observation is the reflection of a more general phenomenon, 
the induction or administration of antibodies that neutralize 
viruses of the SIJT cell-tropic phenotype, which is a eOI11-
monly followed strategy at present, may actually be counter 
productive. 
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CHAPTER 
Summary and General 
Discussion 

Summary and General Discussion 
The studies presented in this thesis aimed at identifying and characterizing envelope protein 
determinants involved in HIV-I induced membrane fusion. Identification of such determinants 
adds to thc understanding of thc complex interactions of the HIV -\ envelope proteins with the 
target cell, that lead to membrane flision as an integral part of viral entry and syncytium 
formation. It also provides information on virus evolution under selective conditions in the host. 
When these studies were initiated most attention was focused on the V3 loop as the principal 
dcterminant controlling cell tropism and syncytium inducing capacity of HI V -I. The results of 
the studies presented here demonstrate however, that in primary virus isolates at least three 
determinants located in different envelope regions control these membrane fusion processes. 
Furthermore, they demonstrate that antibodies may directly modulate the nmction of primary 
H1V-l envelope proteins in membrane nlsion. 
Experimental approach. The studies presented focused on a limited numbel' of genetically 
highly homologous primary envelope proteins which had been obtained from selected vimses 
differing in their syncytium inducing capacity. In most of these studies envelope protein 
functions were studied independently of the rest of the background of the viruses from which 
they had been obtained. The capacity of individual envelope proteins to induce membrane 
fusion was determined in syncytium forming assays upon expression in PBMC or T cell lines. 
To this end recombinant vaccinia viruses expressing envelope genes were generated or envelope 
genes were transfected into target cells upon cloning in an eukaryotic expression vector. To 
determine the capacity of envelope proteins to mediate viral enlly (cell tropism) an envelope 
complementation assay was used. In this assay an envelope gene deleted genome of HIV -I was 
cotransfected into cells with envelope genes of other vimses in order to study envelope gene 
determined phenotypes. The contribution of individual envelopc regions to membrane fbsion 
was determined by functionally testing chimeric envelope genes generated from parental 
envelope genes that display different syncytium inducing capacities. These chimeric envelope 
genes were tested in the syncytium forming assay and in the envelope complementation assay. 
This approach allowed the independent study of thc contribution of different envelope regions 
in the processes underlying syncytium formation and viral entry. The inherent limitation of the 
studies presented in this thesis is that they focus on a set of' glycoproteins Ii'om one or a limited 
number of individuals. This may however also be considered the strength of these studies, sincc 
the consequences of envelope protein variation can be shldied against one and the same 
background. Due to the limitation indicated it should be realized that additional regions beyond 
the ones identified here may be involved in the mernbrane fusion process. However the 
approach chosen resulted in the identification of three regions involved in syncytium formation 
and viral entry, illustrating the complex nature of the phenomena studied. Finally it may be 
postulated that apart from the positive effects of certain envelope regions on membrane fusion 
activity, also negative effects may exist, although no evidence for this supposition was found 
in the studies described in this thesis. 
117 
HIV -1 phenotype analysis: the role of the envelope glycoproteins. During primary HIV-I 
infection, isolated vims populations display a remarkable homogeneity, both in genetic sequence 
(31,60,61) and in biological properties (61). Intra-patient virus variability increases with time 
during which also the specific immune response develops. Extensive sequence analyses of virus 
populations later in the course of HIV -I infection have revealed the presence of quasispecies; 
populations of highly homologous viruses yet all differing from each other (19,46,55). For the 
experiments described in chapters two and three, sets of envelope genes were studied from 
biologically cloned viruses simultaneously obtained from patients at a time that both SI and NSI 
variants were present. These genes may be considered samples taken out of a pool of 
quasispecies. The complete envelope sequences of eight biological clones obtained from two 
individuals (# 16 and #320) were studied in chapter 2. Recombinant vaccinia expression of these 
envelope genes demonstrated that variation of the envelope gene alone may be sufficient to 
explain the observed variable syncytium inducing capacities of the respective parental viruses. 
The predicted protein sequences obtained from the two individuals exhibited amino acid 
variation which was mainly located in the previously denominated variable regions. Intra-patient 
phenotype associated sequence variation (SI versus NSI) was present in many envelope regions 
but appeared not to be conserved between the sets of envelope sequences obtained from the two 
different donors (chapter 2). This analysis did not provide information on the location of 
putative determinants for syncytium formation. Interestingly, analysis of an extended number 
of envelope genes obtained from individual #320, as described in chapter 3, showed that amino 
acid variation determining the syncytium inducing capacity was most likely located in the CI 
to V4 region of gp120. The analysis also revealed, albeit by exclusion, that determinants for 
cell tropism resided in envelope regions outside the V3 region. Furthermore comparison of the 
sequences demonstrated that some of the envelope genes most likely resulted from genetic 
recombination events in vivo. 
In chapter 4 and 7, genetic exchange experiments between envelope genes of SI and NSI 
origin were presented. For these studies the envelope genes obtained from patient # 16 were 
used. It was shown that at least three envelope regions contain determinants for membrane 
fusion. In addition to variation in the V3 region, for which already a role had been 
demonstrated, also variation in the V2 region of gp 120 and in a small region of gp41 (the "AB 
region ll ) was shown to contribute to differences in syncytium inducing capacity. Furthermore 
within this set of envelopes, the V3 region and the AB region were identified as natural 
determinants involved in HIV -I cell tropism. 
The V3 region. Since it was shown that antibodies directed to the V3 loop neutralize HIV-I 
infection (21,27,37) many studies have focused on this envelope region. It was demonstrated 
that infection and syncytium formation are blocked by anti-V3 antibodies after binding of 
gpl20 to CD4 (35,51). Furthermore it had been demonstrated that changes in the V3100p could 
abolish membrane f\Jsion capacity (9,16,22,24) and could influence cell tropism 
(5,10,26,36,50,57). In addition, amino acid variation at two positions at both sides of the 
relatively conserved tip of the V3 loop, was shown to correlate with syncytium inducing 
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capacity and cell tropism (13). Indeed also the V3 loop of the envelope proteins studied here, 
displayed phenotype correlated amino acid variation at these positions. Exchange of a region 
containing the V3 loop, transferred syncytium inducing capacity aller transfection of SupTJ 
cells from SI to NSI envelope backgrounds. Furthermore, the experiments presented in chapter 
4 suggested a functional interaction between the V3 region and other envelope regions in 
syncytium formation. This t1nding is in favour of a multi-determinant process of membrane 
fhsion. 
As shown in chapter 7, the SI derived V3 region contributes to MT2 tropism but not to 
SupTJ tropism. Apparently the process of SupTJ entry is a more restricted event than the 
process of SupTJ syncytium formation, since this SI derived V3 region did confer the capacity 
to induce syncytia in SupTJ cells to an NSI envelope background. Upon sCD4 incubation the 
V3 region exposure is increased (47,48). It has been postulated that the strongly positively 
charged V3 loop interacts with the negatively charged target membrane or its components. 
Others postulated that V3 loop cleavage by a cell surface protease might be necessary to expose 
a cryptic fusion domain (7,29,53). The V3 loop physically interacts with other envelope regions 
(59) and if not directly involved in the process of fusion may transfer conformational changes 
from one region to another and may thus modulate the filllction of other envelope regions in 
membrane fusion. It is however unknown at present through what mechanism the V3 region 
is involved in the process of membrane filsion. 
The V2 region. The experiments with chimeric envelope proteins presented in chapter 4 
identified the V2 region as a determinant involved in syncytium formation in SupTJ cells. This 
region alone did not transfer cell tropism to an NSI envelope background for any of the cells 
tested, including SupTJ cells. This again pointed at differences between membrane fusion 
processes involved in syncytium formation and vims entry. A role for the V2 region in 
syncytium formation, was also supported by results obtained by others with chimeric primary 
viruses (23) and by mutagenesis studies of this region in HIV-l IIlB (54). Neutralizing 
antibodies directed to the V2 region support a filllctional role for this region in membrane 
fusion processes underlying viral entry (8,17,20,40). Indeed, such a role in controlling tropism 
for macrophages in concert with the V3 loop was demonstrated for V2 (28). It is therefore 
conceivable that also for SupTJ tropism the V2 and the V3 regions must act in concert, whereas 
the transfer of each of these SI derived regions alone is sufficient to confer syncytium inducing 
capacity to an NSI envelope background. The V2 region together with the V I region forms a 
double loop stl1lcture through disulfide bonds at a common basis (34). Like the V3 region, also 
exposure of the VIN2 regions is increased aller sCD4 binding (47,48). Functional interactions 
of V2 and V3 with other envelope regions leading to syncytium formation and viral entry 
parallel results of studies demonstrating that V IN2, V3, and C4 interact physically 
(14,28,59)( chapter 4). These interactions provides a rationale for the roles of V2 and V3 in 
membrane fusion processes since the C4 region is involved in both CD4 binding and the 
association of gpl20 to gp41 (25,43). The observation that aiteration of conserved amino acid 
residues in V2 affect association between gpl20 and gp41(54) and that amino acid variation in 
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V2 determines sensitivity to sCD4 neutralization (28), both supp0l1 the importance of these 
interactions in envelope function. 
In chapter 5 it was demonstrated that single mutations in the V2 region based on the 
observed natural sequence variation in this region, did not interfere with V2 controlled 
syncytium formation. Such a fhnctionally robust organization of the V2 region may allow 
escape from immune control without immediate functional consequences for the virus. The 
analysis of genetic envelope variation as presented in chapter 6, suggested such a selective 
pressure on several envelope regions, including the V2 region. The postulated mechanism of 
AAT triplet insertions leading to an increase ofN-linked glycosylation sites may contribute to 
the masking of exposed envelope regions (chapter 6). This mechanism may explain why the 
initially reported correlation of syncytium inducing capacity with sequence length of the V2 
region could not be unequivocally confirmed (12). Possibly increase in V2 sequence length is 
the result of a viral mechanism of escape by means of insertional addition of carbohydrates to 
this functionally import region. In this view, sequence length variation is a reflection of immune 
pressure and not directly linked to functional aspects of membrane fusion. 
Other variable regions of gp120. For the envelope genes studied here, obtained from donor 
# 16, no evidence for a role of the V I region in membrane fusion processes was obtained 
(chapter 4). However, a contribution of VI amino acid variation to cell tropism (4) and 
syncytium formation (54) has been demonstrated by others. The analysis presented in chapter 
6 do reveal sequence length variation of the V I region associated with a preferential insertion 
of AA T triplets. The observation of an excess of non-synonymous over synonymous 
substitutions in this region (and the V2 region) in HIV-I infected individuals, strongly pointed 
at a positive selection for genetic variation (32) and is in line with reports describing 
neutralizing antibodies directed to this region (40). In a study probing the structure of gp 120 
with a large panel of monoclonal antibodies it was demonstrated that on oligomeric gp120-gp41 
complexes, only the V2, the V3 loop, part of the C4 region and perhaps the V I loop are 
exposed (42). Most of the conserved regions might lie within the core of the molecule, which 
is consistent with the hydrophobic nature of these regions. Since upon CD4 binding the V I, V2, 
and the V3 region exposure is increased (47,48), this gpl20 conformation may explain why 
viral phenotype determinants are mapped to these exposed regions. It is tempting to speculate 
that these regions directly interact with the target cell membrane or its components, resulting 
in membrane fusion. Alternatively, there exposure rnay also be associated with rearrangements 
in the oligomeric envelope complex in which these regions e.g. interact with other gpl20 
subunits. Few studies have focused on a role for the V4 and V5 regions in membrane fhsion 
processes. The genetic exchange experiments described in chapter 4, pointed at a possible 
contribution of an envelope region, that included the V4 and V5 regions, to syncytium 
formation. It appeared that this region enhanced the functionality of the V2 and V3 regions in 
the process of syncytium formation. Others demonstrated that partial deletion of V4 did not 
abolished syncytium formation (30), but complete deletion of the V4 region disrupted 
processing of the envelope precursor and a small inse11ion in V5 inhibited CD4 binding (30,58). 
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Additional information is needed to address the functional role(s) of the V4 and V5 regions in 
envelope fhnction. Interestingly the process of AA T triplet reiteration was also observed for 
these sequence length displaying regions V4 and V5 (chapter 6). 
Regions of gp41. On the basis of an observed sequence homology with paramyxoviruses, 
a conserved hydrophobic fusion domain at the amino terminus of the transmembrane protein 
of immunodeficiency vimses was identified (18). Inseliion of hydrophillic amino acid residues 
inhibited syncytium formation and mutations that increase hydrophobicity tend to enhance 
fusion capacity (3,15). These observations are consistent with the postulated role for this 
domain in direct target cell membrane interactions (18,47) as is the prerequisite of gpl60 
cleavage for membrane Ihsion (39). The sequence analysis presented in chapter 2, predicted 
phenotype-associated amino acid variation in the fusion domain of foUl' envelope genes obtained 
from one of the two patients analyzed (patient #16). The fusion domain of the SI derived genes 
of this patient shared a methionine at a position where the NSI genes shared the hydrophillic 
amino acid threonine. Sequencing of 12 additional Ihsion domains revealed that the same 
variation was also present in four other genes derived from another individual. Mutational 
analysis on recombinant vaccinia expressed envelope genes demonstrated however that this 
observed phenotype associated fusion domain variation alone did not interfere with the 
syncytium inducing capacity of the expressed genes. It has however not been excluded that this 
sequence variation contributes to syncytium formation in concert with the V2 Of the V3 regions 
(chapter 4). Indeed, the functional role lor this domain in membrane fusion may be more 
complex since it was observed that insertion of hydrophillic residues does abolish syncytium 
formation of HIV-2 whereas the process viral entty was almost unaffected (52). It is also 
demonstrated that sequence variation in this region of H1V-l can be involved in determining 
cell tropism (2). 
In chapter 7, a discrete region on gp41 (the "AB" region) close to the transmembrane region 
was identified to be involved in determining both syncytium formation and viral entry of SupTl 
and PBMe's. This AB region contained only seven variable amino acid residues. It is 
conceivable, as discussed in chapter 7} that amino acid variation in this region controls the 
membrane fusion processes by influencing the conformational changes in gp41 that may lead 
to the activation of a Hfbsion-attack complex lf in which the fusion domain finally interacts with 
the target membrane (38). Interestingly, similar to the variable regions VI, V2 and V3 of 
gp120, exposure of this region is also increased upon sCD4 binding (47). The presence of a 
conserved cluster of potential glycosylation sites may help to protect vimses from antibodies 
directed to this region. No evidence for insertion of additional glycosylation sites through AA T 
triplet insertions in this region is detected (chapter 6). The analysis of eight envelope proteins 
obtained from donor #320 presented in chapter 3, pointed at a possible determinant for SupTl 
tropism on gp41. Comparison of the amino acid sequence variation in the AB region of 
envelope sequences obtained !i'om individual #320 and # 16 however, did not reveal a consensus 
pattern even when conserved amino acid changes that share biochemical propel1ies were 
considered. Functional and sequence analysis of additional envelope proteins will be needed to 
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clarify if this gp41 AB region is controlling membrane fusion more commonly, as is most likely 
to be the case for the V2 and V3 regions. 
HIV-l entry in the presence of monoclonal antibodies and sCD4. The highly variable 
nature of HI V-I was also demonstmted in the experiments presented in chapter 8. The envelope 
genes of patient # 16 were tested for their capacity to mediate viral entry of SupTl cells in the 
envelope complementation assay in the presence of a selected set of neutralizing antibodies. 
With the 257-D monoclonal antibody directed to the V3 loop, SupTl infection mediated by 
envelope proteins 16.1, 16.2 (both SI), and 16.4 (NSI) was respectively unaffected, strongly 
inhibited, or considerably enhanced (seven fold). Similar results, although less pronounced, 
were obtained with PBMC's, . Enhancement of the infection of 16.4 complemented virus was 
also observed in the presence of monoclonal antibodies directed to the CD4 binding site and 
with sCD4. These results show that primary HlV -1 infections may similarly be enhanced by 
sCD4 as previously reported for HlV-2 and SIVagm (1,6,49,56). This similarity may be a 
reflection of the relative strong association of gpl20 with gp41 for HIV-2, SIVagm, and 
primary HIV-l in contrast to T ceHline adapted HIV-l strains which are neutralized by sCD4 
(41). If preferential antibody dependent enhancement of infection of NSI vimses is a more 
general phenomenon, it is likely that such a mechanism may contribute to the apparent success 
of NSI vimses in infection. 
Interestingly, infectivity of the 16.4 NSI complemented vims could be enhanced by 
antibodies directed to both, the CD4 binding site and the V3 loop. Since the here observed 
mechanism of enhancement differed from other previously described mechanisms in which 
enhancement was mediated by Fc receptor or complement (see chapter 8), the enhancement 
found is likely to be the result of conformational changes of gp 120 introduced by direct 
antibody binding. Such conformational changes might be induced by cross linking oftwo gpl20 
molecules in the multimeric envelope complex by the bivalent antibodies. In this view, cross 
linking through either the V3 loops or the CD4 binding domains is apparently functionally 
similar. A very similar cross linking of two gp 120 molecules may be the result of sCD4 binding 
to the envelope protein complex since it is likely that CD4 binds to the envelope protein 
complex as a dimer (11,33). Recent results revealed that Fab fragments of a CD4 binding site 
specific antibody did not induce enhancement, in contrast to bivalent antibodies (personal 
communication M. Schutten), which supports a role for cross linking in the observed 
mechanism of enhancement. 
Conclusions. The studies presented in this thesis demonstrate that the HIV -1 envelope 
protein induced membrane fusion processes may be controlled by at least three determinants 
located in variable regions on both the surface glycoprotein gp 120 or the transmembrane protein 
gp41. These determinants were identified on the basis of their capacity to contribute to 
syncytium formation in SupTl cells. The gp41 AB region Was furthermore shown to be 
involved in determining differences in tropism for these same cells. The V3 regions contributed 
to tropism for other cells (MT2) and on the basis of recent data obtained by others it is most 
likely that also the V2 region will be involved in membrane fusion processes underlying viral 
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entry (28). Thus within the limitations of the experimental approach, it appeared that for both 
membrane fusion processes studied, amino acid variation in multiple regions may be involved. 
Furthermore the results obtained suggest, that all these regions may also contribute individually 
to the cell specificity in the membrane fusion process underlying viral entry and possibly also 
membrane fusion in syncytium formation. Whether each of these regions physically interacts 
with the target cells in membrane fusion remains to be resolved. F1lI1her progress in the detailed 
understanding of these interactions and their specificities is seriously hampered due to a possible 
control by yet unidentified cellular accessory protein(s). 
It is evident that the regions involved in membrane fusion are all subject to selective 
pressures. Evidence was however provided that the V2 region determined syncytium inducing 
capacity for the envelope genes studied here, was not easily abolished by single mutations. This 
may also hold true for the putative function for this region in the process of viral entry. This 
may be speculated to allow the vinls to escape from e.g. humoral responses by mutations in this 
region, without affecting the process of entry. It is estimated that the highly error prone viral 
RT polymerase may produce up to seven mutations in each progeny viral genome (44,45). 
Furthermore it is likely that envelope regions develop "immunity" from disadvantageous 
immune responses by the addition of carbohydrates e.g. by the presented mechanism of AAT 
triplet insertion. Additional to these mechanisms that may lead to escape, the multi-determinant 
nature of HIV-I induced membrane fusion process (in viral entry) provides another option for 
the virus to persist in hostile environments. The exchange of segments of genetic information 
between different viruses, may enhance the kinetics of viral adaptation considerably. Such an 
exchange by recombination may frequently occur in vivo as shown in chapter 3. Adaptation of 
HIV -I to a broader cellular host range possibly related to escape from immune selection in the 
course of infection, may directly lead to a change in the capacity to induce syncytia. Finally, 
the extremely flexible organization ofHlV-1 is perhaps best illustrated by the observation that 
binding of antibodies to the envelope proteins can even promote viral entry. Enhancement of 
inlectivity was notably observed 'vith antibodies that could neutralize another highly 
homologous primary virus. 
Taken together, the results of this thesis have demonstrated that several envelope regions, 
either alone or in concel1, contribute to the extreme capacity of HIV -I to adapt its phenotype 
to the continuous and permanently changing imlllune response of the host, enabling the virus 
to persist in a hostile environment. 
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Samenvatting 
Het in dit proefschrift beschreven onderzoek had als centraal doe I het identificeren 
en karakteriseren van determinanten van de envelop-eiwitten die betrokken zijn bij 
membraanfusie-processen die geYnduceerd worden door het humaan 
immuundeficientievirus type 1 (HIV-I). Deze processen vormen de basis van virlls-
"entry" en van de vorming van reuzencellen of syncytia. De bestlldering van deze 
determinanten beoogde het inzicht te vergroten in de complexe interacties van de HIV -1-
envelop-eiwitten met de gastheercel. Een tweede doe Is telling was informatie te 
verkrijgen over virllsevolutie onder selectieve condities zoals aanwezig in het 
geYnfecteerde individu. Bij de aanvang van dit onderzoek was de meeste aandacht gericht 
op de functie van het derde variabele domein (V3) van het envelop-eiwit gpl20 van 
HIV -I als determinant van membraanfhsie-processen. Het hier besclu'even onderzoek 
leidt echter tot de conclusie dat tenminste drie envelop-eiwit-determinanten de 
membraanfusie-capaciteit van primaire envelop-eiwit-complexen bepalen; deze 
determinanten zijn gelocaliseerd in drie verschillende envelop-eiwit-domeinen 
(waaronder V3). Bovendien wordt aangetoond dat interactie tussen door de gastheer 
aangemaakte antistoffen en de envelop-eiwitten, niet aileen kan leiden tot virllS-
neutralisatie, maar ook tot een toenall1e van HIV -I-"entry" in de gastheercel. 
De algemene introductie - hoofdstuk I - geeft een kort overzicht van de moleculaire 
biologie van HIV -I en de pathogenese van de HIV -I-infectie bij de mens. In het tweede 
gedeelte van dit hoofdstuk wordt de huidige kennis over de HIV -I-envelop-eiwitten en 
hun functie in membraanfi.lsie-processen samengevat. 
In het tweede hoofdstuk wordt de genetische en fi.mctionele analyse besclu'even van 
acht HIV -I-envelop-genen die centraal staan in het verdere onderzoek. Deze envelop-
genen zijn afkomstig van biologisch gekloneerde virussen. Zij werden verkregen uit 
perifere bloedlYll1focyten van (wee deelnemers (#16 en #320) aan een Amsterdamse 
cohOitstudie van HIV -1-geYnfecteerde individuen. Deze virussen zijn onderling genetisch 
sterk verwant maar verschillen toch in hun syncytium-inducerend vermogen. Door 
middel van recombinant vacciniavirus gemedieerde expressie van de geYsoleerde HIV -1-
genen wordt aangetoond dat de variatie in de envelop-genen voldoende is om het 
verschil in syncytiull1-inducerende vermogen van de oorspronkelijke virussen te 
verklaren. Mutatie-experimenten sluiten echter uit dat de waargenomen genetische 
variatie in het gp41-fhsiedoll1ein aileen verantwoordelijk kan zijn voor het verschil in 
syncytium-vormende capaciteit van deze envelop-gen producten. 
Sequentieanalyse van een groter aantal envelop-genen afkomstig van een van de twee 
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donoren (hoofdstuk 3), laat zien dat hoogst waarschijnlijk aminozuurvariatie in gp120 
verantwoordelijk is voor de waargenomen verschillen in het syncytium-inducerend 
vennogen van de bestudeerde virussen. Deze sequentieanalyse toont ook aan dat 
sommige van de envelop-genen het product zijn van in vivo recombinatie en dat 
determinanten voor SupTl-celtropisme gelegen moeten zijn buiten het V3-domein van 
gp120. 
In hoofdstuk 4 en 7 worden genetische uitwisselingsexperimenten beschreven. De 
localisatie van drie envelop-determinanten die betrokken zijn bij membraanfusie-
processen die de basis vormen voor syncytiumvonning, wordt mogelijk gemaakt door 
transiente expressie van chimere envelop-genen, geconstrueerd van syncytium-
inducerende (SI) en niet-syncytium-inducerende (NSI) envelop-genen. Naast 
aminozuurvariatie in het V3- en het V2-domein van gpl20 blijkt ook een klein, variabel 
gebied van gp41 (het "AB-domein") bij te dragen aan het syncytium-inducerend 
vermogen van primaire envelop-eiwitten. Met behulp van zogenaamde envelop-
complementatie-experimenten wordt bovendien aangetoond dat variatie in zowel het V3-
domein als in het AB-domein de capaciteit beYnvloedt van de virale envelop-eiwitten om 
bepaalde cell en te infecteren. Deze beide domeinen worden dan ook aangemerkt als 
determinanten van celtropisme (hoofdstuk 7). 
In hoofdstuk 5 wordt de bijdrage bepaald die afzonderlijke variabele 
aminozuurresiduen in het V2-domein van de bestudeerde envelop-genen leveren aan 
syncytium-vorming. Hierbij bleek dat enkelvoudige 1l1utaties in het V2-domein, 
gebaseerd op de waargenomen natuurlijke aminozuurvariatie, niet interfereren met 
syncytium-vorming die bepaald wordt door het V2-domein. De kennelijk robuuste 
organisatie van het V2-domein lijkt aan het virus een mogelijkheid te bieden om te 
ontsnappen aan bijvoorbeeld immuundruk zonder directe functionele consequenties. 
Het V2-domein velioont evenals enkele andere envelop-eiwit-domeinen ook variatie 
in lengte. In hoofdstuk 6 wordt door analyse van een grote verzameling "B-clade"-
envelop-gen-sequenties aangetoond dat gebieden met een variabele lengte een afwijkend 
codongebruik hebben. Dit afwijkende codongebruik leidt tot accumulatie van asparagine-
, serine- en threonineresiduen en daannee tot accumulatie van potentiele asparagine-
geassocieerde glycosyleringsplaatsen. Gepostuleerd wordt dat het afwijkende 
codongebruik veroorzaakt wordt door repeterende inse11ie van AAT -tripletten die 
gevolgd worden door puntmutaties en selectie. Het is waarschijnlijk dat de additie van 
suikergroepen zoals waargenomen in het V2-domein, het virus een selectief voordeel 
opleve11 door maskering van dit gebied VOOI' neutraliserende antistoffen. 
In hoofdstuk 8 wOl'dt aangetoond dat de HIV-l-"entry" kan worden bevorderd door 
de aanwezigheid van oplosbare CD4 receptor moleculen. Eenzelfde fenomeen is in 
130 
eerdere studies door anderen al waargenomen voor SIY,gm- en HIY -2-infecties. De 
toename in HIY-l-"entry" wordt eveneens gevonden in envelop-complementatie-
experimenten waarbij monoclonale of polyclonale antistoffen aanwezig zijn. Het blijkt 
dat dezelfde HIY -l-specifieke antistoffen een verschillend effect kunnen hebben op 
virussen met een verschillend fenotype. Antistoffen die een Sl-virus krachtig 
neutraliseren blijken daarentegen de "entry" van een genetisch zeer verwant virus met 
een NSI-fenotype te kllllllen bevorderen. 
De algemene diskussie - die in hoofdstuk 9 is opgenomen - bespreekt tenslotte de 
resultaten van het in dit proefschrifi beschreven onderzoek tegen de achtergrond van de 
virusvariatie die in de gastheer wordt waargenomen. Gepostuleerd wordt dat de 
complexe organisatie van de HIY -l-gemedieerde membraanfusie-processen, bijdraagt aan 
het vermogen van HIY -10m te persisteren in de gastheer. 
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